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DISSERTATION ABSTRACT 
Molecular insights into the uropathogenesis of Enterococcus faecalis and Escherichia 
coli in the context of urinary catheterization 
by 
Pascale Schaaba Guiton 
Doctor of Philosophy in Biology and Biomedical Sciences  
(Molecular Microbiology and Microbial Pathogenesis) 
Washington University in St. Louis, 2012 
Professor Scott J. Hultgren, Chairperson 
Professor Michael G. Caparon, Co-Chairperson 
 
Nosocomial urinary tract infections (UTIs) are a very common result of 
catheterization with 3 to 7% risk of developing catheter-associated UTIs (CAUTIs) each 
day catheterized. As multi-drug resistance increases in uropathogens, it is imperative to 
better understand the effects of catheterization on the urinary tract and pathogenesis. 
Further, microbial colonization and biofilm production on the surface of urinary catheters 
are a common component of CAUTIs. Thus, this dissertation focuses on understanding 
the contribution of known biofilm determinants to urovirulence of Enterococcus faecalis 
(a common nosocomial uropathogen) and uropathogenic Escherichia coli (UPEC) (the 
most common causative agent of UTI), and the effects of catheterization on bladder 
physiology using in vitro and optimized in vivo models. In vitro studies reported here 
demonstrated that E. faecalis produces DNA-dependent biofilms, which require both 
SrtA and Atn for efficient attachment as well as extracellular DNA from autolytic 
processes during the accumulative phase for maturation and architectural stability of the 
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biofilm under both static and hydronamic conditions. Further, in vivo studies optimizing 
and using a rodent model of foreign body-associated UTI to mimic conditions of 
indwelling urinary catheters in humans underscored the importance of biofilm formation, 
although in vivo required only a subset of the identified in vitro biofilm-promoting factors 
such as sortases, for the establishment of persistent enterococcal UTIs despite the acute 
inflammatory response ensuing from urinary implantation. This response was 
characterized in these studies and shown to involve bladder wall edema, partial disruption 
of the epithelial layer, vascular permeability, production of pro-inflammatory cytokines, 
and recruitment of myeloid cells, particularly neutrophils.  During infection of implanted 
murine bladders, it was shown that type 1 pili mediate UPEC adherence and invasion, 
similar to what was observed in non-catheterized bladders. Studies in this murine model 
further demonstrated that microbial reservoirs established during previous UPEC 
infection could serve as a nidus for urinary catheter colonization upon subsequent 
implantation. Specific targeting of type 1 pili with small molecule inhibitors of the pilus 
tip adhesin, FimH, in combination with trimethoprim/sulfamethoxazole prevented UPEC 
CAUTI. This finding establishes a proof-of-principle for the development of novel 
therapies to prevent and eventually treat UPEC CAUTI in the face of the rise of antibiotic 
resistant uropathogens.  
Overall, the optimization and use of the murine model of foreign body-associated 
UTI represents a significant advance in the understanding of the pathophysiology of E. 
faecalis and UPEC uropathogenesis in CAUTIs and is a valuable tool for the 
identification of virulence factors, including enterococcal sortases and UPEC type 1 pili, 
involved in these infections. Further research is required to uncover other biofilm and 
iv 
 
virulence determinants specifically required for UTIs as well as host factors that can 
serve as potential antimicrobial targets and biomarkers for the prevention, diagnosis, and 
treatment of enterococcal and UPEC CAUTIs.  
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INTRODUCTION 
Urinary tract infections 
With more than 11 million cases diagnosed annually and half a million 
hospitalizations1, urinary tract infections (UTIs) are among the most frequent infectious 
diseases acquired in the community and healthcare settings2,3. The associated cost of 
these infections is estimated at $3.5 billion every year in the United States1,4. UTIs are an 
inflammatory bacterial infection of the urinary bladder and urethra (lower UTI or cystitis) 
or in the ureters or kidneys (upper UTI or pyelonephritis) that can be associated with 
symptoms including fever, abdominal and flank pain, and painful urination5.  
UTIs are classified as uncomplicated or complicated based on patient’s medical 
history and the use of instrumentation. Uncomplicated UTI occurs mostly in healthy 
individuals with no abnormalities to the urinary tract. They typically affect young, 
sexually active and non-pregnant women with a lifetime risk of 60.4%6. A subset of these 
women will experience a recurrent episode within 6-12 months7-10. UTIs are also 
prevalent among infants and children and are associated with vesicoureteral reflux 
(VUR), severe renal dysfunction and scarring, and predisposition to recurrent 
infections5,11. On the other hand, complicated UTI is defined by the onset of local and 
systemic symptoms similar to those associated with pyelonephritis, including flank and 
back pain, fever, and malaise, occurring in both men and women of all ages that have 
functional or anatomic abnormalities in their urinary tract, the immunocompromised, 
those suffering from other medical conditions such as nephrolithiasis and fibrosis, or 
individuals undergoing long term urinary catheterization5.  
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Catheter-associated urinary tract infections 
Catheter-associated urinary tract infections (CAUTIs) are the most common 
complications resulting from the use of indwelling urinary catheters12,13 and account for 
40% of all nosocomial infections14 with more than one million cases diagnosed annually 
in hospitals and nursing homes in the United States and an estimated cost of $600 million 
in medical expenditures every year12,15,16. CAUTIs are defined as symptomatic UTIs with 
urine culture of one or more bacterial species greater than 1,000 colony forming unit 
(CFU)/ml with neutrophils present or pyuria, otherwise 105CFU/ml17. The incidence of 
bacteriuria following urinary catheterization is extremely common and occurs at a rate of 
3% to 10% daily18,19 with a 3 to 7% risk each day of developing CAUTIs20. This high 
incidence of bacteriuria in catheterized patients complicates the diagnosis of CAUTIs 
because both asymptomatic and symptomatic patients will have bacteria present in their 
urine21. Yet both bacteriuria and pyuria, strong identifiers of uncomplicated UTIs, are not 
good correlates of CAUTI22. It is thus imperative to identify specific biomarkers of 
CAUTIs for better diagnosis and treatment.  
Empirical antimicrobial therapy using oral antibiotics, including trimethoprim, 
cephalosporins, and fluoroquinolones, are often sufficient to alleviate symptoms of 
UTIs23. However, prevention and treatment are impeded by the ever-increasing rise in 
antibiotics resistance among uropathogenic strains. If left untreated, CAUTIs can lead to 
severe complications such as acute pyelonephritis, bacteremia, urosepsis, and in some 
cases, death18,24. The high incidence of CAUTIs coupled with their medical and economic 
challenges underscore the need for better understanding of CAUTI pathogenesis that can 
help in the development of more effective therapies. 
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Pathophysiology of CAUTIs 
The pathophysiology of CAUTIs involves severe alterations of bladder 
homeostasis following urinary catheterization. Catheterization induces histological and 
immunological changes in the bladder leading to severe bladder wall edema, hematuria, 
urothelial hyperplasia, and immune cell infiltration even in the absence of bacterial 
colonization25-30. The insertion and presence of a urinary catheter also interferes with 
micturition causing urine pooling in the bladder, damages the urothelium preventing 
secretion of inhibitory factors such as Tamm Horsefall proteins and 
mucopolysaccharides, and alters urine characteristics such as osmolarity; all of which are 
innate defense mechanisms that prevent microbial growth in healthy bladders31-34. Thus, 
the disruption of the normal mechanical and antimicrobial defenses of the bladder 
following urinary catheterization33,34 renders the bladder environment vulnerable to 
microbial adhesion, multiplication, and dissemination within the urinary tract35,36. 
Indwelling urinary catheters also provide an additional surface for microbial 
attachment and biofilm formation37. Biofilm on the surface of urinary catheters is a major 
component of the pathophysiology of CAUTIs and other chronic device-associated 
persistent infections such as cystic fibrosis and endocarditis5,38-40. These are bacterial 
communities encased within an extracellular matrix composed of carbohydrates, proteins, 
nucleic acids, and lipids41,42. The development of a biofilm is a complex multi-stage 
process depicted in Fig. 143. It is initiated with a primary adhesion of the bacteria to a 
substratum, which is followed by the formation of microcolonies and production of an 
exopolysaccharide matrix, and finally culminates with the formation of a three 
dimensional multicellular mature structure44.  
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Once formed, biofilms constitute an ideal environment for exchange of genetic 
material, such as genes encoding virulence factors and antibiotic resistance determinants 
among bacteria within the community45,46. Additionally, biofilm matrices allow for the 
flow of water and nutrients as well as ions and various small molecules to bacteria within 
the community42,47 and provide a protective shield against antibiotics, antimicrobial 
 
Figure 1: Proposed model of biofilm formation of the surface of urinary catheters  
Following the insertion of the urinary catheter into the bladder, it is coated by host factors present 
in the urine. Bacteria introduced from the periurethral or extracellular milieu attach to the urinary 
catheters, multiply to produce microcolonies with secretion of an extracellular matrix. The 
microcolonies mature to form mature 3-dimensional structure, called biofilms. Eventually cells 
can detach or are shed for the biofilm to start the process again or disseminate to other tissues. 
Adapted from Reference43. 
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substances, and host immune defenses such as phagocytosis48-54, leading to chronic or 
recurrent infections that are difficult to treat. 
Etiologic agents of UTIs 
Uropathogenic Escherichia coli (UPEC) is the major etiological agent of all UTIs, 
responsible for 80% of community-acquired UTIs and over 50% of nosocomial UTIs55. 
Emerging uropathogenic strains including Pseudomonas, Klebsiella, Staphylococci, and 
Enterococci are responsible for the remainder of UTIs, especially in nosocomial settings. 
Enterococcus faecalis and Enterococcus faecium, responsible for 15 to 30% of CAUTIs, 
are now the third leading cause of hospital-acquired UTIs18,56. UPEC and Enterococci are 
major etiological agents of CAUTIs56 and are often isolated from mono and 
polymicrobial communities on the surface of urinary catheters with other Gram-negative 
and Gram-positive bacteria, including Pseudomonas aeruginosa, Proteus mirabilis, and 
Staphylococcus species57,58. Given their prevalence, medical and economic burden, 
further research is warranted to understand the mechanisms underlying UPEC and 
enterococcal CAUTIs. 
UPEC uropathogenesis  
E. coli, a rod-shaped facultatively anaerobic Gram-negative bacterium, is a 
member of the microflora of the gastrointestinal tract in humans. However, subsets of 
these Enterobacteriacae have acquired virulence factors that enable the establishment of 
various infections in the human host, including sepsis, meningitis, diarrhea, and UTI. 
UPEC, the major cause of all UTIs, belong to the extraintestinal pathogenic E. coli 
(ExPEC) subsets. UPEC are equipped with an arsenal of virulence factors that ensure 
colonization of the urinary tract while evading the host immune defenses43,59. Of 
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particular interest are the surface adhesins and extracellular fibers, including curli, pili, 
Dr adhesins, antigen 43, cellulose and flagella, that mediate adherence to urinary 
catheters and epithelial cells in the urinary tract, promote biofilm formation and 
contribute to the establishment of cystitis and pyelonephritis60,61. The adhesive type 1 pili, 
encoded by fim and which display phase variable expression, are the most prevalent 
virulence factor present in 80 to 100% of UPEC strains 43.  
 
Like many other bacterial fimbriae, 
type 1 pili shown in Fig.2 are 
assembled and translocated to the cell 
surface via the conserved chaperone 
usher pathway. Type 1 pili consist of 
the major subunit FimA that makes up 
the pilus shaft, the tip fibrillum 
composed of FimF and FimG 
subunits, and the tip adhesin 
FimH63,64. Type 1 pili mediate UPEC 
binding to uroepithelial cells65 and are critical for UPEC infections66. The uropathogenic 
cascade of UPEC illustrated in Fig.367 has been extensively characterized using a murine 
model of cystitis60,68,69. It is a multistep process that is initiated with FimH of type 1 pili 
binding to glycoprotrein uroplakins and mannosylated residues on the surface of the 
superficial umbrella cells lining the bladder epithelium70. Following UPEC adhesion to 
urothelial cells, bacteria are internalized via zipper-like mechanisms involving local actin 
rearrangement and rhoGTPases71,72. UPEC replicate rapidly within bladder epithelial 
 
Figure 2: Type 1 pili are critical for UPEC 
adherence to uroepithelial cells.  
Electron micrographs of type 1 pili mediating UPEC 
binding to uroepithelial cell surfaces prior to 
bacterial engulfment. Adapted from Reference62. 
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cells to produce type 1 pili-dependent intracellular bacterial communities (IBCs) that 
possess biofilm-like properties73,74, including positive periodic acid-Schiff (PAS) 
staining, differential gene expression, and morphological differentiation67,73,75. Upon IBC 
maturation, rod-shaped and filamentous bacteria then flux out from the infected cells and 
reinvade neighboring cells and start the process de novo73.  
 
This acute phase of UPEC infection can eventually lead to the development of chronic 
cystitis, pyelonephritis, and the formation of quiescent intracellular reservoirs (QIRs) 
with absence of bacteriuria, which is postulated to be a source of persistent and recurrent 
 
Figure 3: Schematic of the acute phase of UPEC uropathogenic cascade. 
Following attachment and invasion of the superficial umbrella cells of the bladder, UPEC 
replicate, undergo morphological changes and develop intracellular bacterial community 
(IBCs) composed of coccoid and filamentous bacteria. Upon maturation, bacteria emerge 
from the infected cells and can reinvade neighboring cells to start the cycle over or establish 
quiescent intracellular reservoirs (QIRs) that can persist for a long period of time in the 
bladder. Reproduced with permission from Reference67. 
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infections76,77. IBCs are also present in exfoliated uroethelial cells in urine from UTI 
patients, indicating that this pathway occurs during human infections78. The occurrence 
of this uropathogenic cascade following urinary catheterization as well as the role of type 
1 pili and UPEC biofilm in CAUTI have yet to be characterized.  
The detailed understanding of the molecular mechanisms underlying UPEC 
biofilm formation and uropathogenesis has led to the development of small molecule 
inhibitors targeting the assembly (pilicides and curlicides) and function (mannosides) of 
UPEC adhesive structures79-82. Pilicides and curlicides are dihydro thiazolo ring-fused 2-
pyridone derivatives that block protein-protein interactions required for the assembly of 
type 1 pili and of curli amyloid fibers80,83. In contrast, mannosides are specific type 1 
pilus adhesion, FimH, antagonists rationally designed to interfere with FimH interaction 
with mannosylated residues present on the surface of the uroepithelium80,81,84-86. These 
small molecules display anti-biofilm activity against UPEC in vitro and significantly 
attenuate virulence in the urinary tract80,83. Furthermore, mannosides can be used in 
combination with existing antibiotic therapy to prevent and treat UTI in mice87. 
Virulence-based therapeutic approaches may thus provide potential alternatives or 
supplement existing ones in the fight against UTIs, especially CAUTIs.  
Enterococcal biofilm formation and urovirulence 
Unlike UPEC, very little is known about enterococcal uropathogenesis. 
Enterococci are Gram-positive facultative anaerobic lactic acid-producing bacteria found 
as diplococci or in chains in the microbiota of the gastrointestinal tract of humans and 
animals88. They are non-spore forming bacteria that can withstand and grow in harsh 
environmental and physiological conditions, including high salt concentrations (6.5% 
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sodium chloride and 40% (w/v) bile salts), a wide range of pH (4.5-10.0) and 
temperatures (10-45ºC). These physiological properties and the production of 
antimicrobial peptides that are bactericidal to closely related species have led to the use 
of Enterococcus species for biotechnology and as probiotic agents in the food industry88. 
However, Enterococci, especially E. faecalis and E. faecium, are also important 
opportunistic pathogens causing 12% of nosocomial infections89, including UTIs, 
endocarditis and bacteremia which has a high mortality rate up to 61%90.   
The ability of E. faecalis isolates to adhere to and develop biofilms on the surface 
of medical devices such as intravascular and urinary catheters shown in Fig. 291-94, 
coupled with the increasing resistance to virtually all antibiotics, including 
aminoglycosides and glycopeptides such as vancomycin90,95-97, especially in biofilms98,99. 
Vancomycin-resistant enterococci (VRE) have been associated, since their identification 
in Europe in the 1980s100,101, with several 
nosocomial infection outbreaks. In the 
United States, the Center of Disease 
Control and Prevention National Healthcare 
Safety Network reports that from January 
2006 to October 2007, 4% of healthcare-
associated infections result from 
vancomycin-resistant E. faecium56. This 
intrinsic and extrinsic resistance to antibiotics and the transfer of resistance genes to other 
species such Staphylococci102 pose important clinical challenge in the fight against 
enterococcal infections. Several genetic factors and cellular processes, such as cell 
 
Figure 4: Scanning electron micrograph 
of E. faecalis strain OG1RF. 
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surface adhesins, proteases, quorum sensing, autolytic processes and extracellular DNA 
(eDNA), are implicated in biofilm development91,103,104. 
Although the mechanisms of biofilm formation in E. faecalis require further 
research, enterococcal biofilm determinants, including the enterococcal surface protein 
Esp105, the pilus-associated sortase C (SrtC)106, and the endocarditis and biofilm-
associated pilus (Ebp)107, contribute to enterococcal urovirulence. On the other hand, 
other well-characterized adhesins and in vitro biofilm determinants often associated with 
enterococcal UTI isolates like aggregation substance (AS) and the housekeeping sortase 
A (SrtA)108,109 were reported to be dispensable for virulence in the urinary tract108,109. 
Since these conclusions were drawn from studies in murine models where persistent 
enterococcal infections cannot be established, it is imperative to re-examine the existing 
paradigm in an animal model that better mimics the transition of E. faecalis from a 
commensal to a virulent pathogen in the urinary tract.  
Prospectus 
The introduction of multidrug resistant Gram-positive and negative bacteria in the 
sterile environment of the bladder following urinary catheterization leads to the 
development of CAUTIs, major nosocomial infections recalcitrant to antibiotic treatment. 
Biofilm formation on the surface of indwelling urinary catheters is critical during 
CAUTI; however, limited research exists addressing the role of biofilm promoting factors 
in the establishment of CAUTIs, especially caused by UPEC and Enterococcus species.  
Studies addressing the hypothesis that known biofilm determinants of E. faecalis and 
UPEC are also involved in urovirulence following urinary catheterization and can serve 
as novel targets for virulence-based therapy in the prevention and treatment of these 
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infections are presented in the following chapters. The study described in this thesis 
provides molecular details of the temporal and spatial development of E. faecalis 
biofilms. Subsequent chapters describe the optimization and use of a murine model of 
CAUTI to assess the role of known biofilm factors to urovirulence of E. faecalis and the 
consequences of urinary catheterization on the uropathogenic cascade of UPEC.  
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CHAPTER ONE 
ENTEROCOCCAL AUTOLYTIC PROCESSES AND SORTASES MEDIATE 
EXTRACELLULAR DNA-DEPENDENT BIOFILM FORMATION 
Modified from: Guiton, P.S., et al. (2009) Infect Immun. 
ABSTRACT 
Biofilm production is a major attribute of E. faecalis clinical isolates. Although 
factors such as sortases, autolysis and extracellular DNA (eDNA) have been associated 
with E. faecalis biofilm production, the mechanisms underlying their contributions to this 
process requires further investigation. The present study defines important roles for the 
major E. faecalis autolysin (Atn), eDNA, and sortase A (SrtA) during the developmental 
stages of biofilm formation under static and hydrodynamic conditions. Deletion of srtA 
affects the attachment stage and results in deficiency in biofilm production. Autolysin-
deficient mutants are delayed in biofilm development due to defects in primary adherence 
and DNA release, which is particularly important during the accumulative phase for 
maturation and architectural stability of biofilms. Confocal laser scanning and freeze-dry 
electron microscopy of biofilms grown under hydrodynamic conditions revealed that E. 
faecalis produces a DNaseI-sensitive fibrous network important for biofilm stability. This 
DNA-dependent fibrous network is absent in atn-deficient mtutant biofilms. Overall, this 
study establishes the stage-specific requirements of SrtA and Atn and demonstrates a role 
for the major enterococcal autolysin in the pathway leading to DNA release during 
biofilm development in this opportunistic organism.  
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INTRODUCTION 
Bacterial biofilms can withstand harsh environmental stress conditions, including 
low nutrient availability, temperature fluctuations, antibiotic and antimicrobial 
treatments, and host immune responses38,110,111. Medical biofilms are associated with the 
establishment of chronic and persistent infections, including enterococcal 
CAUTIs40,112,113. The ability of E. faecalis to adhere to and develop biofilms 91 on 
medical devices, such as intravascular and urinary catheters, is thought to contribute to its 
pathogenesis.  
Several putative virulence factors and cellular processes have been implicated in 
the development of biofilms in E. faecalis91,92,114-121; however, very little is known about 
their regul91ation and molecular contribution during this process. One of these factors, the 
quorum-sensing two-component transduction signaling system encoded by the fsr locus, 
an important virulence factor in the pathogenesis of E. faecalis, controls biofilm 
formation via positive regulation of the extracellular zinc metalloprotease GelE 
(gelatinase) and the serine protease SprE115,117-120. These proteases were recently shown 
to contribute to enterococcal biofilm formation via regulation of cellular autolysis and 
fratricidal DNA release103,104. In these studies, Thomas et al. also provided the first 
evidence for a critical role of extracellular DNA (eDNA) in E. faecalis biofilms104. eDNA 
is an important component of the extracellular matrix of bacterial biofilms, providing 
structural stability to the biofilm and protection against antimicrobials122-128. However, 
the temporal and spatial requirements of this macromolecule throughout the 
establishment and growth of E. faecalis biofilms is not well characterized.  
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Bacterial murein hydrolases, also referred to as autolysins, have been implicated 
in biofilm production127,129. They are important contributors to cell wall growth and 
regulation as well as several lytic processes130,131. Two autolysins of Staphylococcus 
epidermidis, AtlE and Aae, are adhesins that contribute to bacterial attachment to 
polymeric surfaces and biofilm formation via release of eDNA127,132,133. E. 
faecalis produces several autolysins, which were recently identified and characterized134-
137. The major E. faecalis autolysin, Atn (also known as AtlA), is a predominant 
enterococcal antigen during human infections138. Atn is an N-acetylglucosaminidase134 
important for daughter cell separation139. Disruption of atn in E. faecalis results in 
increased chaining, defects in primary attachment, and decreased biofilm 
production92,103,109,136,137,139. Furthermore, inactivation of this autolysin partially protects 
E. faecalis against the lytic activities of the β-lactams penicillin (in vitro) and amoxicillin 
(both in vitro and in vivo), but does not attenuate virulence in mouse and rabbit models of 
peritonitis and endocarditis, respectively139-141. However, the contribution of Atn to DNA 
release during biofilm formation remains to be established. Recently, Thomas et al. 
provided evidence that inactivation of this autolysin results in a decrease in DNA release 
similar to that of gelatinase-deficient mutants103. Furthermore, they showed that GelE and 
SprE can differentially cleave Atn in vitro, and this processing may underlie the 
mechanism of cell death and DNA release in E. faecalis during biofilm formation.  
Due to their role in cell wall regulation, autolysins may affect the localization of 
cell wall-anchored proteins, which can be important for adhesion during biofilm 
development. In most Gram-positive bacteria, membrane-anchored transpeptidase 
enzymes known as sortases are responsible for sorting and covalently anchoring proteins 
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bearing an LPXTG motif to the cell wall142 143. Thus far, only class A and class C 
sortases have been implicated in enterococcal biofilm formation and virulence106,109. 
Deletion of the gene encoding sortase C, srtC or bps (biofilm and pilus-associated 
sortase), resulted in a significant reduction in biofilm production and attenuation of 
virulence in a mouse model of UTI, unlike deletion of srtA, which had minor effects 
under similar conditions106. However, given the ubiquitous nature of sortases and the 
limited knowledge of the activity and substrates of the sole SrtA characterized in E. 
faecalis, it is plausible that this enzyme may play an important role in E. faecalis 
physiology and/or pathogenesis under different conditions. For instance, SrtA was shown 
to anchor the plasmid-encoded protein Asc10, which is involved in the pheromone-
induced aggregation of E. faecalis144. 
The present study uncovers the contributions of E. faecalis SrtA, Atn and eDNA 
to the major developmental stages from bacterial attachment to the establishment of 
mature biofilms under static and hydrodynamic conditions. The findings indicate that 
both SrtA and Atn contribute to efficient primary adherence to the abiotic surfaces while 
Atn and eDNA promote biofilm maturation and architectural stability during the 
accumulative stage. These findings argue for a role of Atn in the temporal regulation of 
DNA release. Under hydrodynamic shear forces, E. faecalis produces an Atn-dependent 
DNaseI-sensitive extracellular fibrous network. Collectively, this study underscores the 
importance of SrtA and Atn-mediated DNA release at different stages during the 
establishment of E. faecalis biofilms. As a critical component of the extracellular matrix 
of E. faecalis biofilms, eDNA may serve as a novel target for the dissolution of these 
structures.  
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RESULTS 
E. faecalis biofilm development occurs in two major steps 
In order to delineate the major stages of E. faecalis biofilm development, OG1RF 
was monitored for 72h to assess biofilm formation on polyvinyl chloride (PVC) 
coverslips in trypticase soy broth supplemented with 0.25% glucose (TSBG) at 37ºC 
under static conditions. Biofilms were visualized and quantified by CLSM and crystal 
violet-based quantification. CLSM images of 24h and 72h OG1RF biofilms stained with 
the DNA dyes SYTO9 and PI show a slow accumulation of the biofilm during the first 
24h, which was followed by a rapid buildup and increase in density and thickness (Fig. 
5A). Crystal violet-based quantification confirmed this observation and displayed a 
biphasic biofilm growth curve. This curve shows that the biomass accumulated at a 
slower rate between 0 and 24h followed by a significantly faster growth during the 
subsequent 48h with an approximately 6 fold increase in biomass from 24h to 72h (Fig. 
5B).  
eDNA is required for biofilm development  
SYTO9 is a membrane permeable DNA dye whereas PI stains only eDNA and 
DNA of membrane compromised cells. The CLSM images show the presence of yellow 
patches throughout the biofilms, which are representative of SYTO9 and PI co-
localization due to the presence of dead cells or eDNA in these structures (Fig. 5A and 
5C). To determine whether eDNA contributes to biofilm development, OG1RF was 
grown statically in presence of varying DNaseI concentrations, ranging from 0 to 
50µg/ml. DNaseI treatment severely impaired the ability of OG1RF to develop into 
mature biofilms at concentration as low as 0.5µg/ml (data not shown). OG1RF grown in 
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presence of 5µg/ml DNaseI produced 92.3% less biomass at 72h (p=0.0121 by Mann-
Whitney U test) than untreated controls (Fig. 5B), which was in accordance with the 
reduction in volume observed determined by SYTO9 absorbance (Fig. 5D). The 
detrimental effects of DNaseI on biofilm development are not due to bactericidal or 
bacteriostatic activities as DNaseI did not inhibit OG1RF planktonic growth (data not 
shown). CLSM analysis further showed that OG1RF was able to attach to the substratum 
and formed microcolonies in presence of DNaseI; however, it failed to build the large 
compact 3D structures observed at 72h in untreated controls (Fig. 5C). In addition, 
approximately 10 to 15% of the cells present in the DNase I-treated samples stained with 
PI compared to the 30 to 50% in the untreated samples (Fig. 5D). The lower level of PI 
staining in biofilms treated with DNase I indicates a reduction in the number of dead cells 
and/or eDNA. Together, these findings suggest that eDNA in OG1RF biofilms 
contributes to the establishment of mature enterococcal biofilm structures.  
 
18 
 
 
Figure 4: DNA is critical for E. faecalis biofilms under static conditions.  
(A) CLSM images of OG1RF biofilms at 24h and 72h. Biofilms were stained with SYTO9 
(green) and PI (red) and visualized with CLSM. 3D reconstructions of z stacks were generated 
with the Volocity software. (B) Crystal violet-based quantification of OG1RF biofilm biomass. 
Error bars = SEM of at least 3 independent experiments. *p<0.05, ***p<0.0005 by Mann-
Whitney U test  (C) CLSM images of 72h static OG1RF biofilms untreated or treated with 5 
µg/ml of DNaseI continuously or for 3 h post formation. Scale, 1 unit on each side of the grid 
=14.3µm. (D) Quantification of biomass volume (µm3) based on SYTO9 and PI absorbance using 
Volocity software.  Graphs represents data obtained from a representative experiment with 3-4 
randomly chosen fields. Error bars=SD  
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eDNA is required for maintenance of biofilm architectural integrity  
To further characterize the function of eDNA in enterococcal biofilms, the effects of 
DNaseI on mature biofilms were investigated. Mature 72h static biofilms were treated 
with 5µg/ml of DNaseI for 1h, 2h, 3h, and 24h at 37°C followed by crystal violet staining 
or CLSM analysis. DNaseI treatment significantly reduced biofilm biomass by ~30% 
compared untreated controls 2h post treatment (p=0.0428) (Fig. 6A). Three hours 
treatment with DNaseI further reduced the biofilm biomass by 60% (p=0.008) while 
inactivated DNaseI (iDNase I) did not have any significant effects (p=0.7602; Fig. 6A). 
DNaseI inactivation was achieved following incubation at 75 to 100ºC and confirmed by 
its inability to degrade salmon sperm DNA (SSDNA) following 1h incubation at 37ºC 
(Fig. 6B). The biomass was further reduced to 40% of its original thickness (p=0.0003) 
24h post treatment whereas iDNase I had no effect (p=0.5079; Fig. 6C). The disruption of 
mature biofilms following DNaseI treatment was also observed by CLSM (Fig. 5C and 
6C). Disintegration of the biofilm structures occurred at 3h following treatment with 
5µg/ml of DNaseI (Fig. 5C) compared to 1h with 50µg/ml DNaseI concentrations (Fig. 
6C), suggesting that the effect of DNaseI on biofilms is dose and time dependent. 
Overall, these findings indicate that eDNA is an important structural component of E. 
faecalis biofilms and is necessary for maintaining their stability.  
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Figure 5: DNA is required for maintaining biofilm stability. 
(A) Relative biomasses of 72-h OG1RF biofilms treated for 1 h, 2 h, 3 h, or 24 h with 5 µg/ml 
of DNase I or iDNase I at 37°C. Error bars = SEM from three different experiments. *p < 0.05 
** p < 0.01; *** p < 0.0005 by Mann-Whitney U test. (B) 0.8% agarose DNA gel showing the 
activities of DNaseI and heat inactivated DNaseI (iDNase I) at 75ºC and 100ºC for 20 min 
were assayed in TSBG at 37°C for 1h on 100µg/ml of salmon sperm DNA. (C) 72h old 
OG1RF biofilms stained with SYTO9 (green) and PI (red) were untreated or treated 
with 50 µg/ml of DNaseI or iDNase I for 1h, 3h, or 24h. Scale, 1 unit on each side of 
the grid =14.3µm.  
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E. faecalis forms a DNaseI-sensitive fibrous network under hydrodynamic 
conditions 
 
 
Figure 6: E. faecalis produces a DNaseI-sensitive extracellular fibrous network under 
hydrodynamic conditions induces the production. 
The images are freeze-dry electron micrographs (Magnification, x20,000) (A and D) and 
CLSM images (B, C, and E) of 48h OG1RF biofilms untreated (A, B, and C) or treated for 1h 
with 5 µg/ml of DNaseI (D and E). The arrows in (B and C) indicate SYTO9-PI stained fibers. 
Biofilm fibers (in white square) stain only with DNA dyes and not WGA. SYTO9 (green), PI 
(red), and WGA (blue). Scale bars = (A and D) 500nm, (B and E) 20µm, and (C) 10µm.  
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E. faecalis must withstand a variety of environmental conditions, such as urine 
flow in the bladder, for efficient colonization of medical devices. To investigate the 
effects of shear forces on E. faecalis biofilm development, OG1RF biofilms were 
cultivated in TSBG on PVC coverslips placed on an orbital shaker at 37ºC for the 
duration of the experiment. Freeze dry and CLSM micrographs of 48h dynamic biofilms 
show bacteria within the biofilm clustered via long fibrous structures under these 
conditions (Fig. 7A-C) that only stained with the DNA dyes and not with wheat germ 
agglutinin (WGA) that stains carbohydrates on cell surfaces (Fig. 7C). These 
extracellular fibers disappeared within 1h of DNaseI treatment (Fig. 8D-E), which 
correlated with disintegration of the biofilm. Additionally, immunogold transmission 
electron microscopy (TEM) analyses of OG1RF hydrodynamic biofilms labeled with 
mouse anti-dsDNA monoclonal antibody revealed foci inside and at the surface of cells 
as well as in the extracellular matrix surrounding the cells (Fig. 8A, top left panel), while 
examination of biofilms after 1 h of treatment with DNase I showed a reduced presence 
of eDNA (Fig. 8A, top right panel). Approximately 38% of the gold particles labeled the 
extracellular matrix compared to ∼6% following DNase I treatment (Fig. 8B). Similar to 
the results for static conditions, OG1RF grown in the presence of 5 µg/ml of DNase I for 
48 h failed to produce biofilms under hydrodynamic conditions and only 2% of the gold 
particles were found in the extracellular milieu under such conditions (data not shown). 
Treatment with proteinase K did not prevent OG1RF biofilm formation and did not affect 
the formation of the DNase I-sensitive extracellular fibers (data not shown). These results 
indicate that in the presence of hydrodynamic forces E. faecalis produces DNA-
dependent biofilms with a distinct architecture from that of static biofilms. Additionally, 
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the data suggest that eDNA is a major component of the filamentous extracellular 
network in biofilms formed under hydrodynamic conditions that appears to provide cell-
to-cell adhesion and stability in the biofilms.  
 
Deletion of atn results in delayed biofilm formation  
Freeze-dry electron micrographs revealed that lysed cells are constituents of 
enterococcal biofilms (Fig. 9A). This observation led to the hypothesis that Atn, the 
major autolysin of E. faecalis, facilitates DNA release and the formation of the DNase I-
 
Figure 7: Atn contributes to DNA release during biofilm formation.  
(A) Negative staining and immunoelectron microscopy images of 48h OG1RF and OG1RF∆atn 
biofilms with or without 1h of DNase I treatment and labeled with mouse anti-dsDNA 
monoclonal antibody and secondary immunogold. The images are representative images of 10 
random fields. Scale bars = 200 nm. Graph represents quantification of cell-associated or 
extracellular gold particles (indicated by arrowheads in panel A) from 10 independent fields for 
48h dynamic biofilms at a magnification of x30,000.  
24 
 
sensitive extracellular fibrous network. To test this hypothesis, in-frame deletion of the 
autolysin gene (atn) was performed to generate an autolysin-deficient strain in OG1RF, 
OG1RFΔatn.  The ability of OG1RFΔatn to form biofilms in the presence or absence of 
DNaseI was assessed. Deletion of atn did not affect OG1RF growth rate under normal 
culturing conditions (data not shown). As expected, based on the role of autolysins in cell 
lysis and cell division, OG1RFΔatn had a reduced rate of cellular lysis as determined by 
a cellular autolysis assay under both static and hydrodynamic conditions (Fig. 9B) and 
formed longer chains than the parent strain (Fig. 9C). Compared to wild type OG1RF, 
OG1RFΔatn was delayed in its ability to form biofilms under hydrodynamic conditions 
and produced approximately 40% less biomass by 48h as compared to that of the parental 
strain (Fig. 10A). Continuous DNase I treatment resulted in a ∼40% reduction in the 
OG1RFΔatn biomass accumulated by 48 h (p = 0.038) compared to an 87% reduction for 
the wild type (p= 0.0004; Fig. 10A). Similar levels of inhibition are observed following 
1h of DNase I treatment of 48-h OG1RFΔatn biofilms (Fig.10B-C). For 
OG1RFΔatn biofilms, there was a 33% decrease in biomass (p > 0.05) following DNase I 
treatment compared to a 78% reduction for the wild-type structures (p < 0.0001) 
(Fig.10B). CLSM analysis of 48h dynamic OG1RFΔatn biofilms revealed the absence of 
DNase I-sensitive extracellular fibers and very few PI-stained cells (Fig. 10C-D). 
Additionally, reduced amounts of eDNA were detected in the extracellular matrix of the 
mutant biofilms using cryoimmunoelectron microscopy with murine anti-dsDNA 
monoclonal antibody labeling (Fig. 8). Under static conditions, deletion of atn caused a 
similar reduction in biofilm biomass. The structure produced in the absence of atn was 
significantly more resistant to DNaseI treatment compared to wild type biofilms (Fig. 
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10A-C) and the cells within the static biofilms were loosely packed (Fig. 10B). 
Complementation studies could not be performed with OG1RFΔatn expressing atn from 
a vector, perhaps due to the potential cytotoxic effects of Atn in the recipients, as 
previously suggested137. Nonetheless, the above findings indicate that Atn and cellular 
lysis play a role in DNA release during enterococcal biofilm formation. However, the 
ability of OG1RFΔatn to form delayed and partially DNase I-sensitive biofilm suggest 
the existence of Atn-independent mechanisms of DNA release.  
 
Figure 8: Effects of atn deletion. 
(A) Freeze-dry electron micrograph of a 48h dynamic OG1RF biofilm with extracellular fibrous 
network protruding from lysed cells (red square). Magnification, x30,000. Scale bar = 500 nm. 
(B) Cellular autolysis of exponential-phase OG1RF and OG1RF∆atn in trypsin/sodium phosphate 
buffer. Error bars = SEM from at least 3 independent experiments (C) OG1RF and OG1RF∆atn 
cells from 24h TSBG liquid cultures stained with SYTO9 and PI. Scale bar= 10 µm.  
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Figure 9: Characteristics of OG1RF and OG1RF∆atn grown in static conditions. (A) Crystal 
violet-based quantification of OG1RF (WT) and OG1RF∆atn (∆atn) biofilms with or without 
DNaseI treatment at indicated times. (B) CLSM images of 72h WT and ∆atn biofilms untreated, 
treated continuously or post formation with 5 µg/ml of DNaseI. The cross-section images reveal 
the thickness of the biofilms. Scale bar = 28 µm. (C) Crystal violet –based quantification of 72h 
WT and ∆atn biofilms treated with or without DNaseI for 3h *p<0.05, **p<0.005, ***p<0.0005 
by Mann-Whitney U Test. 
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Atn contributes to DNA-independent attachment of E. faecalis to plastic surfaces  
To assess the role of eDNA in initial attachment of E. faecalis to plastic cover 
slips, a primary attachment assay was performed in presence or absence of 5µg/ml of 
DNaseI under static and hydrodynamic conditions. Very few cells were adhered to the 
substratum after 2h in either condition (data not shown). By 4h and 6h, significantly 
fewer OG1RFΔatn cells (40%) than wild-type strain cells were adhered to the surface 
(p < 0.0001; Fig. 11A), suggesting that Atn is required for this process. In contrast 
to atn deletion, DNaseI treatment did not affect the primary attachment at 4h for both 
wild-type strain OG1RF and OG1RFΔatn. Similar levels of wild-type cells were attached 
to the surfaces regardless of the presence of DNaseI at 4 h (p = 0.3527) (Fig. 11A), 
indicating that eDNA is not critical for the initial attachment stage during biofilm 
development. Six hours of continuous DNase I treatment prevented microcolony 
formation (Fig. 11B), and this corresponded with a 33.3% reduction in the number of 
adherent cells. Albeit not statistically significant (p = 0.4359), this reduction suggests that 
DNaseI affects microcolony formation; microcolonies were readily visible at 6 h only in 
untreated samples (Fig. 11B). Furthermore, there was a >500% increase in PI staining 
from 4 h to 6 h compared to approximately 200% increase in the presence of DNase I 
(Fig. 11C), arguing that cell death and eDNA contribute to microcolony formation. 
Similar findings were obtained under hydrodynamic conditions (data not shown).  
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Figure 10: Primary attachment requires srtA and atn, but not eDNA.  
(A) Primary attachment of OG1RF (WT), OG1RFΔatn (Δatn), OG1RFΔsrtA (ΔsrtA), and 
OG1RFΔsrtA/srtA (ΔsrtA/srtA) was determined by crystal violet staining following static 
incubation on PVC coverslips for 4 to 6 h at 37°C in TSBG with or without 5 µg/ml of DNase I. 
error bars =SEM for at least three independent experiments. *, p < 0.05**, p < 0.01; ***, p< 
0.0001 by the Mann-Whitney U test. (B) Representative CLSM images of 4h and 6h OG1RF (wt) 
adherent cells in the presence or absence of DNase I stained with SYTO9 (green) and PI (red). 
The arrows indicate microcolonies in 6h samples. One unit on each side of each grid equals 14.3 
µm. (C) Quantification of the change in fluorescence of SYTO9 and PI relative to the total 
fluorescence from adhering cells from 4 h to 6 h post inoculation from 12 randomly chosen fields 
from two independent experiments using the VOLOCITY software.  
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Deletion of srtA results defect in primary adhesion  
Given that autolysins are involved in cell wall growth and regulation, it is 
conceivable that deletion of atn causes mislocalization of adhesion factors critical for 
primary attachment and biofilm development. Sortases are ubiquitous enzymes with 
critical role in adhesion and virulence of Gram-positive bacteria. Given their role in cell 
wall protein sorting and anchoring, SrtA substrates on the cell surface may, 
hypothetically, contribute to initial stages of biofilm development. To investigate the role 
of SrtA in biofilm formation under static and hydrodynamic conditions, an in-frame 
deletion of srtA was generated in OG1RF, OG1RFΔsrtA. Deletion of srtA had no effect 
on cell viability and cell growth (data not shown). Similar to OG1RFΔatn, OG1RFΔsrtA 
was also significantly deficient in primary attachment under static (p=0.0001; Fig. 11A) 
and shaking conditions (data not shown). Forty percent fewer OG1RFΔsrtA cells than 
parental strain cells adhered to the coverslips after 4h of incubation. The complemented 
strain OG1RFΔsrtA/srtA exhibited wild-type levels of adherence by 6h, showing 
significantly more adherence than OG1RFΔsrtA (p = 0.0022; Fig. 11A). It is not clear 
why the complementation effect was delayed and thus not observed at 4h; however, this 
may have been the result of plasmid loss in the complemented strain population, which 
allowed only a small subset to efficiently adhere to the substratum, leading to the 
observed delay. Furthermore, preliminary data from TEM analysis of OG1RF, 
OG1RFΔatn, OG1RFΔsrtA, OG1RFΔsrtA/srtA grown statically in TSBG for 24h 
indicated that OG1RFΔsrtA produced fewer pili compared to wild type and the other 
strains (Fig. 12).  Together, these findings suggest that SrtA and likely a SrtA substrate(s) 
play a role in promoting efficient initiation of biofilm development in E. faecalis. 
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Figure 11: Piliation in OG1RF and isogenic mutants 
Bacteria were grown statically in TSBG for 24h and prepared for TEM. Pili were counted on 500 
cells per strain. Arrows indicate pili. Graph represents the percentage of piliation relative to 
number of cells counted. Magnification, Scale bar = Experiment was performed once.  
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srtA deletion results in defects in biofilm production 
OG1RFΔsrtA was significantly defective in biofilm formation under static 
conditions; it produced ∼60% less biomass than the wild type at 24 h (p = 0.0142) and 
even less (~40% reduction) biomass than the wild type at later time points (p = 0.0244; 
Fig. 13A). This defect in biofilm was complemented in OG1RFΔsrtA/srtA under static 
conditions (Fig. 13B-C). OG1RFΔsrtA and the complemented strain formed 3D biofilm 
structures that were sensitive 5µg/ml of DNaseI similar to wild type (data not shown). 
Additionally, the role of srtA in biofilm formation was assessed in presence of shear 
forces. In contrast to static conditions, the srtA-deficient mutant was severely defective 
under hydrodynamic shear forces (Fig. 13D). The impairment observed under these 
conditions was even more pronounced compared to static conditions. 
OG1RFΔsrtA/srtA exhibited a wild-type phenotype under these conditions (Fig. 13D), 
forming mature biofilms containing SYTO9-PI-stained extracellular fibers. These 
findings suggest that DNA release and extracellular fibrous network formation occur 
independent of SrtA.  
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Figure 12: SrtA promotes high levels of DNA-dependent biofilm development.  
 (A) Crystal violet staining based quantification of OG1RF WT and OG1RFΔsrtA biofilm 
development and of (B) 72h OG1RF WT, OG1RFΔsrtA, and OG1RFΔsrtA/srtA static biofilms. 
Error bars = SEM of 3 different experiments. *p<0.05, **p<0.01 by Mann-Whitney’s test. (C-D) 
3D reconstruction of CLSM images of static 72h biofilms (C) and 48h dynamic biofilms (D) of 
OG1RF, OG1RFΔsrtA and OG1RFΔsrtA/srtA stained with SYTO9 (green) and PI (red). Scale, 1 
unit on each side of the grid =14.3µm. White arrows indicate SYTO9-PI stained fibers. Scale 
bar=10µm. 
33 
 
DISCUSSION 
Despite the identification of a myriad of genetic factors and cellular processes 
involved in E. faecalis biofilm formation91,92,103,104,106,109,114,115,145-150, the molecular 
mechanisms underlying E. faecalis biofilm are yet to be defined.  In this study, two major 
steps are delineated during E. faecalis biofilm formation: an initial attachment stage 
involving binding to an abiotic surface followed by an accumulative phase during which 
intercellular interactions to generate mature multicellular 3D biofilm structures. This 
report provides evidence of the temporal and spatial contribution of Atn-mediated 
autolytic processes and of the housekeeping sortase (SrtA) during biofilm formation.  
The extracellular matrix of bacterial biofilms provides a safe haven for microbes 
within the community protecting them from various environmental stresses42,47. eDNA is 
a crucial structural component of the extracellular matrices of both Gram-negative and 
Gram-positive bacteria biofilms. This macromolecule mediates primary attachment, cell-
to-cell adhesion, mature 3D biofilm architecture, and antimicrobial activities122,125,128,151-
153. Thomas et al. showed that the vancomycin-resistant strain E. faecalis (V583) is 
unable to produce biofilms in presence of DNase I104. Similarly, E faecalis OG1RF strain, 
used in this study, is defective in biofilm formation following DNase I treatment. This 
enzyme can also disintegrate mature OG1RF biofilms, implying that eDNA is an 
important component of the extracellular matrix of E. faecalis biofilms and that this 
macromolecule is involved in cellular clustering during biomass accumulation. Although 
eDNA has similar functions under static and hydrodynamic conditions, its spatial 
contribution varies. Static biofilms are more compact with higher cell densities than 
biofilms formed in the presence of shear forces. Under hydrodynamic conditions, E. 
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faecalis produces a DNase I-sensitive fibrous network, reminiscent of a stable fibrous 
eDNA network of the aquatic Gram-negative bacterium strain F8154,155. Likewise, 
nontypeable Haemophilus influenza biofilms formed in vivo contain extracellular fibrous 
DNA networks156 derived from neutrophil extracellular traps157. Notably, Kristich et al. 
also reported the presence of a filamentous extracellular network in enterococcal biofilms 
of both wild type and transposon-inactivated atn mutant strains grown statically on 
nitrocellulose membranes109. However, the composition of this structure was not 
characterized.  
Previous reports have implicated Atn in primary attachment and biofilm 
production92,109, but its contribution to this process, especially in DNA release, remains to 
be established. Atn is an important mediator of cell length and cell lysis during E. 
faecalis growth. Unlike autolysins described for other Gram-positive bacteria such as Aae 
and AtlE in S. epidermidis127,133, Atn contributes to initial adhesion in a DNA-
independent fashion. Inactivation of this autolysin leads to increased cellular 
chaining139,158 that may reduce binding sites or increase cell surface charges causing 
lower cell deposition rate, thus explaining the adherence defects observed in atn-deficient 
strains. Repulsive interactions occurring between abiotic surfaces and bacteria as well as 
between adherent cells and incoming cells caused by surface charges were previously 
shown to influence the initial adhesion of bacteria to substrata159,160. Alternatively, 
defects in autolytic processes may alter the cell wall structure and localization of surface 
proteins required for attachment during biofilm formation, resulting in the deficient 
attachment and reduced biomass observed following atn deletion. In streptococcal 
species, biofilm production and bacterial colonization of abiotic surfaces are decreased 
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with disruption of srtA and genes encoding SrtA-dependent cell wall proteins161,162. The 
enterococcal housekeeping sortase (SrtA) is a biofilm-promoting factor. In contrast to 
previous reports for E. faecalis106, deletion of srtA, in the present study, severely 
hampered adherence to plastic substrata and subsequent biofilm growth, especially under 
hydrodynamic conditions. These observations corroborate findings of Kristich et al. 109 in 
which transposon-mediated disruption of srtA results in approximately 30% decreased 
biofilm biomass compared to the parental strain using the microtiter biofilm assay. 
Together, these findings argue that SrtA plays a critical role in biofilm development in E. 
faecalis, especially in presence of shear forces. Sortase-dependent substrates have diverse 
functions ranging from adhesion and biofilm formation to immune evasion during 
pathogenesis163,164. LPXTG surface proteins, including aggregation substance (AS), the 
enterococcal surface protein (Esp), the endocarditis and biofilm-associated pilus (Ebp), a 
member of the microbial surface component recognizing adhesive matrix molecules 
(MSCRAMMs) (ace), and the recently characterized EF3314, are the most studied 
proteins in E. faecalis and E. faecium. They mediate binding to host extracellular matrix 
proteins such as collagen and fibrinogen and promote enterococcal biofilm formation and 
virulence in animal models of enterococcal pathogenesis, including endocarditis and 
UTI145,150,165-169. Sortases and sortase substrates are thus attractive drug targets given that 
most of these cell wall proteins are involved in bacterial virulence. However, since srtA-
deficient mutant biofilm are sensitive to DNase I treatment, it is unlikely that this gene 
plays a role in DNA release. 
DNA release occurs from autolytic processes or competence induction in 
bacteria121,126,151. Freeze-dry electron micrographs in this study reveal extracellular fibers 
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protruding from lysed cells present in enterococcal biofilms. The findings reported here 
demonstrate that Atn is involved in DNA release during the accumulative phase of 
biofilm development in E. faecalis. This is in agreement with several reports highlighting 
the contribution of autolytic processes during biofilm formation121,170,171. Recently, the 
enterococcal proteases GelE and SprE, both under positive regulation of the fsr quorum 
sensing signaling, were shown to contribute to biofilm formation by regulating cellular 
autolysis104. GelE mediates DNA release during planktonic and biofilm modes of growth, 
in contrast to SprE, which acts as a negative regulator of autolysis and biofilm 
production. It is thus postulated that during biofilm formation fratricidal mechanisms 
underlie cell death and DNA release, which may result from the interactions between 
GelE and Atn103,121. However, certain E. faecalis laboratory and clinical strains, including 
OG1X further discussed in the second chapter of this dissertation, are able to produce 
biofilms in the absence of GelE172, implying that E. faecalis may also employ GelE-
independent DNA-dependent or independent mechanisms for biofilm formation.  
Atn-mediated DNA release occurs at a specific time during the biofilm process. 
This finding implicates a temporal regulation of DNA release during biofilm formation. 
DNA release may occur in response to a particular cell density. It is possible that upon 
reaching critical mass following initial attachment, E. faecalis activates the fsr-quorum-
sensing signaling pathway and the expression of autolytic factors, such as GelE and SprE. 
GelE cleavage of Atn, shown to occur in vitro103, may then induce Atn-mediated cell 
death in a subpopulation103 leading to DNA release and biofilm maturation and 
stabilization.  
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However, the ability of atn-deficient strains to produce DNA-dependent biofilms, 
albeit in a delayed fashion, is consistent with slower accumulation of eDNA from the 
actions of other autolytic factors in E. faecalis134,173. Mesnage et al. characterized two 
additional peptidoglycan hydrolases, AtlB and AtlC, in the JH2-2 strain of E. faecalis, 
which they showed to have compensatory functions in cell separation and autolysis in the 
absence of the major N-acetylglucosaminidase, AtlA or Atn134. It is likely that DNA 
release is the result of the synergistic activities of these autolytic enzymes during the 
establishment of E. faecalis biofilms. Further research is thus warranted to identify the 
regulatory pathway leading DNA release during biofilm formation.  
Biofilm formation is a complex and highly regulated process involving a 
combination of genetic and environmental factors critical for specific developmental 
stages174. The present study uncovered a critical function for SrtA and provided strong 
evidence for the role of Atn in DNA release and biofilm production. Further research is 
required to identify SrtA-dependent proteins important for biofilm formation, in addition 
to those already characterized and involved in biofilm production, adherence to host cells 
and virulence in several models of enterococcal infections166-169,175,176. As an 
opportunistic pathogen, it is conceivable that E. faecalis employ several mechanisms to 
establish biofilms. eDNA is a critical component of the extracellular matrix of DNA-
dependent biofilms produced by E. faecalis as well as E. faecium and E. 
gallinarum clinical isolates (data not shown). eDNA is crucial for maintaining the 
architectural integrity and the stability of enterococcal biofilm. The events mediating 
DNA release, localization, and interactions with other components of this protective 
structure require further investigation. Identifying the components and the regulatory 
38 
 
network of the extracellular matrix of enterococcal biofilms will be of great importance 
in the eradication of these pathogens. 
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CHAPTER TWO 
BIOFILM FORMATION IS CRITICAL FOR ENTEROCOCCAL VIRULENCE 
IN AN OPTIMIZED MURINE MODEL OF FOREIGN BODY-ASSOCIATED 
URINARY TRACT INFECTIONS 
Modified from:  
Guiton, P.S., et al. (2009) Infect Immun. and 
Guiton, P.S., et al, manuscript in preparation 
ABSTRACT 
Catheter-associated urinary tract infections (CAUTIs) constitute the majority of 
nosocomial UTIs and pose significant clinical challenges. The insertion and presence of 
urinary catheters elicit major histological and immunological changes that render the 
bladder susceptible to microbial invasion, colonization, and dissemination. Enterococcal 
species are among the predominant causative agents of CAUTIs. However, very little is 
known about the pathophysiology of enterococci-mediated UTIs.  This study optimizes a 
rodent model of foreign body-associated UTI in order to mimic conditions of indwelling 
urinary catheters in patients.  Studies in this model uncover valuable details of the 
molecular constituents of foreign body-induced inflammatory responses and demonstrate 
their ineffectiveness against E. faecalis in catheterized animals.  Enterococcal biofilm 
formation on the foreign body in vivo is essential for the establishment of persistent UTIs 
in the face of the massive inflammatory response ensuing from urinary implantation. 
Notably, only a subset of enterococcal in vitro biofilm-promoting factors, including 
sortases, is critical for biofilm formation and urovirulence.  Overall, this murine model 
represents a significant advance in the understanding of CAUTIs and underscores the 
contribution of urinary catheterization to E. faecalis uropathogenesis.  It is also a valuable 
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tool for the identification of biofilm and virulence determinants that can serve as potential 
antimicrobial targets for the treatment of enterococcal infections.  
INTRODUCTION 
Urinary catheterization is the primary cause of 80% of hospital-acquired UTIs177. 
The insertion and presence of indwelling urinary catheters disrupts the normal 
mechanical and host defenses of the urinary tract, allows extracellular microbes access 
into the sterile environment of the bladder by ascending through the catheter lumen or 
from the urethral meatus along the catheter, and provides an additional surface for 
biofilm formation and the establishment of persistent infections30,32-36,178,179. Even in the 
absence of microbial colonization, urinary catheterization is associated histological and 
immunological alterations in the bladder, including bladder wall edema, inflammatory 
cytokine production, immune cell infiltration, and mucosal lesions of the bladders and 
kidneys 26-30 which can lead to bladder cancers180,181. However, the molecular 
mechanisms underlying these responses require further research. The high incidence rate 
coupled with the medical and economic hurdles associated with catheter-associated 
urinary tract infections (CAUTIs) underscore the need for a better understanding of 
CAUTI pathogenesis.  
Enterococci, infrequently associated with community-acquired UTIs, play a 
prominent role in the pathogenesis of CAUTIs56. E. faecalis is among the predominant 
pathogens isolated from polymicrobial communities on the surface of indwelling urinary 
catheters and biliary stents182-186. However, the mechanisms underlying E. faecalis 
uropathogenesis are poorly defined. Several rodent models have been developed to 
investigate E. faecalis pathogenesis in the urinary tract in single and mixed infections 
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with other Gram-negative pathogens105,187-191.  These models involve the transurethral 
inoculation of low to high volumes of bacterial suspensions (50 to 200µl containing 107 
to 108 CFU bacteria) into the bladders of healthy or streptozocin-induced diabetic 
animals191. The experimental conditions defined by these models are primarily useful for 
the study of E. faecalis-mediated pyelonephritis, but are inadequate for the investigation 
of persistent enterococcal CAUTIs as the bacteria are readily cleared from the bladder 
and fail to establish chronic cystitis105,190,191. Nonetheless, findings obtained from studies 
in these models have implicated several enterococcal factors in UTI pathogenesis, 
including the enterococcal surface protein Esp105, the enterococcal biofilm and pilus-
associated sortase C (SrtC or bps)106, and the endocarditis and biofilm-associated pilus 
(Ebp)145. However, well-characterized adhesins and biofilm determinants often associated 
with enterococcal UTI isolates192,193 such as the aggregation substance (AS) and the 
housekeeping sortase (SrtA)108,109, were reported to be dispensable for virulence in the 
urinary tract106,108.  Since these conclusions were drawn from models where persistent 
infections cannot be established, it is imperative to re-examine the existing paradigm in 
an animal model that better mimics the transition of E. faecalis from a commensal to a 
virulent pathogen in the urinary tract.  
This present study reports the optimization and use of a rodent model of foreign 
body-associated UTI developed in rats by Kurosaka et al.29 and adapted in mice by 
Kadurugamuwa et al.194 to investigate the pathophysiology of enterococcal CAUTIs. The 
report details unappreciated characteristics of the physiological changes in the bladder 
ensuing from urinary implantation. Findings from this murine model substantiate the 
allegations that biofilm formation is a major enterococcal virulence factor that is critical 
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for the establishment of persistent cystitis and pyelonephritis. Of the enterococcal in vitro 
biofilm determinants examined thus far, the enterococcal sortases and pili, as well as the 
enterococcal enhanced expression of pheromone (Eep) metalloprotease and the 
transcription factor AhrC from the ArgR family, contribute to uropathogenesis in 
catheterized animals whereas the autolytic factors GelE and Atn are dispensable.  This 
optimized murine model is thus well suited to identify host and enterococcal factors 
critical for pathogenesis in the urinary tract and will provide a better understanding of the 
mechanisms underlying the pathophysiology of CAUTIs.   
RESULTS 
Part I: Optimization and characterization of the murine model of foreign body-
associated UTIs.  
Urinary implantation elicits severe histological changes in the murine bladder akin to 
observations in human urinary catheterization. In order to study the pathophysiology of 
CAUTI associated with the presence of urinary catheters, 4-5mm long pieces of silicone 
tubing (implant) were transurethrally introduced into the bladders of seven to eight week 
old C57BL/6Ncr female mice as described in the Materials and Methods section and 
illustrated on Fig. 14. Silicone was chosen instead of polyethylene tubing29 as it is the 
most common material used in All Silicone Foley urinary catheters in humans195,196. The 
recovery of silicone implants inside the murine bladders on the day of animals sacrifice 
was greater than 95% at 24h and approximately 75% seven days following implantation 
(data not shown). The data presented here represent animals with bladder implant at the 
time of sacrifice.  
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Compared to non-implanted animals (Fig.15A and D), histological analyses of 
H/E stained bladder sections 24h post implantation reveal mucosal hyperplasia, 
submucosal edema with polymorphonuclear leukocyte (PMN) infiltration into the lamina 
propria and epithelium, and urothelial sloughing in implanted animals (Fig.15B and E). 
Damage to the uroepithelium in implanted bladders was also observed by 
immunofluorescence microscopy using anti-uroplakin III antibody, which stains the 
luminal surface of the terminally differentiated superficial umbrella cells of the bladder.  
Comparison of bladder sections at 24 h post implantation showed discontinuity of 
uroplakin staining of implanted bladders (Fig. 15H) versus continuous epithelial staining 
of non-implanted bladders (Fig. 15G), indicating the loss of superficial umbrella cells in 
the former. These data suggest that implantation with a foreign body elicits major 
 
Figure 13: Schematic of transurethral urinary implantation.  
Silicone implant is transurethrally introduced in the murine bladder by pushing a 
section of polyethylene tubing (PE) into the urethra with the help of tweezers.  
The silicone implant can remain in the bladder at least 7 days post implantation.  
Adapted from Reference 29. 
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architectural changes in the bladder associated with activation of the host immune 
response. 
 
Implant-mediated bladder edema and vascular permeability occurs independently of 
the neurogenic inflammatory pathway. The onset of bladder wall edema, classic 
 
Figure 14: Implantation-mediated histological changes are associated with enterococcal 
colonization of the murine bladder.   
(A-F) H/E staining of bladder sections from PBS-treated non-implanted (A, D), PBS-treated 
implanted (B, E), or OG1RF infected implanted (C, F) mice 24 hpi observed under light 
microscope at 40X (A-C) and 63X (D-F) magnifications. Arrow in (E) indicates damage to the 
uroepithelium. U=uroepithelium, LP=lamina propria, L=lumen, M=muscularis. (G-I) 
Representative CLSM images of the sections from the same animals as in (A-F) immunolabeled 
with goat anti-mouse uroplakin III (green), rabbit anti-Lancefield Group D antigen (red), and 
counterstained with TOPRO-3 nuclear dye (blue). Dashed line separates the lumen (L) from the 
uroepithelium surface (U). Scale bar =10µm. 
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consequence of urinary catheterization in humans30, was further assessed by bladder 
weight determination at 3, 6, 9, 12, 18, and 24h post implantation and compared to non-
implanted animals. The murine bladder of implanted animals significantly increases in 
weight as early as 3h post implantation (p=0.0011 by the Mann Whitney U test) and 
reaches approximately 60mg by 24h (Fig.16A). Histological analysis of H/E stained 
bladder tissue sections from implanted animals at each time point depicts the gradual 
progression of bladder wall edema over time, corroborating the significant increase in 
bladder weight (Fig. 16B). The implant-induced edema can be attributed to plasma 
protein extravasation (PPE) in the tissue as assessed by Evans blue extravasation assay 
performed 6h post implantation (Fig. 16C). Approximately 60µg of Evans blue per gram 
of bladder tissue was extravasated and recovered from implanted bladders following 
intravenous injection in the murine tail vein, a significantly higher amount compared to 
40µg/g from non-implanted controls (p=0.0348).  
Bladder wall edema and vascular permeability are hallmarks of the neurogenic 
inflammatory pathway in the urinary tract in response to chemical irritants such as 
cyclophosphamide, capsaicin, and bacterial endotoxin197,198. The neurogenic 
inflammatory pathway is activated in response to the stimulation of sensory neurons 
innervating the bladder and the release of proinflammatory neuropeptides such as 
substance P, neurokinin A, and calcitonin gene-related peptide (CGRP)197, which induces 
edema, neutrophil infiltration, the formation of reactive oxygen species, and contribute to 
pain197,198. This neurogenic inflammation can be inhibited by administration of specific 
small molecules inhibitors, including CP-99,994 and CP-96,345 which are specific 
neurokinin 1 receptor (NK1R) antagonists199-202, aminoguanidine (AG) which is an 
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irreversible inhibitor of the inducible nitric oxide synthase (iNOS)203-205, and alfuzosin 
which is an antagonist of alpha 1 adrenoreceptors present on the surface of sensory 
neurons206. To assess the contribution of the neurogenic inflammatory pathway in 
implant-induced edema, animals were treated with CP-99,994 or CP-96,345 (5-10mg/kg, 
i.p. or i.v.) and AG (200mg/kg, i.p.) administered respectively 30 min and 1h prior to 
implantation. A second dose of each compound was given 3h post implantation and PPE 
was assessed 6h post implantation. Phosphate buffered saline (PBS) or appropriate 
vehicle control was administered in the same manner as in the treatment group.  No 
inhibitory effects were observed following treatments with neurogenic pathway 
inhibitory chemicals. PPE occurs at similar levels (~60ug/g) in compounds-treated 
implanted animals and vehicle-treated implanted animals (Fig.16C). Likewise, these 
treatments do not alter the increase in bladder weight post implantation (data not shown). 
Similar to the NK1R and iNOS inhibitors, preliminary evidence suggests that treatment 
with alfuzosin (60µg/kg, i.v.) does not prevent bladder weight increase nor inhibit 
vascular permeability in implanted bladders (data not shown). Additionally, no detectable 
levels of SP, the NK1R ligand that induces neurogenic inflammation, could be detected 
by mass spectrometry in implanted animals for 3h (data not shown). Immunofluorescence 
microscopy of implanted and non-implanted bladders at 6h and 24h stained with 
antibodies raised against SP and NK1R reveal no major changes in the expression or 
localization of these two mediators of neurogenic inflammation (data not shown). 
Together, these findings indicate that the NK1R-induced neurogenic inflammation is not 
a major contributor in the onset of bladder wall edema and vascular permeability.  
47 
 
Urinary implantation leads to the upregulation of specific inflammatory markers and 
the specific recruitment of myeloid-derived cells in the murine bladder. To identify the 
 
Figure 15: Urinary implantation induces edema and plasma protein extravasation.   
(A) Bladder weights of non-implanted (control) and implanted (+)at the indicated time (B ) H/E 
staining of bladder sections from non-implanted and implanted animals at indicated time points 
observed under light microscope at 10X magnification.  (C) Plasma protein leakage in bladder 
tissue determined by Evans blue content at 6hpi in non-implanted animals treated with saline and 
implanted animals treated with saline, dexamethasone (10mg/kg, i.p.), aminoguanidine (AG, 2 
doses of 200mg/kg i.p.), CP99994 (2 doses 5mg/kg, i.p.). (D) Bladder weights at 24hpi of non-
implanted and implanted mice in presence or absence of E. faecalis OG1RF strain. Graphs 
represent the mean of each dataset from at least two independent experiments; Error bars=SEM; 
*p<0.05, ns: p>0.05 by the Mann Whitney U test. 
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soluble and cellular constituents of the bladder immunological responses to the silicone 
implant, multiplex bead arrays and flow cytometry assays were performed on bladder 
homogenates and suspensions in non-implanted and implanted animals at 24h post 
implantation.  Of the 23 cytokines examined, only interleukin 6 (IL-6), G-CSF 
(Granulocyte-Colony Stimulating Factor), and KC (Keratinocyte-derived Cytokine) were 
consistently present in implanted bladder homogenates at least two-fold above the levels 
of non-implanted animals at 24 hpi (Fig. 17). Conversely, GM-CSF (Granulocyte 
Monocyte-Colony Stimulating Factor) and MIP-1α (Macrophage Inflammatory Protein 1 
alpha) showed at least two fold decreased expression in implanted animals compared to 
non-implanted animals 24 hpi (Fig. 17). Flow cytometry experiments reveal that 
CD11b+Gr1+ myeloid cells account for approximately 15% of the live population in 
implanted animals compared to 1% in non-implanted controls (p<0.0001; Fig.18A). No 
difference was observed in lymphocyte numbers in presence or absence of implant at 
24hpi (Fig. 18A). Specific markers were used to further specify the myeloid cells. This 
analysis reveals a 1-2 log increase in eosinophils (SiglecF+), basophils (FccR1+), and 
monocytes (CD11b+Ly6G-Ly6C+) specifically in implanted animals (Fig.18B).  
Additionally, macrophages (CD11b+F4/80+MHCII- and CD11b+F4/80+MHCII+) are 
present with approximately 1 and 1.5 log, respectively, over non-implanted controls (Fig. 
18B). Neutrophils (CD11b+Gr1+Ly6GhiLy6Clo) are the most abundant immune cells 
recruited in response to urinary implantation with approximately 3 log more cells relative 
non-implanted controls (Fig. 18B).  Further studies using an antibody raised against the 
neutrophil-specific receptor NB1 (also known as CD177)207 corroborates the above 
findings that PMNs are the major immune infiltrates in implanted murine bladders (data 
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not shown). There was no change in the number of dendritic cells 
(CD11b+CD11c+MHCII+/-) or mast cells (cKit+) present in implanted animals compared 
to non-implanted controls (data not shown). Together, these results indicate that the 
silicone implant elicits a specific inflammatory response in the bladder characterized by 
the up-regulation of pro-inflammatory cytokines and myeloid infiltrates. 
 
 
 
Figure 16: Cytokine profiles following urinary implantation with and without enterococcal 
challenge.  
Graph represents whole bladder cytokine expression of implanted animals inoculated with PBS 
(gray bars) or OG1RF (black bars) at 24 hpi. Cytokines reported are expressed with at least two-
fold difference relative to non-implanted controls.  Data from a representative experiment of 4 
independent experiments with n=5mice/condition/experiment. Error bars =SEM.  *p<0.05, p-
value by the Mann Whitney U test. 
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Figure 17: Neutrophils are important cellular infiltrates during enterococcal CAUTI.  
Cellular infiltrates from non-implanted (white bars), implanted (black bars), or implanted and 
infected with E. faecalis OG1RF (gray bars) at 24hpi derived from flow cytometry analysis. Non-
activated and activated macrophages (CD11b+F4/80+MHCII- and CD11b+F4/80+MHCII+, 
respectively), neutrophils (CD11b+Ly6GhiLy6Clo), monocytes (CD11b+Ly6G-Ly6C+), eosinophils 
(SiglecF+), and basophils (FccR1+). Data are the mean derived from at least two independent 
experiments with n=3-5/experiment/condition; Error bars represent SEM; *p<0.05, **p<0.005, 
***p<0.0005 value by the Mann Whitney U test.   
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Part 2: Enterococcal biofilm formation and virulence following urinary 
implantation 
E. faecalis establishes persistent infections in the bladders and kidneys in an optimized 
murine model of CAUTI.  In order to study the pathophysiology of E. faecalis-mediated 
CAUTIs, mice were inoculated with 1-3.5x107 CFU of E. faecalis strain OG1RF by 
transurethral catheterization immediately following urinary implantation. In mock-
infection studies with PBS, no bacteria were recovered from implants or organs (data not 
shown).  At 24-hour post infection (hpi), OG1RF is recovered from the implants with a 
median of 9.76x105 CFU/ml (Fig. 19A).  Bacterial titers on the abiotic surfaces increase 
significantly over the course of the infection (7 days) to a median of 8.64x106 CFU/ml 
(Fig. 19A).  In implanted animals, OG1RF reaches a median titer of 3.2x106CFU/ml 24 
hpi in the bladders, which is significantly higher (p=0.0011) than bacterial titers 
(2.7x103CFU/ml) recovered from the bladders of non-implanted animals (Fig. 19B). 
Similarly, bacterial titers from the kidneys increase significantly from 24 hpi to 7 dpi in 
implanted animals (Fig. 19C).  OG1RF was readily cleared from the bladders and the 
kidneys within 48 hpi in the absence of implants (Fig. 19B-C). In addition, bacterial titers 
are significantly lower in tissues derived from animals that have lost their implants during 
the course of infection compared to tissues with retrieved implants (Fig. 20), with the 
exception of bladder titers at 48 hpi (p=0.0737) and kidneys titers at 72 hpi (p=0.130) 
(Fig. 21). These data suggest that the presence of the implants contributes to increased 
bacterial colonization and persistence in the urinary tract.  
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Figure 18: E. faecalis establishes persistent colonization of silicone implants, bladder, and 
kidneys in a murine model of CAUTI.   
 (A) Bacterial titers on logarithmic scale (log scale) from silicone implants retrieved from 
female C57Bl/6Ncr mice infected with OG1RF for 24, 48, 72 hpi, and 7 dpi. (B-C) Graphs 
represent bacterial titers from homogenized bladders (B) and kidneys (C) from non-implanted 
(○) or implanted (●) of animals infected with OG1RF for 24, 48, 72 hpi, or 7 dpi.  Horizontal 
dashed lines represent the limit of detection for viable bacteria. Each symbol represents a mouse 
from two independent experiments with n=5/condition. The horizontal bars represent the 
median of each dataset; *p<0.05, **p<0.005, and ***p<0.0005 by the Mann Whitney U test.  
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E. faecalis produces biofilm on the surface of the silicone implant in vivo.  To 
determine whether bacteria recovered from silicone implants are within biofilms, we 
examined 15 implants retrieved 72 hpi from murine bladders from three independent 
experiments by scanning electron microscopy (SEM).  In mock-infection, the implants 
were coated on the outside and in the lumen with host factors found in the urine as 
previously reported208 (data not shown).  A similar film appears on 12 implants retrieved 
from animals infected with OG1RF.  In approximately 70% of the silicone implants 
retrieved from infected animals, bacteria are readily observed in clumps both on the outer 
surface (Fig. 21A-B) or filling the entire lumen (Fig. 21C-F). The coccoid 
 
Figure 19: Implant loss from murine bladders correlates with lower bladder and kidney 
infection.   
Graphs represent bacterial titers in log scale recovered from the bladders (A) and the kidneys (B) 
of animals that have lost the implants (L-○) or retained the implants (R-●) at the indicated time of 
sacrifice. Experiment was done at least 3 times with n=5/experiment.  The horizontal dotted line 
depicts the limit of detection.  The horizontal bar represents the median of each dataset, *p<0.05, 
**p<0.005, ns = p>0.05 by the Mann-Whitney U test.  
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microorganisms are embedded in a thick extracellular matrix (Fig. 21E-F). The reason for 
the absence of biofilms from the remaining implants is not certain, but could be attributed 
to sample processing prior to visualization since those animals also exhibited 
significantly enhanced infection in the bladders and kidneys. These findings indicate that 
enterococcal biofilms are produced in vivo on indwelling silicone material during the 
course of the infection. 
 
 
Figure 20: E. faecalis produces biofilms on the surface of silicone implants in vivo.  
Representative scanning electron micrographs of silicone implants retrieved from murine 
bladders infected with OG1RF at 72 hpi showing bacterial biofilms on the outer surface (A-B) 
and the filling the lumen (C-F) of the silicone implant. Bacteria (white arrowhead) are often 
associated with host cells, indicated by black arrowhead in (C). Both bacteria and host immune 
cells can also be found embedded in a thick extracellular material, indicated by arrow, in the 
lumen of the silicone implant 72 hpi (E-F). Areas in the black box on (A, C, E) are magnified in 
(B, D, F). Scale bars in µm: 20 (A, C), 5 (B, D, F), and 100 (E).  
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E. faecalis enhances the inflammatory response in implanted animals.  The histology 
of the uroepithelium of implanted bladders following infection with E. faecalis OG1RF is 
similar to that of mock-infected implanted animals in that the bladder remains edematous, 
distended, and sometimes hemorrhagic (Fig.15C and F). In contrast, non-implanted 
bladders infected with OG1RF show no major histological changes and appear similar to 
the bladders of mock-infected non-implanted controls (data not shown), in agreement 
with previous reports with other E. faecalis strains190. Immunolabeling of E. faecalis with 
antibody against the Lancefield streptococcal group D antigen in histology sections show 
bacterial staining in the bladder lumen of infected animals with implants (Fig. 15I). E. 
faecalis is also found in association with the surface of the uroplakin-positive and 
uroplakin-negative uroepithelium and occasionally found in the submucosal areas (Fig. 
22). In contrast, very few bacteria were observed in the bladders of non-implanted 
animals 24 hpi (data not shown). No labeling was observed in mock-infected animals 
with or without implants (Fig. 15G and H), reaffirming the specificity of the antibody 
staining. Furthermore, enterococcal challenge does not affect murine bladder weight in 
presence or absence of urinary implants, as shown in Fig. 16D. The presence of E. 
faecalis slightly enhances the expression of IL-6, IL-12(p40), G-CSF, and KC and 
specifically induces the production of IL-1β and MIP-1α (back to non-implanted levels) 
in implanted animals compared to implanted mock-infected controls (Fig. 17). E. 
faecalis OG1RF infection of non-implanted animals results in no significant changes in 
the expression of the cytokines tested compared to mock infection (data not shown). 
Similar to uninfected implanted animals, CD11b+Gr1+ myeloid cells are the majority of 
cellular infiltrates at 24h in implanted animals with E. faecalis infection (Fig. 18A). They 
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account for approximately 30% of live populations in these animals, significantly higher 
than implanted controls in the absence of E. faecalis (p<0.00001).  This increase in 
myeloid cells in presence of E. faecalis is primarily due to the recruitment of neutrophils 
with a significant increase of approximately 1 log over mock-infected implanted controls 
(p<0.001) (Fig.18B). Interestingly, similar numbers of macrophages, monocytes, 
basophils, and eosinophils are present in the bladders of implanted animals even in 
presence of E. faecalis (Fig. 18B), indicating that recruitment and activation of these 
immune cells occur specifically in response to the silicone implant. There are no 
significant changes in the number of dendritic cells (CD11b+CD11c+MHCII+/-) present in 
implanted animals compared to non-implanted controls even in presence of E. faecalis 
(data not shown).  
 
 
Figure 21: E. faecalis localization in implanted animals.  
Representative CLSM images of bladder sections from implanted mice infected with OG1RF 24 
and 72hpi immunolabeled with antibodies against uroplakin III (green), Lancefield Group D 
antigen (red), and counterstained with TOPRO-3 nuclear dye (blue). Bacteria are present in the 
bladder lumen (A), uroepithelial surface (B), and areas denuded of uroplakin staining (C).  Scale 
bar =28µm (A) 5µm (B) and 14 µm (C).  
57 
 
Part 3: Relative contributions of known biofilm determinants to E. faecalis 
uropathogenesis  
To assess the role of biofilm formation in enterococcal colonization of and persistence in 
the urinary tract, implanted animals were infected with OG1RF, a gelatinase-defective 
strain OG1X, or OG1RF isogenic in frame deletion mutants of known biofilm 
determinants.  
E. faecalis biofilm formation and virulence in the urinary tract occur independently of 
autolytic factors. OG1X is a nitrosoguanidine-induced gelatinase (gelE)-defective mutant 
of the oral isolate OG1, the same parental strain as OG1RF209. Despite OG1X defect in 
gelatinase production, this strain produces biofilms to a similar extent as OG1RF on PVC 
coverslips in TSBG at 37ºC under static conditions as determined by crystal violet 
staining-based quantification (Fig. 23A). Notably, OG1X biofilms are also sensitive to 
DNaseI treatment under these conditions.  Yet, when introduced in implanted animals, 
OG1X is recovered at significantly lower CFU than OG1RF from implants and bladders 
(p<0.0001) and is unable to ascend to the kidneys following urinary implantation 24hpi 
(Fig. 23B), indicating a severe attenuation in urovirulence.  This observation led to the 
hypothesis that GelE may be necessary for virulence in the urinary tract. However, 
infection of implanted animals with an OG1RF isogenic gelE-deficient strain 
(OG1RF∆gelE) causes similar colonization patterns as the parental strain (Fig. 23C), with 
slightly (albeit significant, p=0.0002) higher bacterial titers recovered from implants 
24hpi. Furthermore, deletion of the major autolysis atn critical for DNA release during in 
vitro biofilm formation does not affect virulence in this murine model up to 7 days post 
infection (Fig. 23D and data not shown). Together, these data indicate that the autolytic 
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factors GelE and Atn (see chapter one) are dispensable for enterococcal virulence and 
OG1X may harbor additional mutations in genes required for urovirulence.  
 
 
Figure 22: GelE and Atn are dispensable for enterococcal virulence in implanted animals. 
(A) Comparison of OG1RF and OG1X biofilm formation on PVC coverslips in presence and 
absence of 5µg/ml of DNaseI in TSBG at 37ºC for 24h. n=3 independent experiments. Error 
bars=SEM (B-D) Graphs represent CFU enumeration of OG1RF, OG1X, OG1RF isogenic in-
frame gelE- and atn-deficient mutants recovered from retrieved implants, bladders and kidneys 
24 hpi with each strain. Horizontal dashed lines represent the limit of detection for viable 
bacteria. Each experiment was performed in duplicate n=4-5/strain/experiment. The horizontal 
bars represent the median of each dataset; *p<0.05; ***p<0.0005, ns = p>0.05 by the Mann 
Whitney U test.  
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Both enterococcal sortases contribute to implant and urinary tract colonization.  
The housekeeping and pilus-associated sortases, SrtA and SrtC respectively, are 
important mediators of biofilm formation106,109,210. Additionally, deletion of srtC results 
in attenuation of E. faecalis virulence in a murine model of ascending UTIs106. In contrast 
to GelE and Atn, infection of implanted mice with srtA-deficient OG1RF strain 
(OG1RFΔsrtA) causes a 105-fold decrease in bacterial titers recovered from the implants 
(Fig. 24A) and an approximately 103 decrease in CFUs from both bladders and kidneys 
compared to wild type infection (Fig. 24B-C).  This defect can be partially rescued by 
ectopic expression of a wild type copy of srtA in OG1RFΔsrtA. The complemented strain 
OG1RFΔsrtA/srtA (OG1RFΔsrtAc) is recovered at levels similar to wild type titers from 
the implants and organs (Fig. 24A-C). The lack of full complementation is not entirely 
understood, but may be due to plasmid loss during infection based on higher colony 
counts in the absence of selective antibiotic. A similar attenuation in virulence is 
observed upon deletion of srtC (Fig. 24A-C) whereby OG1RFΔsrtC is recovered at 
significantly lower titers from the implants (p=0.0017), the bladder, and the kidneys 
(p<0.0001 and p=0.0031, respectively) compared to wild type OG1RF. Similar findings 
are observed at 48 hpi (data not shown).  Scanning electron micrographs reveal very few 
OG1RFΔsrtA cells present on the surface or in the lumen of retrieved implants 72 hpi in 
contrast to the complemented strain, the atn-deficient, or wild type strains that heavily 
colonize the implants (Fig. 24D). These results indicate that contrary to GelE and Atn, 
SrtA and SrtC or more specifically, SrtA-dependent substrate(s) and the enterococcal 
pilus (Ebp) (data not shown), are involved in biofilm production and necessary for full 
virulence in the urinary tract of implanted animals.  
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Eep and AhrC contribute to E. faecalis pathogenesis in the urinary tract. The 
enterococcal enhanced expression of pheromone (Eep) protein is a metalloprotease 
 
Figure 23: Sortase A is critical for implant colonization and virulence in the urinary tract. 
(A-C) Graphs represent bacterial titers from retrieved implants (A), homogenized bladders (B), 
and kidneys (C) from implanted mice infected for 24 hrs with OG1RFwt (●), OG1RFΔsrtC(◊) 
OG1RFΔsrtA (□), or OG1RFΔsrtA/srtA (■). Horizontal dashed lines represent the limit of 
detection for viable bacteria. Each symbol represents a mouse and each experiment was done at 
least twice with n=5/strain. The horizontal bars indicate the median of each dataset; *p<0.05, 
**p<0.005, ***p<0.0001, and ns for p>0.05 by the Mann Whitney U test. (D) Representative 
scanning electron micrographs of silicone implants retrieved from murine bladders 72 hpi with 
OG1RFwt, OG1RFΔsrtA, OG1RFΔsrtA/srtA (ΔsrtAc), and OG1RFΔatn. Scale bars = 5µm for 
OG1RFwt, OG1RFΔsrtA, and OG1RFΔsrtAc; 2.5µm for OG1RFΔatn. 
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involved in the processing of sex pheromones during conjugation211,212. RIVET screens 
identified the eep locus as one of several transcriptionally upregulated promoters during 
E. faecalis biofilm formation in vitro and in	  vivo114,213.  Furthermore, in-frame deletion of 
eep in OG1RF in the absence of all conjugative plasmids results in significant virulence 
attenuation in a rabbit model of endocarditis, indicating this metalloprotease also has a 
role in virulence that is unrelated to conjugation/sex pheromones (Frank, K.L. et al, 
unpublished and personal communication).  Preliminary evidence suggests that 
OG1RF∆eep has altered biofilm architecture relative to the parental strain (Frank, K.L., 
et al, unpublished and personal communication). Similarly, transposon insertion in 
ef0983, a locus encoding a member of the ArgR family of transcription factors (ahrC), 
results in biofilm defects109 and virulence attenuation in the rabbit model of endocarditis 
(Frank K. L. et al, unpublished and personal communication), involving AhrC as a 
biofilm-promoting and enterococcal virulence factor. The contributions of Eep and AhrC 
to enterococcal uropathogenesis were assessed using the murine model of foreign body-
associated UTI. OG1RF∆eep and OG1RFΩef0983 were introduced in implanted animals 
and bacterial titers were assessed 24hpi and compared to the parental strain. Both strains 
are recovered at significantly lower titers from implants and kidneys compared to the 
parental strain (p<0.05 in all cases) (Fig. 25). However, whereas no defects were 
observed in bladder colonization with OG1RF∆eep (p>0.05), OG1RFΩef0983 was 
significantly attenuated in the bladder (p=0.0003) as shown on (Fig. 25) (Frank, K.L., 
Guiton, P.S., et al, manuscript in preparation). Together, these findings indicate that both 
genes contribute to urovirulence and furthermore underscore the usefulness of the 
optimized murine model of CAUTI for the identification of novel virulence factors 
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specifically involved in enterococcal colonization of the urinary tract that are also critical 
for other enterococcal diseases.  
 
Part 4. Role of implant-mediated inflammation during E. faecalis pathogenesis in 
the urinary tract 
Induction of bladder inflammation is not sufficient for the establishment of successful 
E. faecalis infection without a foreign body.  To address the effects of implant-mediated 
inflammation on enterococcal infection, animals were implanted for 24h prior to infection 
 
Figure 24: Eep and AhrC promote enterococcal uropathogenesis   
Graph represents bacterial titers from retrieved implants, homogenized bladders, 
and kidneys from implanted mice infected for 24 hrs with OG1RF (●), OG1RFΔeep 
(■) OG1RFΩEF0983 (▲). Horizontal dashed lines represent the limit of detection 
for viable bacteria. Each symbol represents a mouse and each experiment was done 
at least twice with n=5/strain. The horizontal bars indicate the median of each 
dataset; *p<0.05, ***p<0.0005, and ns for p>0.05 by the Mann Whitney U test.  
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with E. faecalis OG1RF strain and bacterial titers from the implant and organs were 
compared to titers recovered from animals implanted and simultaneously infected. As 
shown on Fig. 26A, E. faecalis is able to colonize the implants and organs of pre-
implanted animals to similar levels as the control group, indicating that E. faecalis is 
resistant to the implant-induced inflammatory response, which does not enhance nor 
prevent enterococcal colonization.  
Furthermore, to assess whether any type of cystitis predisposes the bladder to E. 
faecalis infection in the absence of foreign body, murine hemorrhagic cystitis was 
induced via treatment with cyclophosphamide (CYP) (150kg/mg, i.p.). CYP-induced 
cystitis is a well-characterized model of bladder inflammation and involves among 
others, the induction of the neurogenic inflammatory pathway described above198,214. 
Even though implant-mediated inflammation occurs independently of the neurogenic 
inflammatory pathway, it shares some commonalities with CYP-induced cystitis such as 
bladder wall edema, mucosal damage, and neutrophil infiltration203,204,215,216 (Fig. 26B).  
E. faecalis introduced in non-implanted CYP-treated animals are rapidly cleared from the 
urinary tract similar to saline-treated non-implanted controls at 6hpi (Fig. 26C). By 
24hpi, bacteria are recovered at very low levels (102-103 CFU/ml in organs) from both 
experimental groups compared to implanted animals whose organs remain colonized at 
very high titers (105-106CFU/ml in organs as well as implant; data not shown). Together, 
these findings indicate that the inflammatory state of the bladder is not sufficient to 
promote E. faecalis infection of the urinary tract in the absence of a foreign body.  
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Glucocorticoid treatment partially inhibits implant-induced inflammation and 
enhances E. faecalis urovirulence. Since induction of bladder inflammation does not 
alter the pathogenesis of E. faecalis, further experiments were performed in implanted 
 
Figure 25: Inflammation is not sufficient enterococcal urinary tract colonization  
(A) CFU enumeration of OG1RF from implant, homogenized bladders and kidneys of animals 
pre-implanted (Pre-imp) 24h prior to or implanted (imp) on the day of bacterial challenge. (B) 
H/E staining of bladder sections of 6 h cyclophosphamide (CYP)-treated or implanted mice 
observed under light microscope, magnification 20X. Experiment was performed in duplicate 
with n≥3-5/group. (C) Graph represents OG1RF titers at 6hpi from retrieved implants, 
homogenized bladders, and kidneys from non-implanted CYP- or saline-treated and implanted 
(Imp) animals. For (A) and (C) The horizontal bars indicate the median of each dataset. Two 
independent experiments performed with n=5-10/condition/experiment.  *p<0.05, **p<0.005 
value by the Mann Whitney U test. 
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animals in presence of an anti-inflammatory and immunosuppressive agent to further 
assess the role of implant-induced inflammation during enterococcal CAUTI. 
Dexamethasone, a well-characterized glucocorticoid, was administered in mice at a 
concentration of 10mg/kg, i.p. 30 min prior to implantation. This treatment inhibits the 
increase in bladder weight and the onset of edema up to 9h post implantation compared to 
saline treated controls (Fig. 27A) and causes similar degree of vascular permeability 
relative to non-implanted animals at 6hpi (Fig. 16C). However, by 12h post implantation, 
the bladders of dexamethasone-treated animals were as edematous and inflamed as 
saline-treated implanted controls (Fig. 27B). Supplemental dosages of dexamethasone 
administered 30 min prior to implantation and at 9h post implantation did not prevent 
edema at 24h post implantation (data not shown). Interestingly, preliminary cytokine 
profiling at 24h post implantation reveals that dexamethasone-treated and implanted 
animals have significantly reduced G-CSF, KC, and interleukins 1β, 6, 12p40, and 17, 
compared to saline-treated implanted controls (Fig. 28B). These soluble inflammatory 
markers are upregulated at least two-fold in saline-treated implanted animals over non-
implanted mock-infected controls following urinary implantation (Fig. 28B). 
Furthermore, dexamethasone-treatment significantly (p<0.05) reduced the infiltration of 
monocytes, basophils and eosinophils in the bladder of implanted animals compared to 
implanted controls at 24h post implantation (data not shown). Together, these data 
indicate that activation of glucocorticoid-sensitive immune pathways contributes to the 
onset of bladder wall edema, vascular permeability, pro-inflammatory cytokine 
expression, and cellular recruitment following urinary implantation.  
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The effects of dexamethasone treatment on enterococcal virulence in implanted animals 
were assessed at 6h and 24hpi. As shown in Fig. 28A, enterococcal titers were ~1 log 
significantly higher (p=0.0424) on implants recovered from dexamethasone-treated 
animals compared to saline-treated implanted controls at 6hpi. No significant difference 
in bacterial titers was observed in the bladder and kidneys between the two groups. By 
24hpi, E. faecalis recovery from implants was similar in dexamethasone- and saline-
treated animals (Fig. 28A). Interestingly, preliminary evidence indicate that enterococcal 
infection in dexamethasone-treated animals restores the production of pro-inflammatory 
markers, including IL-6, (Fig. 28B) and myeloid cell recruitment back to the levels 
observed in saline-treated implanted controls (data not shown), suggesting that E. faecalis 
infection induces a dexamethasone-independent immune response that is ineffective at 
preventing and clearing E. faecalis from the urinary tract in the presence of a silicone 
implant.  
Implanted IL-6- and TLR-2-defective mice are susceptible to enterococcal infections 
similar to their wild type littermates. Since IL6 is the most up-regulated pro-
inflammatory cytokine in response to urinary implantation, its contribution to the 
inflammatory response during E. faecalis infection was determined following OG1RF 
inoculation of implanted IL6-deficient mice.  E. faecalis is recovered from implants, 
bladder, and kidneys of IL6-deficient animals at similar levels as their littermate wild 
type controls (Fig. 29). Notably, preliminary data indicate that the absence of this 
cytokine does not affect the overall inflammatory response at 24hpi as assessed by 
cytokine profiling and flow cytometry analysis of wild type and IL-6-deficient animals 
with or without implants in presence or absence of E. faecalis (data not shown). 
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Together, although IL-6 is highly induced following urinary implantation, it is not a 
critical mediator of the inflammatory response in implanted animals with or without E. 
faecalis infections.  
 
Figure 26: Dexamethasone treatment delays onset of bladder edema.  
(A) Bladder weights of female C57Bl/6Ncr at the indicated time points treated with saline 
or dexamethasone (10mg/kg, i.p.) 30 min prior to implantation. White bars from the same 
dataset represent weight of non-implanted animals’ bladders. Experiment was done at least 
twice with n=5/experiment/time point, except at 12 and 18h (experiment performed once).  
Error bar = SEM. **p<0.005, ***p<0.005 by the Mann-Whitney U test. (B) H/E staining 
of bladder sections obtained at the indicated time points from non-implanted and implanted 
animals treated with saline or dexamethasone (10mg/kg, i.p.) observed under light 
microscope at 40X magnification.  
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Figure 27: Dexamethasone treatment enhances early enterococcal implant colonization.   
(A) Graph represents OG1RF titers at 6 and 24hpi from retrieved implants, homogenized 
bladders, and kidneys from saline or dexamethasone-treated implanted mice. The horizontal bars 
indicate the median of each dataset from at least two independent experiments with n=5-
10/condition/experiment. The horizontal dashed lines represent the limit of detection. (B) Graph 
represents bladder cytokines with at least two fold differential expression relative to uninfected 
non-implanted animals at 24 hpi of non-implanted and saline- or dexamethasone-treated 
implanted animals with or without OG1RF from at least two independent experiments n=2-
3/condition/experiment. Error bars = SEM.  *p<0.05, **p<0.005 by the Mann Whitney U test.  
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Given that myeloid cells, the primary responders to silicone implants, are critical for the 
host pathogen recognition via expression of Toll-like receptors217 and TLR2 recognizes 
lipoteichoic acid on the surface of Gram positive bacteria218, the contribution of TLR-2 
was specifically assessed during E. faecalis infection. Implanted TLR-2-defective mice 
are as susceptible to E. faecalis colonization as their wild type littermates (Fig. 29). 
Preliminary confirmatory evidence was obtained from enterococcal infections of mice 
deficient in the TLR adaptors MyD88 and TRIF, independently (data not shown). 
Therefore, these findings suggest that the Toll-like receptor pathway is not critical in the 
host immune recognition of E. faecalis, in agreement with the limited activation of 
macrophages even in the presence of high levels of E. faecalis.   
 
Figure 28: Defects in IL6 and TLR2 do not alter E. faecalis uropathogenesis.  
Graph represents OG1RF titers at 6 and 24hpi from retrieved implants, homogenized bladders, and 
kidneys of WT, TLR-2- and IL-6- deficient mice. The horizontal bars indicate the median of each 
dataset from at least two independent experiments with n=5/condition/experiment. The horizontal 
dashed lines represent the limit of detection. 
70 
 
Neutrophil recruitment contributes to anti-enterococcal responses. Neutrophils are the 
major immune cells recruited in response to E. faecalis infection in the urinary tract of 
implanted animals (Fig. 18B). To assess the contribution of neutrophils to the 
inflammatory response during E. faecalis infection, mice were rendered neutropenic 
following anti-ly6G treatment219 administered i.p. 3 days and 1 day prior to implantation 
and bacterial challenge. At 24hpi, there was an approximately 1 to 1.5 log increase in 
CFU recovered from implants and organs of neutrophil-depleted animals compared to 
isotype-control antibody-treated implanted animals (p<0.05 in all cases) (Fig. 30). 
Together, these findings indicate that neutrophils are important for controlling 
enterococcal colonization of the urinary tract during CAUTI.  
 
Figure 29: Neutrophil depletion enhances enterococcal CAUTI. 
Graph represents OG1RF titers at 24hpi on implants, in homogenized bladders and kidneys of 
implanted isotype IgG control- (Isotype) and anti-Ly6G- (anti-PMNs) treated mice. The 
horizontal bars indicate the median of each dataset from two independent experiments with 
n=10/condition/experiment. The horizontal dashed lines represent the limit of detection for 
implant and organs. *p<0.05, **p<0.005 value by the Mann Whitney U test. 
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DISCUSSION 
Enterococci, normally commensal bacteria of the human oral cavity and 
gastrointestinal tract, have become important opportunistic pathogens in hospital settings.  
While not historically regarded as an uropathogen in uncomplicated community acquired 
cystitis, E. faecalis is now considered a major agent of hospital-acquired UTIs56 where 
catheterization and indwelling medical devices can negatively impact patients’ defenses 
against pathogens56. However, the lack of a robust animal model of enterococcal UTI has 
impeded the study of this pathogen within the urinary tract.  In previously established 
models of ascending UTIs, E. faecalis fails to establish persistent bladder colonization 
and primarily displays tropism to the kidneys before rapid clearance by the host105,187-191.  
The absence of persistent infections in these murine models reflects the profile of E. 
faecalis in community-acquired UTIs where this bacterium represents less than 5% of 
clinical isolates220. As an opportunistic pathogen, E. faecalis requires alterations in 
bladder homeostasis following urinary catheterization in order to achieve successful 
infection of the urinary tract.  
In this study, the pathophysiology of E. faecalis-mediated CAUTIs was 
characterized using a murine model of foreign body-associated UTI modified from 
previous studies29,194.  In this murine model, E. faecalis colonizes and persists within the 
urinary tract at very high titers. The striking difference in enterococcal bladder 
colonization and virulence from previous models is a direct consequence of implantation, 
which elicits major histological and immunological changes in the bladder similar to 
those observed in spinal cord injured and post-surgical patients with indwelling urinary 
catheters25-27,30. The importance of the bladder implant during E. faecalis uropathogenesis 
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was made evident from the efficient bacterial clearance and the significantly lower titers 
recovered from the urinary tract in the absence and/or with the loss of implants, even in 
inflamed bladders following cyclophosphamide treatments. This is because the implant 
provides an abiotic surface for enterococcal biofilm production within the bladder.  
 
Biofilms are central to the pathogenesis of chronic infections, including 
CAUTIs38,40,112. Enterococcal biofilms on the surface of implants is essential for the 
 
Figure 30: Model of enterococcal uropathogenesis in the context of urinary 
catheterization.  
The insertion and presence of a foreign body within the bladder induces an acute 
inflammatory response involving edema, neutrophilia, and the production of pro-
inflammatory cytokines and chemokines. This inflammatory response does not promote E. 
faecalis infection. It is postulated that the failure of the host to block and disrupt enterococcal 
biofilms produced on the surface of the foreign body leads to successful enterococcal 
infections. Biofilm formation, involving the actions of SrtA and SrtC, as well as other known 
and unknown biofilm determinants is critical for E. faecalis uropathogenesis.  
73 
 
establishment of persistent enterococcal urovirulence as demonstrated by virulence 
attenuation of strains with mutations in genes encoding known and yet to be identified 
biofilm determinants. Bacteria within biofilms, protected from the host immune 
assaults49, may continuously seed the bladder preventing effective clearance by the host 
and leading to persistent cystitis and pyelonephritis. It is important to note that not all 
known in vitro biofilm-promoting or virulence factors are involved in E. faecalis 
pathogenesis within the urinary tract as shown in the present study.  Specifically, 
autolytic factors, such as GelE and Atn, are important mediators of DNA release during 
biofilm growth in vitro103,104,121,127,210 and GelE a major virulence factor in animals 
models of endocarditis221. Deletions of both atn and gelE do not alter enterococcal 
biofilm formation on the implants nor virulence in the urinary tract. The ability of E. 
faecalis to colonize the implants and establish persistent infections in the absence of both 
Atn and GelE argues that extracellular DNA may not be an important contributor of the 
extracellular matrix of enterococcal biofilms in vivo in the urinary tract or its release may 
occur in an Atn/GelE-independent manner. Furthermore, the ability of the E. faecalis 
gelE-defective OG1X strain to produce DNA-dependent biofilms in vitro, but yet unable 
to colonize the implants and organs in the urinary tract, further supports the claim that 
GelE is not a critical virulence factor for enterococcal uropathogenesis. However, since 
OG1X was derived from chemical mutagenesis209, it is likely that additional mutations 
that may compensate for the loss of GelE production during DNA-dependent biofilms 
and/or are necessary for E. faecalis uropathogenesis in vivo. Consistent with these 
findings was the observation that gelatinase is not expressed in 71/163 clinical isolates172 
of E. faecalis and the presence of gelE does not correlate with gelatinase expression192 or 
74 
 
their ability to produce biofilms in vitro172.  However, a recent study by Arciola et al 
found a correlation with a high GelE phenotype and the ability to form biofilms from 
orthopedic implant infections222, indicating that the factors utilized by enterococci in 
forming biofilms may depend on substrate and/or site of infection. Identification of the 
major components of the extracellular matrix of in vivo enterococcal biofilms and the 
single nucleotide polymorphisms (SNPs) between OG1RF and OG1X will lead to a better 
understanding of enterococcal CAUTIs and will be of valuable interest for designing 
therapeutics that promote the prevention and disruption of these structures. 
While GelE and Atn are dispensable for E. faecalis pathogenesis, the enterococcal 
enhanced expression of pheromone (Eep) metalloprotease, the transcriptional regulator 
AhrC, and the enterococcal sortases are important mediators of full virulence in 
implanted animals. In particular, sortases A and C are well-established biofilm-promoting 
factors in E. faecalis106,109,210.  Recent studies have shown that sortases, which are 
transpeptidases that anchor LPXTG-containing surface proteins to the cell wall of Gram-
positive bacteria143, plays important roles in in vitro biofilm development106,109,210.  
Deletions of both srtA and srtC in E. faecalis prevent adherence and subsequent biofilm 
growth on abiotic surfaces210.  Although Kemp et al reported that disruption of srtA, 
unlike srtC, did not significantly affect virulence in a murine model of ascending UTI106, 
results from the murine model of enterococcal CAUTI reveal that SrtA contributes to E. 
faecalis virulence in the urinary tract.  The srtA-deficient mutant is unable to colonize the 
implants in vivo and is significantly attenuated in CAUTI. Similar results were obtained 
following infection of implanted animals with a srtC-deficient mutant. These findings 
further underscore the importance of biofilm production during E. faecalis pathogenesis 
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and strongly suggest that SrtA-dependent substrates and the enterococcal endocarditis- 
and biofilm associated pili (ebp) found in most clinical isolates of E. faecalis and several 
E. faecium strains167,223 are involved in attachment to abiotic surfaces and/or to abraded 
uroepithelium in vivo during the establishment of CAUTI. Evidence obtained in 
collaboration with Hailyn V. Nielsen at Washington University in St. Louis who 
generated a deletion mutant of the ebp operon in OG1RF demonstrates a function for Ebp 
in virulence during CAUTI (Nielsen, H.V., Guiton, P.S., et al, manuscript in preparation), 
in agreement with previous reports that mutations in this operon significantly reduces 
biofilm formation and attenuates virulence in a murine model of ascending UTIs in E. 
faecalis and E. faecium107,145,167,223. It will be of particular interest to understand the 
molecular mechanisms underlying the role of Epb during CAUTI and identify additional 
SrtA-dependent substrates116 critical for urovirulence as they represent attractive targets 
for drug development given their ubiquitous nature and important functions in virulence 
116,164. For example, recently characterized LPxTG motif-containing proteins, EF3314 
and SrgA, contribute to enterococcal biofilm formation169,224. EF3314 is also involved in 
E. faecalis adherence to host cells and survival within macrophages and Caenorhabditis 
elegans169. Furthermore, surface proteins known as microbial surface components 
recognizing adhesive matrix molecules (MSCRAMMs), which include putative SrtA 
substrates, have been identified in E. faecium and E. faecalis225-227. MSCRAMMs, such 
as enterococcal collagen-binding adhesin ace165,228 or the SagA-like SalA and SalB 
proteins229, can bind to host cells via interactions with extracellular matrix components 
like collagen and fibrinogen. Several proteins from this family have been implicated in 
enterococcal virulence properties, biofilm formation, endocarditis and UTIs91,167,230,231. 
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The disruption of urothelial surfaces, as a result of urinary catheterization, may expose 
receptors that SrtA-dependent cell surface proteins, such as MSCRAMMs, can recognize 
to promote attachment, biofilm formation and persistent colonization.  
Additionally, the findings in this report helps unravel critical aspects of the 
interplay between inflammation and enterococcal colonization, providing new details of 
the molecular mechanisms leading to implant-mediated inflammatory response and its 
role on the outcome of E. faecalis infection. The bladder responses to urinary 
catheterization are characterized by severe uroepithelial damage, the onset of bladder 
wall edema from increased vascular permeability, and upregulation of inducible nitric 
oxide synthase (preliminary data not shown). The presence of the implant stimulates the 
production of pro-inflammatory cytokines, including IL-6 and KC (IL-8 or CXCL1) 
previously shown to be induced following catheter-mediated abrasions of bladder 
epithelial cells in vitro232, and G-CSF. In contrast, GM-CSF and MIP-1α (CCL3) 
expression was decreased following implantation. The presence of E. faecalis in 
implanted animals, albeit at very high titers, slightly enhances the inflammatory response 
with a specific increase in the production of IL-1β, GM-CSF and MIP-1α (the latter back 
to non-implanted, uninfected control levels) during CAUTI. These cytokines are 
produced by epithelial cells, neutrophils and other immune cells and are important 
mediators of the inflammatory response to mucosal injuries and microbial infections233-
238. In particular, IL-1β was shown to be released during UPEC-mediated acute cystitis239. 
This cytokine profile of implanted bladders is in agreement with the identity of the 
myeloid cell infiltrates primarily in response to urinary implantation. Neutrophils, whose 
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presence is doubled in E. faecalis infected implanted animals, are the primary responders 
followed by monocytes, macrophages, basophils, and some eosinophils.  
All the above immune characteristics, from edema to neutrophilia, are associated 
with activation of the neurogenic inflammatory pathway in various experimental models 
of cystitis, including cyclophosphamide-induced hemorrhagic cystitis214.  This is an 
inflammatory response triggered by the release of proinflammatory neuropeptides and 
activation of surface receptors, including NK1R, on the surface of sensory neurons197. 
However, NK1R and α1-adrenoreceptor-mediated neurogenic inflammatory responses 
are not major contributors of implant-induced cystitis in mice since treatment with 
specific NK1R antagonists and α1-adrenoreceptor as well as iNOS inhibitors did not 
prevent plasma protein leakage and edema as was previously shown in bladder cystitis or 
other experimental models involving activation of the neurogenic pathway204,206,240. This 
is further supported by preliminary evidence from implantation of cKit-deficient mutant 
mice revealing that mast cells, important cellular components of the neurogenic 
pathway198,241,242, are not major inducers of edema and vascular permeability following 
urinary implantation (data not shown). Although the contribution of other factors 
involved in the neurogenic inflammatory response, including bradykinins and NK2 
receptors, need to be assessed, identifying the effects of urinary implantation on factors 
involved in vascular permeability, such as calcium channels, calveolin, RhoGTPases, 
sphingosine kinases (SPHK1) and protein tyrosine phosphatases (SHP2)243, may shed 
light into the mechanisms underlying the onset of bladder wall edema following 
catheterization. 
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In contrast to studies with inhibitors of the neurogenic inflammatory response, 
glucocorticoid treatment delays the onset of implant-associated edema and partially 
decreases cytokine production and cellular recruitment following urinary catheterization, 
thus implicating glucocorticoid-responsive inflammatory pathways in the immune 
response during the early stages of urinary implantation. Synthetic glucocorticoids such 
as dexamethasone are the most effective anti-inflammatory agents used to date for the 
treatment of chronic inflammatory diseases244. They are both anti-inflammatory and 
immunosuppressive molecules whose mechanisms of action involve in part 
transcriptional regulation via interaction and activation of glucocorticoid receptors (GR) 
in the host cytoplasm as well as post transcriptional and translational regulation of a 
myriad of genes encoding proteins for cellular and immune processes244,245. 
Glucocorticoids are known inhibitors of inflammatory processes mediated by interleukins 
(1β, 2, 6, and 8) and other pro-inflammatory cytokines such as (GM-CSF and TNF-α), 
cyclo-oxygenases (particularly COX-2), and iNOS. The unresponsiveness to 
dexamethasone observed in the later stages of urinary implantation has previously been 
reported in patients suffering from other inflammatory diseases246, including asthma247, 
inclusion body myositis (IBM)248, and nephrotic syndrome (NS) in children249. In the 
case of the implanted bladders, glucocorticoid refractoriness could be attributed to the 
ongoing exposure to the foreign body250, the high levels of neutrophils in the bladder 
which have been previously associated with corticosteroid-resistant asthma250, a 
significant reduction in glucorticoid receptors251 due to increased urothelial exfoliation, 
or other cellular and immunological pathways that can circumvent the effects of 
dexamethasone250. These may include an increased expression of the dominant negative 
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form of the glucorticoid receptors (GRβ) on immune cells such as neutrophils and 
macrophages rendering them insensitive to dexamethasone treatment252,253, upregulation 
of certain cytokines including IL-2, IL-4, and IL-13, or from activation of the mitogen-
activated protein kinase (MAPK) signaling pathways250. Notably, the suppression of the 
early phase of implant-mediated cystitis following glucocorticoid treatment or iNOS 
inhibition (data not shown) led to a significant increase in enterococcal implant 
colonization. Remarkably, enterococcal infection in dexamethasone-treated animals 
induces an immune response similar to that elicited by the implants in uninfected saline-
treated controls. These findings suggest that E. faecalis possesses immune evasion 
mechanisms that allow its survival in the face of this glucocorticoid-resistant immune 
response and that implant-mediated bladder inflammation as in the case of pre-implanted 
animals did not alter the outcome of infection. The acute inflammatory response induced 
by the implant may even alter or impair the host response to bacteria, as was 
demonstrated for E. faecium peritonitis following treatment with turpentine or casein 
prior to bacterial challenge254. 
E. faecalis colonization is also significantly increased in the bladders of 
neutropenic mice following urinary implantation, corroborating previous reports of that 
neutrophils are important mediators of the anti-enterococcal host response in humans and 
other animal models of infections236,255-257. Previous studies demonstrated that E. faecalis 
and E. faecium isolated from saliva and root canals are efficiently killed by neutrophils 
recruited to the site of infection258 and that TLR-2 is involved in the immune response 
against E. faecium259. However, the immune functions of neutrophils during E. faecalis 
infections of the urinary tract occur in a TLR-2 and IL-6 independent manner as infection 
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of implanted animals deficient in these immune modulators did not alter the outcome of 
infection. Further research is required to establish the contribution of macrophages and 
other immune cells, the toll like receptors, IL8, and G-CSF signaling pathways in the host 
immune response to enterococcal CAUTI.  
Despite the role of neutrophils in controlling E. faecalis infection, this bacterium 
is still able to colonize the urinary tract of implanted immunocompetent mice, implying 
the presence of potential mechanisms to help E. faecalis avoid and/or resistant neutrophil 
killing. Recent studies have demonstrated that the cell wall anchored pheromone-
inducible aggregation substance (AS) and the enterococcal polysaccharide antigen (Epa) 
in E. faecalis are involved in resistance to neutrophil-mediated killing260-262. However, 
the E. faecalis OG1RF strain used in the present study does not bear AS, arguing for 
alternative mechanisms of immune evasion, such as the downregulation of integrin 4 
expression of the surface of neutrophils263, alteration of the neutrophil properties 
rendering them non responsive to bacterial infections as is the case during enterococcal 
sepsis in thermally injured patients and mice236,256,257 or survival within immune cells 
such as macrophages which is a well characterized virulence attribute of enterococci 
186,264-271. Together, these findings indicate that the inflammatory response to the urinary 
implant can be deleterious to E. faecalis, but is inefficient at controlling bacterial 
proliferation and colonization over time. Furthermore, this report is in accord with 
epidemiological reports of severe enterococcal infections increasingly occurring in 
immunosuppressed and immunocompromised patients272-275.  
In addition to promoting persistent enterococcal cystitis, the presence of the 
silicone implants in the bladder allows E. faecalis to gradually and successfully ascend to 
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the kidneys and establish renal colonization in implanted animals. The onset of acute 
pyelonephritis has been described in post-mortem studies of the elderly with indwelling 
catheters at the time of death276. In the clinical setting, the removal of infected indwelling 
urinary catheters is one of the most effective methods used to resolve bacteriuria and 
CAUTIs34,40. However, removing the indwelling medical device, even combined with 
long course of antibiotics treatment40, may not be sufficient for complete resolution of the 
infection, especially with the rise in antibiotic resistance observed in nosocomial 
settings277. In addition, implant removal upon infection in other device-associated 
infections like prosthetic valve endocarditis is not in itself efficacious278-280, and thus may 
not be a suitable therapeutic approach in all instances.  Understanding the pathogenesis of 
CAUTIs may lead to new and better ways to treat and prevent these diseases. 
The optimized murine model of foreign-body associated UTI presented here is 
highly relevant for the investigation of the mechanisms underlying enterococcal-mediated 
CAUTIs since it couples biofilm production to enterococcal virulence during E. faecalis 
uropathogenesis. Findings from this study in this murine model led to the conclusion that 
the acute inflammatory response induced by urinary catheterization, partially responsive 
to glucocorticoid treatment, does not promote enterococcal infection rather the 
establishment of successful infections by this opportunistic pathogen results from the 
failure of the immune response, especially neutrophils, to prevent, block, or disrupt 
biofilm formation, rendering this process a major target in the fight against enterococcal 
CAUTIs (Fig. 31). This murine model represents a valuable and robust tool for 
understanding the mechanisms underlying urinary catheter-mediated cystitis and for the 
identification and characterization of novel biofilm determinants, bacterial virulence 
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factors as well as host responses pertinent to the pathogenesis of E. faecalis in the urinary 
tract.  Importantly, it will serve as an ideal platform for testing anti-biofilm compounds 
and potential therapeutics for the prevention and treatment of enterococcal CAUTIs.  
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CHAPTER THREE 
CONSEQUENCES OF URINARY CATHETERIZATION ON 
UROPATHOGENIC ESCHERICHIA COLI PATHOGENESIS 
Modified from: Guiton, P.S., et al. manuscript submitted. 
 
ABSTRACT 
Catheter-associated urinary tract infections (CAUTIs) caused by multidrug 
resistant pathogens including uropathogenic Escherichia coli (UPEC) constitute the 
majority of nosocomial UTIs and pose significant clinical challenges. Urinary 
catheterization elicits major histological and immunological alterations in the bladder that 
can favor microbial colonization and dissemination in the urinary tract. The present study 
reports the consequences of these biological perturbations on uropathogenic Escherichia 
coli (UPEC) pathogenesis and virulence-based preventative measures using an optimized 
murine model of foreign body-associated urinary tract infection (UTI). The findings 
obtained demonstrate that type 1 pili mediate UPEC adherence and invasion into bladder 
epithelial cells in catheterized bladders as seen in non-catheterized bladders as well as to 
the urinary implant. Specific targeting of type 1 pili with small molecule inhibitors in 
combination with trimethoprim/sulfamethoxazole prevents UPEC CAUTI. This study 
further demonstrates that bacterial reservoirs established during previous UPEC infection 
can serve as a nidus for urinary catheter colonization. This study provides novel insight 
into UPEC pathogenesis in the context of urinary catheterization, and investigates novel 
therapies that target critical mechanisms for this pathophysiology. By doing so, it 
establishes a proof-of-principle for the development of novel therapies to prevent and 
eventually treat these infections in the face of the rise of antibiotic resistant uropathogens. 
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INTRODUCTION 
CAUTIs often arise from multidrug resistant Gram-positive and Gram-negative 
bacterial colonization and biofilm aggregation on the surface of indwelling urologic 
devices such as urinary catheters, rendering treatment very difficult33,40,56. Uropathogenic 
Escherichia coli (UPEC), the primary cause of community-acquired UTI, account for 
50% of nosocomial UTIs, including CAUTIs55. Yet, very little is known about its 
pathogenesis following urinary catheterization. Urinary catheterization results in the 
disruption of the normal mechanical and antimicrobial defenses of the bladder25,26,29,30,281.  
Previous reports using human biopsies and rodent models of infections have shown that 
the catheterized bladder is edematous and highly inflamed with immune cell infiltration 
and pro-inflammatory cytokine production, an environment quite different from that 
which UPEC encounters in a non-catheterized bladder62,71-73,75,77,282 . We hypothesized 
that these profound catheter-related changes may affect UPEC pathogenesis.  
The UPEC pathogenic cascade has been extensively characterized in a non-
catheterized murine model of cystitis. UPEC elaborate on their surface adhesive type 1 
pili, which mediate binding to and invasion of superficial umbrella cells lining the 
bladder epithelium60. Once intracellular UPEC can escape into the cytoplasm, replicate 
rapidly and undergo morphological differentiation within bladder epithelial cells to 
produce mature intracellular bacterial communities (IBCs) of ~104-105 bacteria with 
biofilm-like properties73,74. UPEC then flux out from infected cells and can reinvade 
neighboring cells and start the process de novo73. This acute phase of UPEC infection can 
lead to the development of chronic cystitis, pyelonephritis, and the formation of quiescent 
intracellular reservoirs (QIRs) with absence of bacteriuria77. Detailed understanding of 
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the critical steps of this pathogenic cascade has led to the development of small molecule 
inhibitors called mannosides84.  Mannosides specifically target the bacterial type 1 pili tip 
adhesin, FimH, which binds to mannosylated residues present on the surface of the 
bladder epithelium. Rationally designed to interfere and prevent FimH interaction with 
these residues, mannosides inhibit UPEC binding and invasion of the superficial umbrella 
cells during urinary tract infections (UTIs)84. Mannosides, in combination with existing 
antibiotic-based UTI therapy, have recently been shown to be effective in preventing and 
treating UPEC infections in non-catheterized infection models87. The present study 
investigates whether this therapeutic approach could be beneficial in the prevention and 
treatment of CAUTIs.    
In this report, the optimized murine model of foreign body-associated UTI that 
closely mimics CAUTI29 was used to investigate the consequences of urinary 
catheterization on the pathophysiology of UPEC infection. For these studies, several 
UPEC virulence parameters, including the contribution of type 1 pili, IBC formation, and 
QIR reactivation, were assessed. The results obtained indicate that urinary catheterization 
provides UPEC with the opportunity to exploit the extracellular milieu of the bladder via 
type 1 pili-mediated biofilm formation on the surface of the foreign body, which results 
in a shift in the niche population. Administration of mannosides in combination with 
trimethoprim/sulfamethoxazole prior to urinary catheterization prevents UPEC 
colonization of the urinary tract. This report provides important insights into the 
mechanisms underlying UPEC-mediated CAUTI, and informs efforts to design better 
therapeutic approaches to prevent and potentially treat these infections.  
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RESULTS 
UPEC adherence, invasion, and IBC morphology are unaltered in catheterized 
bladders.   
To assess the effects of urinary catheterization on UPEC colonization patterns in 
the urinary tract, 4-5mm platinum-cured silicone tubing sections (referred to as implants) 
were implanted in the bladders of C57Bl/6Ncr female mice, which were then 
immediately infected with 1-2x107 CFU of the well-studied virulent UPEC strain 
UTI89282 by transurethral catheterization. CFU enumeration was compared to non-
implanted animals similarly infected with UTI89 up to 7 days post infection. UPEC 
colonized the bladder and kidneys of implanted animals to similar levels as in non-
implanted animals (Fig. 32). In addition to the organs, UPEC was also recovered at very 
high titers from the implants, on which they established biofilms as determined by 
scanning electron microscopy at 48hpi (data not shown). 
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IBC formation occurs in the pathogenesis of UPEC in non-catheterized patients78 and has 
been shown in mouse models to be critical for infection. To assess the effects of urinary 
catheterization on IBC formation, implanted and non-implanted mice were infected with 
UTI89 as described above. Ex vivo gentamicin protection assays62 performed at 3hpi 
revealed no statistical difference in either the extracellular or intracellular UPEC 
populations in the presence or absence of implants (Fig. 33), indicating no gross defect in 
bacterial invasion in implanted animals. IBC formation within both implanted and non-
implanted bladders was assessed by LacZ staining and confocal scanning laser 
microscopy (CSLM) at 6hpi (Fig. 34A-C). Inoculation of UPEC into implanted animals 
resulted in significantly fewer IBCs with a median of 8 IBCs/bladder (p=0.0044) (Fig. 
34B) compared to non-implanted animals in which IBC numbers ranged up to >250 
IBCs/bladder with a median of 55 IBCs/bladder. Yet, bacterial CFU in implanted 
 
Figure 31: Bladder implantation does not alter the overall colonization pattern of UPEC. 
Graphs represent bacterial titers in log scale from retrieved implants (A), homogenized bladders 
(B), and kidneys (C) from non-implanted (○) or implanted (●) animals infected with 1-2x107 
CFU in 50µl inoculum of E. coli strain UTI89 for 24, 48, 72 hpi, or 7 dpi.  Horizontal dashed 
lines represent the limit of detection for viable bacteria. Each symbol represents a mouse from 
two independent experiments with n=5/condition. The horizontal bars represent the median of 
each dataset; *p<0.05, **p<0.005, and ***p<0.0005 by the Mann Whitney U test. 
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bladders were similar to those in non-implanted animals (data not shown). This 
observation led to the reasoning that IBC morphology might be different in implanted 
animals. However, IBCs formed in implanted animals were observed to be overall similar 
in size and shape as those produced in non-implanted bladders (Fig. 34C).  UPEC were 
also seen to produce multiple IBCs within one umbrella cell and filamentous bacterial 
clumps in both catheter implanted and non-implanted bladders at 6hpi (Fig. 35).  UPEC 
colonization at 6hpi was selectively localized in the remaining umbrella cells and not 
observed in the exposed underlying epithelium in implanted bladders (Fig. 35). Together, 
these findings indicate that urinary catheterization negatively impacts IBC formation by 
UPEC, possibly due to a correlated increase in exfoliation of the superficial umbrella 
cells283. 
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Figure 32: No defect in UTI89 invasion following implantation.  
Graph represents bacterial titers from homogenized bladders from non-implanted (○) or implanted 
(●) animals infected with UTI89 3hpi following ex vivo gentamicin protection assay.  Horizontal 
dashed lines represent the limit of detection for viable bacteria (Int=intracellular, Ext=Extracellular). 
Each symbol represents a mouse from two independent experiments with n=5/condition. The 
horizontal bars represent the median of each dataset; p value by the Mann Whitney U test.  
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Figure 33: Uropathogenic E. coli produces IBCs in the superficial umbrella cells of 
implanted bladders. 
(A) Representative images of splayed bladders of female C57Bl/6Ncr mice infected with UTI89 
6hpi in the absence (non-implanted) or presence (Implanted) of implants following LacZ staining. 
Each black arrow indicates a purple speck, indicative of an IBC. (B) Quantification of IBC 
formation following LacZ staining at 6hpi. Each symbol represents IBC number from a single 
mouse from two independent experiments with n=5/group. p value obtained from the Mann 
Whitney U test. (C) Representative CLSM images of whole bladders from non-implanted and 
implanted animals infected with UTI89 ectopically expressing GFP (Green), stained with DNA 
dye SYTO83 (Red) and Alexa-fluor 633-conjugate of WGA (Blue) reveal the presence of IBC 
within umbrella cells. Scale bar =20µm. 
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Bacteria originating from bacterial reservoirs can seed urinary implant 
colonization.  
One troubling possible outcome of the UPEC pathogenic cascade is the 
establishment of quiescent intracellular reservoirs (QIRs) in the underlying epithelial 
layers, which have been shown, can be a source of recurrent UTIs (rUTIs)77,284. QIRs 
were shown to be reactivated following treatment with protamine sulfate, a chemical that 
leads to exfoliation of the superficial umbrella cells of the uroepithelium 77. Like 
protamine sulfate, urinary catheterization causes severe damage to the protective 
 
Figure 34: IBC and filamentation occur following urinary catheterization 
Representative CLSM images of whole bladders from non-implanted and implanted animals 
infected with UTI89 ectopically expressing GFP (Green), stained with DNA dye SYTO83 (Red) 
and Alexa-fluor 633-conjugate of WGA (Blue) reveal the presence of multiple IBCs within single 
umbrella cells (A-B), that unlike non-implanted bladders (C), the underlying epithelium is 
exposed following urinary catheterization (D-F), depict the absence of bacterial colonization of 
the exposed underlying epithelium in implanted animals (D-F), and the presence of filamenting 
bacteria in umbrella cells (E-F). Scale bar =20µm. 
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uroepithelial layer77. Thus, urinary catheterization might also reactivate QIRs, resulting in 
bacteriuria, catheter colonization and further dissemination. To test this hypothesis, mice 
were infected with 1-2x107 CFU UTI89HK::GFP and infection allowed to resolve over 
the course of 2 weeks. On day 14 post-infection, urine was collected from each animal to 
assess infection state prior to urinary implantation of a subset of these animals.  Those 
animals in which titering of urines 14 dpi indicated bacteriuria (≥104 CFU/ml) were 
considered to have active (non-resolved and/or recurrent) infection and were removed 
from further analysis. The remaining mice were presumed to either have completely 
cleared the infection or to have established QIRs. 3 or 5 days post implantation, 
reservoirs activation was assessed by bacterial colonization of implants and bladder. On 
day 3 post implantation, UPEC UTI89HK::GFP was recovered from implants in 3 of 26 
implanted mice (~11.5%) and one mouse had bladder colonization (> 104 CFU) compared 
to none of 22 similarly infected but non-implanted animals (Fig. 36A). For mice assessed 
at 5 days post-implantation, UTI89HK::GFP was recovered from implants of 4 out 32 
animals (~13%) with two of them having bladder titers greater than 104 CFU/ml (Fig. 
36B) compared to 0 out of 23 in non-implanted animals. Interestingly, there were overall 
significantly fewer bacteria recovered from the bladders of implanted animals compared 
to non-implanted animals at 5 dpi (p=0.017; Fig. 37B), suggesting that either reactivated 
reservoirs are cleared by the immune response prior to day 5 following implantation or 
increased exfoliation prevents establishment of persistent infections. Together, these data 
indicate that urinary catheter colonization can occur from previous urinary infections 
even if those infections appear by bacteriuria counts to have been resolved.  
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Figure 35: Bacterial reservoir reactivation can lead to implant and bladder colonization.   
Graphs represent bacterial titers in log scale recovered from implants, homogenized bladders and 
kidneys of non-bacteriuric animals 14days post infection with UTI89HK::GFP that were non-
implanted or implanted for 3 day (A) or 5days (B). Horizontal dashed lines represent the limit of 
detection for viable bacteria. Each symbol represents a mouse from at least two independent 
experiments with n=10-20/group/experiment. The horizontal bars represent the median of each 
dataset; p value by the Mann Whitney U test. 
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FimH is required for biofilm formation and UPEC colonization of the urinary tract 
following catheter implantation.  
Biofilm formation is a critical component of UPEC CAUTI pathophysiology33,37. 
Type 1 pili are major UPEC virulence factors that have been shown to be critical for 
biofilm aggregation, IBC formation, and other aspects of UPEC uropathogenesis. Thus, 
the contribution of these extracellular pili as well as other UPEC fibers, including curli 
which contribute to biofilm formation285 or S pili associated with E. coli clinical isolates 
producing strong biofilms286-288, to biofilm formation in filtered human urine under flow 
conditions and UPEC-mediated CAUTI in vivo.  Deletion of the gene for the tip adhesin 
of type 1 pili, fimH, in UTI89 resulted in significantly (p<0.0001) lower biomass (Fig. 
37A) and an approximate 2-fold reduction in adherent viable bacteria (Fig. 37B) in 
biofilms formed in human urine in vitro.   These data indicate that type 1 pili are a major 
contributor to UPEC biofilm formation in urine. The biofilm defect was specifically 
associated with the fimH mutant under these conditions, and was not observed following 
deletions of the sfa operon to prevent S pili formation, csgA required for curli fiber 
formation, or a component of the flagellar system fliC (data not shown).  
In vivo, similar to findings in a murine model of cystitis, UTI89∆fimH is severely 
attenuated in the murine model of foreign body-associated UTI (Fig. 37C).  UTI89∆fimH 
displayed >3 log fewer CFU in the bladder and was unable to ascend to the kidneys at 
24hpi. Further, deletion of fimH resulted in significant reduction in implant colonization 
(p<0.0001).  
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Figure 36: Deletion of fimH reduces biofilm formation and attenuates UPEC virulence.  
Graphs represent crystal violet based quantification (A) and CFU enumeration in logarithmic 
scale (log scale) (B) of 24h old UTI89 and UTI89∆fimH (∆fimH) biofilms under human urine 
flow on silicone tubing at 37ºC indicating that ∆fimH is defective in biofilm formation under 
these conditions. Bars represent mean of three independent experiments, error bars indicate 
standard error of the mean (SEM). p values from Mann Whitney U test. (C) Graph represents 
bacterial titers in log scale recovered from implants, homogenized bladders and kidneys of non-
implanted (open symbols) and implanted (closed symbols) infected with either UTI89 (square) or 
∆fimH (circle) for 24h.  Horizontal dashed lines represent the limit of detection for viable 
bacteria. Each symbol represents a mouse from at least two independent experiments with 
n=5/group. The horizontal bars represent the median of each dataset; *p<0.05 and ***p<0.0005 
by the Mann Whitney U test. 
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Similar to in vitro experiments, S-pili are not required for CAUTI since UTI89∆sfaA-H is 
as virulent as wild type UTI89 and a double deletion of both sfaA-H and fimB-H 
recapitulated the UTI89∆fimH phenotype (Fig. 38A). Furthermore, components of the 
curli system important for biofilm formation in vitro under certain conditions, but not in 
human urine (Fig. 3A-B), were also dispensable during CAUTI (Fig. 38B). The residual 
binding to implants and bladders in implanted animals could therefore be attributed to 
other pili or biofilm determinants. Together, these data strongly suggest that the tip 
adhesin FimH of type I pili is a critical determinant of UPEC virulence in mediating 
biofilm formation and virulence during CAUTI.  
Mannoside treatment reduces IBC formation.  
Having established that FimH is required for UPEC virulence in implanted 
bladders, this adhesion was investigated as a potential therapeutic target for CAUTI using 
small molecules inhibitors designed to interfere with FimH binding to mannosylated 
residues84.  This family of small molecules, called mannosides, has recently been shown 
to prevent acute and chronic UPEC infections and potentiated the effectiveness of 
antibiotics in combinatorial treatment87. To investigate the potential therapeutic effects of 
mannosides on CAUTI, the inhibitory effects of methyl-α-D-mannopyranoside (methyl 
mannose) on UTI89 biofilm formation in urine under flow was determined. Similar to the 
deletion of fimH (Fig. 37A-B), UTI89 biofilms grown in presence of 1% methyl mannose 
had significantly reduced biomass (p=0.0022) and biofilm-adherent cells (p=0.0012), 
compared to untreated controls (Fig. 39).  Since methyl mannose is a FimH antagonist, 
these data confirm the critical role of type 1 pili to biofilm formation in urine as was 
previously described for biofilms formed in LB media.  
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The effects of mannoside treatment were then assessed in vivo by using IBC 
formation as well as implant and urinary tract colonization as benchmarks of disease 
progression. Mice were treated intraperitoneally (i.p.) with saline or 5mg/kg of 
mannoside ZH5684 in PBS 30min prior to urinary implantation. Mannosides, including 
ZH56, are more potent than methyl mannose in preventing and disrupting UTI89 biofilm 
in vitro. Methyl mannose, previously shown to inhibit UTI89 biofilm at 100mM in LB 
 
Figure 37: S pili and curli are not critical for UPEC virulence following urinary 
catheterization. 
Graphs represent bacterial titers in log scale recovered at 24hpi from implants, homogenized 
bladders and kidneys of (A) implanted animals infected with either UTI89 (●) or UTI89 mutant 
strains deficient in type 1 pili, ∆fimH (■), S pili ∆sfaA-H(▲), both type 1 and S pili ∆sfaA-
H∆fimB-H(♦) and (B) non-implanted (open symbols) or implanted (closed symbols) animals 
infected with UTI89 (○,●), ∆fimH (□, ■) or UTI89 mutant strains deficient in curli components 
∆csgA (∆,▲) and ∆csgB∆csgG (♦,◊).  Horizontal dashed lines represent the limit of detection for 
viable bacteria. Each symbol represents a mouse from at least two independent experiments with 
n=5/group. The horizontal bars represent the median of each dataset; *p<0.05 and ***p<0.005 
**p<0.0005 by the Mann Whitney U test. 
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using the 96-well biofilm assay289 was used for the in vitro urine catheter biofilm studies 
while the more potent mannoside was reserved for the in vivo studies due to its increased 
affinity and stability. Catheter implantation was immediately followed by transurethral 
inoculation of UTI89. IBC formation and bacterial colonization were assayed by LacZ 
staining and CFU enumeration of implants, bladders, and kidneys at 6hpi and 24hpi, 
respectively. As shown in Fig. 40A and 40B, mannoside treatment further reduced IBC 
formation (p=0.0051) and bladder colonization (p=0.0114) in implanted animals at 6hpi, 
suggesting that this treatment prevents intracellular infection.  While eliminated from 
their intracellular niche, data further indicated that UPEC were able to persist in the 
extracellular milieu where they can colonize the surface of the implants to relatively 
similar levels as saline-treated animals (p=0.0547) (Fig. 40B). No statistical difference 
was observed in kidney colonization in the presence or absence of mannosides (Fig. 
40B). By 24hpi, a time point at which the mannosides have been eliminated from the 
bladder87, similar bacterial loads were recovered from implants, bladders, and kidneys in 
implanted animals in the presence or absence of mannoside treatment (data not shown). 
Furthermore, treatment with mannosides did not have an effect on established UPEC 
CAUTI (data not shown).   
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Mannoside treatment increases the efficiency of TMP-SMZ in preventing UPEC 
colonization.  
In order to examine whether mannosides could prevent establishment of CAUTI 
when used in combination with antibiotics, animals were treated with 54 and 270µg/ml of 
trimethoprim-sulfamethoxazole (TMP-SMZ), respectively, in their drinking water for 3 
days and then treated with saline or mannoside (5mg/kg) i.p. 30 min prior to implantation 
and bacterial inoculation. At 6hpi, UPEC colonized the implants and bladders at 
significantly lower levels in animals that only received antibiotics compared to those who 
received water or were only administered mannoside (Fig. 40B). Interestingly, mannoside 
treatment in addition to TMP-SMZ further decreased UPEC colonization of implants, 
bladders, and kidneys compared to treatment with antibiotic alone (p<0.0005 in all 
 
Figure 38: Methyl mannose inhibits UPEC biofilm in human urine 
Graphs represent crystal violet based quantification (A) and CFU enumeration in logarithmic 
scale (log scale) (B) of 24h old UTI89 biofilms in human urine with or without 1% methyl 
mannose under flow on silicone tubing at 37ºC indicating that methyl mannose prevents UPEC 
biofilm formation. Bars represent mean of three independent experiments, error bars indicate 
standard error of the mean (SEM). p values from Mann Whitney U test. 
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cases). Together, these findings indicate that virulence-targeted therapies in combination 
with established antibiotic treatment can help prevent or delay the onset of CAUTI.  
101 
 
 
Figure 39: Mannoside treatment prevents IBC formation and UPEC virulence when use in 
combination with TMP-SMZ.  (A) Graph represents IBC enumeration from LacZ staining of 
splayed bladders of female C57Bl/6Ncr mice treated i.p. with mannoside or saline prior to 
transurethral implantation and inoculation with UTI89 6hpi. (B) Graph represents bacterial titers 
in log scale recovered at 6hpi from implants, homogenized bladders and kidneys of animals 
treated with saline (○), mannoside (□),TMP-SMZ (●) and TMP-SMZ+Mannoside (■) prior to 
urinary implantation and inoculation with UTI89.  Horizontal dashed lines represent the limit of 
detection for viable bacteria. Each symbol represents IBC number or bacterial titer from a single 
mouse from two independent experiments with n=5/group. The horizontal bars represent the 
median of each dataset; *p<0.05, **p<0.0005, ***p<0.0005, ns corresponds to p>0.05 by the 
Mann Whitney U test. 
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DISCUSSION 
UPEC is the major etiological agents of CAUTI56. Yet, the molecular mechanisms 
of urinary catheter and bladder colonization following urinary catheterization have not 
been elucidated. Studies in an optimized murine model of foreign body-associated UTI281 
show that urinary catheterization favors UPEC exploitation of the bladder extracellular 
milieu. This occurs via type 1 pili-dependent biofilm formation on the surface of silicone 
implants in the murine bladder. The data further indicate that of the biofilm determinants 
tested, type 1 pili are necessary for implant, bladder, and kidney colonization during 
CAUTI; providing definitive experimental evidence for previous reports postulating that 
type 1 pili may be required for UPEC persistence during CAUTIs290. Interestingly, fimH-
deficient UPEC strains have the ability to adhere to some extent to the surface of the 
foreign body, probably using other biofilm determinants such as other chaperone-usher 
pili systems, curli, or surface adhesins43.   
In addition to colonizing the foreign body in the bladder lumen, UPEC is able to 
exploit intracellular niches in implanted animals, albeit to a lesser degree than in non-
implanted animals, by invading and producing IBCs in the early stages of infection.  
Reduced IBC formation in implanted animals may be a result of loss of the host 
superficial facet cells in which IBCs form due to increased exfoliation or damage to the 
uroepithelium following urinary catheterization25,26,29,30,281,283,291. Nonetheless, this 
finding is of particular interest for treatment strategies against UPEC-mediated CAUTI. 
In humans, removal of the contaminated urinary catheter is the preferred method for 
treatment of these infections34,40; however, the presence of bacteria in an intracellular 
compartment protected from host immune defenses and antibiotic treatment requires 
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more comprehensive approaches as intracellular UPEC can lead to re-infection of a novel 
catheter or serve as a nidus for future UTI.  
Quiescent intracellular reservoirs are an important outcome of UPEC pathogenic 
cascade because they are proposed to be a mechanism of recurrent UTI following damage 
to the uroepithelium77. Findings from the current study indicate that urinary implantation 
of animals with a history of UTI can lead to bladder infection and implant colonization 
with the UPEC causing the first infection. This finding suggests that in addition to 
introduction of extracellular and periurethral bacteria 36, urinary catheter colonization can 
occur from bacteria originating from pre-existing reservoirs or other niches within the 
urinary tract not appreciated by assessment of bacteriuria. Interestingly, by day 5 
following implantation in animals with a history of UTI, there is overall a significant 
reduction in the number of QIRs compared to that in non-implanted animals as assessed 
by bladder CFU. This reduction in bacterial load could be a result of enhanced immune-
mediated clearance of infected cells or to exfoliation of infected cells in implanted 
animals. These hypotheses are currently being evaluated.  
The identification of FimH as a critical virulence factor during UPEC CAUTI 
provides an interesting avenue for the development of novel preventative measures 
against these infections.  The results presented here suggest that the use of small 
molecules inhibitors, such as mannosides, in combination with existing UTI treatment 
regimes, can lead to prevention or delay of UPEC colonization. Mannosides, were 
rationally designed to interfere with FimH-mediated binding to mannosylated proteins on 
the surface of the uroepithelium84. Recent studies show that the use of mannosides in 
combination with antibiotics is highly effective in preventing IBC formation and acute 
104 
 
stages of UPEC infection as well as treating chronic cystitis87. Similarly, pretreatment 
with mannosides further prevents IBC formation following UPEC infection of implanted 
bladders and reduces UPEC binding to the uroepithelium. However, the presence of the 
abiotic implant surface provided a favorable environment for adherence of extracellular 
bacteria. The inability of mannoside treatment to eliminate UPEC from the implant, given 
that the experimental evidence that mannose inhibits UPEC biofilm on catheter material 
in urine in vitro, may be due to the lack of urine flow in this implanted murine model. It 
is possible that if it were possible to truly catheterize mice in a manner analogous to 
clinical catheterization of humans in which urine flows through the catheter that 
mannoside may have a more efficacious effect on implant clearance. Nonetheless, by 
preventing invasion and shifting UPEC niche to the extracellular milieu, mannoside 
enhanced the bacteriocidal efficacy of antibiotics, such as TMP-SMZ, which does not 
cross host cell membranes. Mannosides could be used in combination with bacterial 
interference strategy being offered as alternatives in the prevention of CAUTI. Previous 
reports have shown that pre-colonization of urinary catheters with an avirulent E. coli 
strain 83972 delays the onset of CAUTI in catheterized patients292. Thus, it is quite 
possible that if used in combination with mannosides, UPEC will be kept from the 
intracellular niche as well as from binding to the catheter during bacterial interference 
with the avirulent strain. Though, the avirulent strain should be able to colonize the 
catheter in a type 1-independent manner, which is not the case for E. coli strain 83972293. 
The therapeutic effects of mannoside could not be recapitulated in our model of CAUTI 
(data not shown), possibly because the small molecules are ineffective at disrupting 
established biofilms in vivo. It is a well-established fact that the extracellular matrix of 
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bacterial biofilms is impermeable to antimicrobial and antibiotics, providing a safe haven 
for the microbes within42,54.  
 Urinary catheterization is a necessary medical procedure that causes major 
damage to the urinary tract. Pathogens, such as UPEC, take advantage of this 
compromised environment to exploit new and existing niches and establish severe 
infections.  This report uncovers important molecular mechanisms underlying UPEC 
pathogenesis following urinary catheterization. It raises important questions regarding the 
deleterious consequences of urinary catheterization and the origins of urinary catheter 
colonization. These novel aspects of CAUTI pathophysiology should thus be taken into 
consideration for the development of anti-virulence based preventative and therapeutic 
approaches against these infections.  
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DISCUSSION AND FUTURE DIRECTIONS 
The management of CAUTIs has recently gained considerable interest in 
healthcare settings20,21,56 due to the rise in multidrug resistant pathogens and given the 
significant medical and societal burdens associated with these infections12,56. However, 
the paucity of data describing the molecular mechanisms underlying the pathophysiology 
of CAUTIs contributes to the high prevalence, difficult diagnoses, and ineffective 
treatment regimens associated with these infections5,12. 
In the present dissertation, in vitro biofilm assays and a murine model were 
optimized to closely replicate the key characteristics of CAUTIs. These served as 
valuable tools to unravel previously unappreciated details underlying the detrimental 
effects of urinary catheterization on bladder homeostasis and revealed the microbial and 
immunological factors contributing to enterococcal and UPEC establishment of CAUTIs. 
Surprisingly, some in vitro biofilm determinants, such as Atn, GelE, and UPEC S pili 
were not found to play a role in biofilm formation based on the CAUTI model whereas 
enterococcal sortases and UPEC type 1 pili were major contributors of virulence. 
Furthermore, studies revealed that the pathogenic cascade of UPEC is quantitatively 
altered in presence of foreign bodies due to a multitude of factors in addition to urothelial 
exfoliation5,12. Importantly, evidence presented in this dissertation show for the first time 
that bacteria reservoirs in the bladder established during previous infections are a 
potential third source for urinary catheter colonization. This is a risk that has not been 
previously considered and has major implications for clinical management and decision-
making in the context of CAUTIs and other medical-associated infections. Ultimately, 
this study yielded insight towards the development of novel therapeutic approaches by 
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establishing the efficiency of specific inhibitors of UPEC type 1 pili tip adhesin FimH, 
namely mannosides, as alternative virulence-based preventative measures in the fight 
against CAUTIs.  
In addition to the milestones achieved in unraveling the molecular factors 
involved in the pathogenesis of E. faecalis and UPEC CAUTIs and unappreciated aspects 
of CAUTI pathophysiology, this dissertation has multiple ramifications and opens up 
exciting avenues of research in various areas ranging from basic science research to 
clinical management of CAUTIs and other biofilm-associated infections. 
Implications for enterococcal and UPEC pathogenesis: 
Findings from this dissertation represent advance our understanding in the study 
of E. faecalis uropathogenesis as well UPEC pathogenesis in the context of urinary 
catheterization. Biofilm formation on the surface of urinary catheters, a central 
component of CAUTIs, was demonstrated here to be an essential virulence property for 
E. faecalis colonization of and persistence within the urinary tract. In vitro studies 
performed in this work showed that the enterococcal autolytic factor Atn mediates DNA 
release at a specific time during the establishment of DNA-dependent E. faecalis 
biofilms. Extracellular DNA (eDNA), was found to be a major component of the 
extracellular matrix of enterococcal biofilms in vitro, and to be critical for the maturation 
and architectural stability of these structures. These findings are in agreement with 
previous reports by Thomas et al, which showed that gelatinase (GelE) contributes to 
DNA release during biofilm formation by regulating autolytic processes probably via 
cleavage of Atn103,104. GelE is a well-established virulence factor in a rabbit model 
enterococcal endocarditis where biofilm formation occurs on the surface of heart 
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valves221. Yet, Atn and GelE were dispensable for biofilm formation and virulence in the 
urinary tract in the CAUTI model. These findings question whether eDNA is important 
for biofilm formation in the urinary tract. Investigation of the regulation of autolytic 
processes in E. faecalis will help uncover complementary pathways involved in DNA 
release, as DNA-dependent biofilm formation may be critical in other enterococcal 
infections and in an agricultural environment221,294. Furthermore, E. faecalis may employ 
eDNA-independent pathways to establish biofilms on the surface of urinary catheters.   
The enterococcal factors identified to promote biofilm formation and virulence in 
the urinary tract were sortases SrtA and SrtC, the enhanced expression of pheromone 
protease (Eep), and the transcription factor AhrC.  Thus, sortase substrates, which are cell 
surface proteins, may represent attractive targets for antimicrobial therapies given their 
ubiquitous nature and various functions in bacterial physiology and pathogenesis116,143. E. 
faecalis encodes over 30 LPxTG motif containing proteins116, including the endocarditis 
and biofilm-associated pilus (Ebp), a structure which contributes to enterococcal UTI 
pathogenesis107 (Nielsen, H.V., Guiton, P.S., et al, manuscript in preparation). Expression 
studies in vitro and in vivo and direct mutagenesis of candidate genes may help uncover 
relevant biofilm and urovirulence-promoting substrates. As for UPEC, of the known 
biofilm determinants examined, including the amyloid fibers curli and S pili, only type 1 
pili were found to be essential for biofilm formation and virulence in the murine model of 
foreign body associated UTIs.  
The physiological requirements to produce and maintain biofilms in the urinary 
tract require further research. Genetic and biochemical approaches can be used to 
uncover the molecular details of the interactions within biofilm communities. Microarray 
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analyses of cells extracted from in vivo biofilms at different time during the infection 
process can identify genes that are important for metabolic processes, extracellular matrix 
formation, or immune evasion during CAUTI. In addition to microarray analyses 
following infections, identification of SNPs between E. faecalis OG1RF and OG1X 
strains can provide potential candidates for novel biofilm determinants and virulence 
factors. In collaboration with Kimberly Kline, Ph.D., Fredrik Henriques and Brigitta 
Henriques-Normark, M.D., Ph.D., 69 SNPs were identified in coding regions between the 
two strains and 11 were sequenced and confirmed (Tables 1 and 2). These genes have 
putative functions ranging from cell surface proteins to energy transduction. Investigation 
of their roles to E. faecalis biofilm and virulence will provide more insights into the 
drastic defect observed with OG1X in vivo.  
Furthermore, the composition of the extracellular matrix of both E. faecalis and 
UPEC biofilms can be determined by isolating the matrix of biofilms from the surface of 
urinary implants from mice and from urinary catheters isolated from human patients and 
analyzing them using and optimizing previously established methods65. The molecular 
basis of how these structures change overtime can be investigated to provide insight into 
the biofilm developmental processes. Ideally, the constituents of these extracellular 
matrices, if identified and characterized, can be useful targets for the disruption and 
dissolution of biofilms on the surface of urinary catheters. 
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Table 1: List of the putative functions of the 69 SNPs identified in coding 
regions between OG1RF and OG1X 
Putative functions Number of 
different 
genes 
Putative functions Number of 
different 
genes 
Replication 1 Lipid transport and 
metabolism 
1 
Transcription 8 Transport, unknown 
substrates 
4 
Translation 3 Energy metabolism 4 
 
Inorganic transport 
1 Membrane/cell wall 10 with 2 
putative 
SrtA 
substrates 
 
Nucleoside transport and 
metabolism 
3 Signal transduction 1 
Amino acid transport and 
metabolism 
8 Defense mechanism 4 
Carbohydrate transport and 
metabolism 
4 Unknown function 
and hypothetical 
proteins 
17 
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Remarkably, the establishment of persistent enterococcal and UPEC CAUTIs 
occur despite the induction of an acute inflammation response following urinary 
catheterization. The host immune response within the catheterized murine bladder 
consists of the onset of massive bladder wall edema due to an increased in vascular 
permeability, the production of pro-inflammatory cytokines, and the recruitment of 
myeloid cells, especially neutrophils. This robust response fails to prevent and clear 
bacterial infection. One hypothesis is that the acute immune response to a urinary catheter 
alters the adequate response to uropathogens or favors biofilm formation as shown for 
Methicillin-Resistant S. aureus295. Unlike E. faecalis, UPEC induces a robust 
Table 2: List of 11 genes with sequenced and confirmed SNPs between OG1RF and OG1X 
Gene with confirmed 
SNPs 
Putative function AA Change 
OG1RF   OG1X 
EF0243 Branched-chain amino acid transport system 
II carrier protein (bnrQ) 
Val Iso 
EF3157 Glycosyl hydrolase, family 65 Ser Asn 
EF1513 Pheromone binding protein Ser Asn 
EF1218 Spermidine/putrescine ABC transporter, 
permease protein 
Pro Ser 
EF2575 Carbamate kinase Gly Asp 
EF2983 Glutamyl-tRNA(Gln) amidotransferase, A 
subunit, putative 
Ala Thr 
EF3285 PTS system, IIC component Ser Phe 
EF3290 Sensor histidine kinase Glu Lys 
EF1778 Phosphoribosylaminoimidazolecarboxamide 
formyltransferase/IMP cyclohydrolase 
(purH) 
Arg Gln 
EF2587 Inosine-uridine preferring nucleoside 
hydrolase 
Arg Thr 
EF1349 Glycosyl hydrolase, family 13 His Tyr 
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inflammatory response in non-catheterized animals76,190,239. Comparison of this immune 
response to that elicited during UPEC-mediated CAUTI can provide insight into the 
above hypothesis. Alternatively, E. faecalis and UPEC may employ several molecular 
immune evasion mechanisms to withstand and escape the deleterious effects of the 
immune system activated during CAUTI, such as subversion of neutrophil killing, 
invasion into the host cells260,261,266,269,296-298, or incorporation of host-derived components 
to produce biofilms as shown for Nontypeable Haemophilus influenza157,299, thus 
potentially rendering the biofilms less immunogenic.  
This dissertation focused on the immune response 24h following urinary 
implantation with or without bacterial challenge. It will be informative to examine the 
changes of the immune response over time. This can be achieved by microarray and 
quantitative real time PCR analyses of bladder cells at different times following urinary 
implantation in the presence or absence of the bacteria of interest. Not only will these 
experiments allow the identification of the immune pathways leading to bladder 
inflammation after catheterization, they will help uncover the effects of bacterial 
colonization on these immune pathways. A pathway that is activated in response to 
bacteria and detrimental to the infectious agent can be modified and exploited for 
enhancing the antibacterial response whereas infection-promoting pathways could be 
targeted for downregulation or inhibition.  
It will be of great interest to investigate the mechanisms underlying UPEC and 
enterococcal dissemination to the kidneys as well as the complications ensuing from 
urinary catheterization, including pyelonephritis and bacteremia. The onset of edema may 
cause reflux to the kidneys300, and hence may promote bacterial colonization of these 
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organs. On the other hand, bacteria may have mechanisms to hijack the host cells and 
disseminate to other organs. The role of the host in bacterial dissemination can potentially 
be addressed following experimental depletion of host immune populations of interest.  
Implications for microbial physiology and intra- and inter-microbial interactions:   
CAUTIs are polymicrobial in nature37,57,58. Thus, these studies should be extended 
to mixed microbial communities given that the molecular interactions within constituents 
of polymicrobial communities on the surface of urinary catheters are poorly defined. Are 
all microbes found together or in specific consortia? Do they interact with each other to 
the same extent? Is there particular microbial associations during CAUTI progression as 
suggested by Macleod et al.58? What are the molecular factors underlying these 
preferential associations? Is the host immune response altered in presence of various 
bacteria? Is the host response to one pathogen favorable or detrimental to another? 
Introduction of other uropathogens such as P. aeruginosa, P. mirabilis, and other Gram-
positive bacteria while studying CAUTI will contribute to a better understanding of the 
intra and inter-species interactions occurring during these infections. 
It is proposed that E. coli and Enterococci are among the first to colonize urinary 
catheters and the microbial population is altered over time with colonization by P. 
aeruginosa, P. mirabilis, Providencia stuartii, Morganella morganii37. Data obtained in 
the course of this thesis indicate that live E. coli UTI89 and supernatants from stationary 
E. coli cultures inhibit enterococcal biofilm in vitro (Fig. 41A-C, Guiton et al, 
unpublished). Similar findings were obtained with the commensal E. coli strain MG1655 
(data not shown). On the other hand, UPEC does not affect E. faecalis biofilm formation 
and virulence in vivo when introduced at a 1:1 ratio in implanted animals (Fig. 41D-E; 
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Guiton, P.S. et al, unpublished).  Both bacterial species are recovered on the surface of 
implants and organs to the same extent as in single infections. Similar results were 
obtained in the kidneys (data not shown).  Together, this indicates that the molecular 
dynamics of in vitro and in vivo biofilm formations in mixed communities are different. 
Identification of the E. coli in vitro inhibitory factor(s) may represent a target to prevent 
in vivo infections. Studies from the K2 pyelonephritis isolate CFT073 identified an 
inhibitory polysaccharide fragment301. However, UTI89 and MG1655 produce K1 and 
K12 capsules, respectively302,303, suggesting the inhibitory factor identified in the present 
study is unique. It will be of interest to understand why UPEC does not inhibit 
enterococcal biofilms in vivo. Can it be that the anti-biofilm substance(s) is/are not 
produced in the urinary tract, produced and degraded, or present in too minute quantities 
in vivo to be effective against E. faecalis biofilms? Further research on this topic will 
contribute to a better understanding of the interactions between UPEC and E. faecalis and 
provide insight into potential novel anti-biofilm agents against enterococcal biofilms.  
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Figure 40: Differential interactions between E. faecalis and UPEC in vitro and in vivo.  
Representative CLSM images of (A) single and mixed OG1RF and UTI89 dynamic biofilms in 
TSBG and (B) of OG1RF shaking and static biofilms grown in TSBG supplemented with 
minimal media (M63+niacin+glycerol) or filter-sterilized UTI89 supernatants from stationary 
cultures in minimal media grown for 48h on PVC coverslips at 37ºC. SYTO89 and PI were used 
to stain bacterial DNA in all experiments. In mixed biofilms, OG1RF was stained additionally 
with WGA (pink punctuates in middle panel in A). (C) Crystal violet based quantification of 24h 
OG1RF biofilms grown in TSBG supplemented with either minimal media or UTI89 supernatant. 
Error bars =SEM from two independent experiments. (D-E) Graphs represent bacterial titers in 
log scale from implants and bladders of animals inoculated for 24 and 48h with OG1RF (●), 
UTI89 (■), or a mixture of OG1RF (○) and UTI89 (□) at a 1:1 ratio.  Horizontal dashed lines 
represent LOD for viable bacteria. The horizontal bars represent the median of each dataset;   
*p<0.05, **p<0.0005, ***p<0.0005, ns corresponds to p>0.05 by the Mann Whitney U test.  
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Implications for bladder cell biology and physiology:  
The presence of a foreign body within the urinary tract alters the bladder 
environment and homeostasis, resulting in cellular proliferation, urothelial damage, 
increased exfoliation, and the induction of a massive inflammatory response. All these 
detrimental biological changes may lead to bladder carcinogenesis, as in the case of 
patients with spinal cord injuries who are at higher risk of developing bladder cancer 
following urinary catheterization27,180,181. Important questions regarding the rate of 
bladder exfoliation, urothelial cell division and differentiation, and the epithelial 
responses to urinary catheterization could possibly be addressed by comparing responses 
following bladder implantation in animals with different genetic backgrounds. Further 
research may be warranted to investigate the development of bladder tumors following 
urinary catheterization. Simply, to start, the effects of urinary catheterization could be 
assessed on the production and function of several known markers of bladder cancer, 
such as RhoGDI2304 and Oct-3/4305. Additionally, further optimization of the murine 
model of CAUTI is required to ensure long term catheterization that may provide a novel 
tool for the study of urothelial tumorigenesis and metastasis in mice, similar to a previous 
model developed by Reis et al, but without involving the transurethral introduction of 
human carcinoma cells as in the orthotopic models of bladder cancers306 or administration 
of chemicals such as organic arsenicals in the bladder307,308. Understanding the 
consequences of urinary catheterization on bladder homeostasis may provide insights into 
the damage and side effects resulting from this necessary medical process. 
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Clinical implications 
The findings from this work question the very answer to “What is a UTI?” The 
current clinical definition refers to UTI as “the presence of bacteria within the urinary 
tract”5 and even with the different classifications of UTIs, undoubtedly does not 
encompass all the variations and presentations the disease can take. CAUTIs are rarely 
symptomatic; yet, bacteriuria, which is almost inescapable following urinary 
catheterization12, and pyuria. Pyuria is not a good correlate of CAUTIs22. The 
establishment of intracellular niches in the presence of urinary catheters is a major 
discovery in the pathophysiology of UPEC-mediated CAUTI (Chapter three). Thus, 
bacterial counts equal to or greater than 1000 CFU/ml and pyuria, which occurs 
regardless of microbial colonization, as demonstrated here, are not enough for defining 
appropriate treatment course for intracellular microbial populations. It is thus imperative 
to identify new diagnostic tools in order to have better preventative or therapeutic 
regimens for CAUTI patients. Work outlined herein establishes a new origin for catheter 
colonization, in addition to the intraluminal and extraluminal portals178, implying that 
patients with history of UTIs may be at greater risk of CAUTI and rUTIs after catheter 
removal. The favored CAUTI treatment strategy, which is the removal of contaminated 
urinary catheter following bacteriuria, should be reconsidered in light of the findings 
presented here. Intracellular bacteria or pre-existing reservoirs from previous UTIs can 
resurface and cause recurrent infection even in the absence of catheters. It is thus 
imperative to re-examine the paradigms for diagnosing and treating CAUTIs. 
In addition to leukocyte esterase and nitrite currently used as biomarkers of 
UTIs309, it will be very advantageous to have additional host and bacterial biomarkers 
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that provide more insights into the type of infection and the stages of the disease. These 
biomarkers may include small molecules produced by multidrug resistant bacteria or the 
host immune cells during infections and biomaterials shed from biofilms during 
infections that can be detected in the urine. Bacterial DNA, polysaccharide fragments 
from the extracellular matrix of biofilms or particular proteins from the host secreted only 
in the presence of particular bacterial species may be among these biomarkers. 
Furthermore, this thesis shows that immunosuppression favors enterococcal infections, 
since dexamethasone treatment and neutrophil depletion enhance infections; 
corroborating the predominance of CAUTI among immunosuppressed and 
immunocompromised individuals5. This finding also implies that immunosuppression in 
a patient undergoing urinary catheterization should not be a favored approach in trying to 
reduce the inflammation and other side effects ensuing from catheterization or during the 
treatment regimens against CAUTIs. 
Drug development  
CAUTIs originate primarily from multidrug resistant bacteria. The identification 
of intracellular populations, as in the case of UPEC CAUTI coupled with the ever-
increasing antibiotic resistance, especially within biofilms, underscores the need for 
better preventative and therapeutics approaches. As demonstrated in this dissertation, 
mannosides, which specifically target the FimH adhesin of UPEC, prevented the 
establishment of IBCs and, in combination with existing antibiotic-based therapy, 
prevented the establishment of implant and organ colonization in the murine model of 
CAUTIs. Thus, virulence-based approaches in addition to antimicrobial-coated catheters 
or bacterial interference approaches as previously proposed293,310 can be novel avenues of 
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research for preventing and treating CAUTI. Surface proteins, such as LPxTG motif-
containing cell wall proteins in Gram positive bacteria, are also attractive targets for 
virulence-based approaches as they are readily accessible, important for binding to 
abiotic surfaces as well as urothelial cells, and can be mediators of bacterial immune 
evasion.  
Studies in this thesis also demonstrated that urinary catheterization induces 
urothelial damage and significant reduction in UPEC IBC formation. It is thus plausible 
that the use of abiotic irritants that induce urothelial exfoliation and/or release anti-
biofilm agents such as mannosides in a controlled manner may be an effective treatment 
for women suffering from chronic and recurrent UTIs. It will be of interest to evaluate 
chemicals or devices that can enhance bladder exfoliation to remove intracellular 
reservoirs without favoring microbial colonization and causing further damage to the 
bladder. Such strategy may be helpful to reduce the rate of recurrent infections.  
 
CONCLUDING REMARKS 
CAUTIs are major nosocomial infections afflicting humans of both sexes and all 
ages and associated with important medical and societal burdens. The present dissertation 
provides a better understanding of these infections, particularly caused by UPEC and E. 
faecalis, using an optimized murine model of CAUTI. The study presented here describe 
important characteristics of CAUTIs, raise important questions regarding diagnostic 
approaches and propose novel preventative and therapeutic approaches against CAUTIs 
based on the identification and targeting of important biofilm determinants and virulence 
factors. The implications of the current report underscore the need for more research and 
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increased clinical attention to CAUTIs for a better management of these infections and 
ultimately the patients’ welfare. 
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MATERIALS AND METHODS 
Bacterial strains and growth conditions 
All strains used in this study and their characteristics are listed in Table 3.  
For E. faecalis: Unless otherwise specified, all experiments were initiated from an 
overnight culture in brain heart infusion broth (BHI; Becton Dickinson, Franklin Lakes, 
NJ) of a single bacterial colony grown on BHI agar plate supplemented with the 
appropriate antibiotics. Liquid cultures were grown statically at 37°C for 18 hours.   
For E. coli: bacteria from a single colony from Luria Bertoni (LB, Becton Dickinson) 
agar plate supplemented with the appropriate antibiotics were inoculated into LB broth 
and grown statically at 37°C for 18 hours or 2 x 24h. 
Antibiotics used for bacterial selection: Rifampicin (Rif), Fusidic acid (Fus), Kanamycin 
(Kan), Chloroamphenicol (Cm), and Streptomycin (Str); from Sigma-Aldrich, Inc., St. 
Louis, MO.  
Genetic manipulations and sequencing 
Table 4 lists the plasmids used in this study.  
For E. faecalis: In-frame deletion constructs were made in temperature sensitive plasmid 
pJRS233311,312 for genes of interest based on the complete genome of E. faecalis V583313; 
all references to genomic loci below are based on this annotation (GenBank accession 
number AE016830). Chromosomal integrants were selected as previously described314 
with primers listed in Table 5.  Complementation of indicated genes was done using a 
pABG5-derived pAL1 plasmid expressing the gene of interest under the rofA 
promoter312,314,315.   
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For E. coli: Genetic mutations were generated as previously in described using λ Red 
Recombinase system316,317. 
DNA sequencing and sequence manipulations 
Genes of interest were separately amplified in PCR reactions using OG1RF and OG1X 
colonies or purified genomic DNA as template. The primers used for amplification are 
listed in Table 7. Forward (F1 or 2) primers were used for amplification of the upstream 
region and Reverse (R1) primers were for amplification of the downstream region of the 
genes of interest annotated according to the genome sequence of E. faecalis V583313. 
PCR were performed as described in Chen et al318. Products were purified using the 
QIAquick PCR purification kit according to manufacturer’s guidelines (Qiagen) and 
submitted for capillary sequencing with primers listed in table 7 using an ABI 3730xl 
instrument (Genewiz, Inc.). Base calling and assembly was done using Phred and 
Phrad319,320. Sequences were aligned using CLUSTAL W321 with default parameters and 
trimmed to the start and stop codons of genes as annotated in the OG1RF and V583 
genome sequences168,313.  
Inhibitors and chemicals 
The drug treatments used in this study, their relevant modes of action, and references of 
dosage and effectiveness are described in Table 7. Vehicles were saline or DMSO as 
indicated. 
Mouse strains 
Six to seven week-old female wild-type C57BL/6Ncr mice purchased from the National 
Cancer Institute (NCI) were used in this study.  Six to seven week old female C57BL/6J, 
interleukin 6 mutant B6.129S-IL6tm1kopf/J (referred to in this study as IL6-/-), Toll Like 
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Receptor 2 mutant B6.129-Tlr2tm1Kir/J (referred to in this study as TLR2-/-), Rag 
B6.129S7-Rag1tm1Mom/J mice were obtained from Jackson Laboratories. MyD88, Trif, and 
cKit-mutant female mice from Jackson Laboratories were bred at Washington University 
in St Louis. Experiments were performed following one-week adaptation in the animal 
facility.  All studies and procedures were approved by the Animal Studies Committee at 
Washington University School of Medicine.  
Cultivation and quantification of biofilms   
Bacterial preparation for biofilms: Stationary phase bacteria from overnight cultures 
were diluted to OD600 of 0.2 in fresh growth medium followed by an immediate 1:100 
dilution (1-2x106 CFU/ml) in biofilm media: TSBG composed of tryptic soy broth (TSB; 
Becton Dickinson, Sparks, MD) supplemented with 0.25% of glucose (Sigma-Aldrich), 
LB, or human urine. Urine was collected from healthy volunteers as approved by the 
Institutional Review Board of Washington University in St. Louis. Pooled urine were 
spun at 10,000 x g for 15min, filtered through 33µM filters, and, if necessary, stored at 
4ºC for no more than 3 days. Mixed biofilms were grown in TSBG with bacterial strains 
mixed at a 1:1 ratio prior to media inoculation. Supernatants from stationary phase UTI89 
cultures grown in minimal medium (M63 salts with niacin and glycerol) or LB under 
static conditions at 37ºC were spun at maximum speed, filter-sterilized, and were added 
to TSBG at 1:4 ratio (20% supernatant to 80%TSBG) prior to OG1RF inoculation. 
Supernatants from stationary cultures of OG1RF in BHI and sterile minimal medium, LB, 
and BHI were supplemented to TSBG when indicated and used as controls.  
Coverslip-based assays: Biofilms were grown as described by Gilmore et al.322 and 
modified as follow: 5ml of diluted cultures were placed in each well of sterile 6-well 
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tissue-culture flat bottom plates (Techno Plastic Products, St Louis, MO) containing a 
UV-sterilized 22x22mm plastic cover slip (Fisher scientific, Pittsburgh, PA). Plates were 
incubated at 37°C statically or under dynamic conditions (100RPM) on an orbit shaker 
(model 3520; Lab-Line Instruments, Inc., Melrose Park, IL) for the duration of the 
experiments.  At 24hr intervals, media were removed by aspiration and the cover slips 
were washed twice with 5ml of autoclaved water for 3 minutes at 100RPM on orbit 
shaker at room temperature (22-25°C) and fresh media added. At selected time points, 
biofilms were washed and air-dried. Biofilms were then stained with 0.5% crystal violet 
(Sigma-Aldrich, Inc., St Louis, MO) for 10 minutes at room temperature. Excess dye was 
removed with autoclaved water and air-dried at room temperature. Biofilms were then 
dissolved with 500µl 33% acetic acid (Fisher Scientific, Fair Lawn, NJ). Biomass was 
quantified colorimetrically by measuring the absorbance at OD595 with a microplate 
reader (Molecular Devices, Sunnyvale, CA). Experiments were performed independently 
at least three times with three coverslips/condition/experiment. 
Fluid flow-based assay: Biofilms were grown as described by Ferrieres et al.323on All 
Silicone Foley catheters (Bard Medical, GA) or silicone tubing (Thermo Fisher Scientific 
Inc.) and modified as follows. All tubing and connectors in the system were autoclaved 
and ethanol sterilized prior to use. The system was assembled similar to the previously 
described flow-chamber system.  Priming of the catheter or the silicone tubing occurred 
at 37ºC for 20min by flowing pre-warmed pooled human urine. Pooled samples were 
spun at 10000xg for 15min, filtered through 33µM filters, and, if necessary, stored at 4ºC 
for no more than 3 days.  Three milliliters of stationary-phase E. coli from 
overnight cultures were diluted to 1-2x106 CFU/ml in human urine and injected into the 
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catheter or silicone tubing using a 30 cc gauge needle. The bacteria were allowed to 
attach to the substratum for 1 h before urine flow via Watson-Marlow peristaltic pump 
205S was resumed at 0.5 ml min−1. When indicated, urine was supplemented with 1% 
methyl-α-D-mannopyranoside (Sigma-Aldrich) prior to the experiment. After 24 hours, 
the remaining medium was exchanged for sterile ddH2O that was allowed to flow at 0.5 
ml min−1to remove residual urine and non-adherent bacteria in the system. The liquid 
from catheter or silicone tubing was then removed by capillary action onto absorbent 
paper. The tubing was cut into pieces for CFU enumeration or crystal violet staining, 
respectively. For CFU enumeration, at least three pieces (1cm in length) of incubated 
tubing were separately further cut into smaller pieces and placed into 1ml PBS. Adherent 
cells were detached by sonication (10min) and vigorous vortexing (3min). Viable 
bacterial counts were assessed by serial dilution on BHI or LB agar plate with appropriate 
antibiotics. Crystal violet staining was used to determine biofilm biomass. At least 3 
pieces of incubated tubing (3cm in length) were filled with 0.5% crystal violet at room 
temperature for 10 min. Excess dye was removed by washing three times with ddH2O 
and dried by capillary action on absorbent paper. The bound crystal violet was then 
dissolved in 200 µl of 33% acetic acid and absorbance measured at 595nm. The amount 
of biofilm was expressed as CFU/ml per cm2 and A595/cm2. The experiment was 
repeated at least twice with different urine samples.  
Primary adherence assay 
Biofilms were set up according to the coverslip-based assay described above. Cells were 
allowed to attach for 2h, 4h, and 6h at 37°C under static or shaking conditions. After 
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desired incubation times, cover slips were washed once with sterile water and processed 
as described above. Adherent cells were quantified by OD595 measurements.  
DNase I assays  
DNase I (Sigma Aldrich) or heat inactivated DNase I (30 minutes at 100°C) was added at 
a final concentration of 5µg/ml, unless otherwise stated in coverslip-based biofilm assays. 
Heat-inactivation of DNase I was verified by its inability to digest 100µg/ml of salmon 
sperm DNA or purified enterococcal genomic DNA in TSBG for 1h or 24h at 37°C. 
DNase I was either supplemented continuously every 24hrs from the beginning of the 
experiment or added to preformed biofilms for the time indicated. Experiments were 
performed independently in triplicate with three cover slips/condition/experiment. 
Bacteria and biofilm visualization  
By Confocal Laser Scanning Microscopy: All confocal microscopy was performed on 
an LSM 510 Meta Laser Scanning Confocal microscope (Carl Zeiss, Thornwood, NY), 
using a 63X oil immersion objective. Images were acquired using the LSM Image 
Examiner software (Carl Zeiss, Thornwood, NY).  3D reconstruction of biofilm images 
were generated using Volocity software (Improvision, Inc., Waltham, MA).  Washed 
plastic cover slips were stained for 15 minutes in the dark at room temperature with 1ml 
of 3µM of SYTO9 mixed with 3µM of propidium iodide (PI) from Molecular Probes, 
Eugene, OR.  When indicated, 1µg/ml of Alexa Fluor 633-conjuaged Wheat Germ 
Agglutinin (WGA) was added for carbohydrate staining324. Excess dye was removed by 
aspiration and biofilms were washed twice with 1X phosphate buffer saline (PBS) 
solution or water.  Stained cover slips were mounted on glass slides using Prolong® Gold 
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Antifade (Molecular Probes) followed by image acquisition. Microscopy was performed 
on two coverslips/condition/experiment with at least two independent experiments. 
By Freeze Dry Electron Microscopy: Biofilms grown on glass cover slips in TSBG 
under hydrodynamic conditions for 48h on were fixed with 2% glutaraldehyde in 100mM 
NaCl, 30mM Hepes, 2mM CaCl2 and 75mM Sucrose, pH 7.2 for 1 hour.  Samples were 
rinsed in deionized water to remove aldehyde and buffer, and quick-frozen by forceful 
impact against a copper block cooled to 4°K with liquid helium. Frozen cultures were 
stored in liquid nitrogen until mounting in a Balzers 301 vacuum evaporator, wherein 
they were freeze-dried for 20 minutes at –80°C and then rotary-replicated with 2 nm of 
platinum deposited from an electron-beam gun mounted at 15 degrees above the 
horizontal.  The Pt-replica was then stabilized with a carbon film deposited from a 70° 
angle.  Replicas were floated off the glass onto concentrated hydrofluoric acid, then 
transferred through several rinses of deionized water and picked up on formvar-coated 
grids.  Replicas were examined in a JEOL 100CX microscope and photographed with an 
AMT digital camera. 
By Transmission Electron Microscopy: For immunolocalization of DNA at the 
ultrastructural level, 48h dynamic biofilms were fixed in 4% paraformaldehyde/0.05% 
glutaraldehyde (Polysciences Inc., Warrington, PA) in 100mM PIPES/0.5mM MgCl2, pH 
7.2 for 1 hr at 4°C.  Samples were then embedded in 10% gelatin and infiltrated 
overnight with 2.3M sucrose/20% polyvinyl pyrrolidone in PIPES/MgCl2 at 4°C.  
Samples were trimmed, frozen in liquid nitrogen, and sectioned with a Leica Ultracut 
UCT cryo-ultramicrotome (Leica Microsystems Inc., Bannockburn, IL).  50 nm sections 
were blocked with 5% Fetal Bovine Serum (FBS)/5% Normal Goat Serum (NGS) for 30 
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min and subsequently incubated with mouse anti-double-stranded DNA (anti-dsDNA) 
monoclonal antibody (Abcam, Cambridge, MA) for 1 hr at room temperature.  Sections 
were then washed in block buffer and probed with 18nm colloidal gold-conjugated anti-
mouse secondary antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove 
PA) for 1 hr at room temperature. Sections were washed in PIPES buffer followed by a 
water rinse, and stained with 0.3% uranyl acetate/2% polyvinyl alcohol.  Samples were 
viewed with a JEOL 1200EX transmission electron microscope (JEOL USA Inc., 
Peabody, MA). All labeling experiments were conducted in parallel with controls 
omitting the primary antibody.  These controls were consistently negative at the 
concentration of colloidal gold conjugated secondary antibodies used in these studies. 
Quantification was based on gold particles labeling from 13 independent fields at 30000X 
magnification. 
By Negative staining and analysis by electron microscopy: Bacteria were grown 
overnight in BHI and diluted as described above in TSBG. They were allowed to grow 
statically for 6h at 37°C. Cells were pelleted and resuspended in 1X phosphate buffered 
saline (PBS). Bacteria were allowed to absorb onto formvar/carbon-coated copper grids 
for 1 min.  Grids were washed in dH2O and stained with 1% aqueous uranyl acetate (Ted 
Pella Inc., Redding CA) for 1 min.  Excess liquid was gently wicked off and grids were 
allowed to air dry.  Samples were viewed on a JEOL 1200EX transmission electron 
microscope (JEOL USA, Peabody, MA) at an accelerating voltage of 80kV. 
By Scanning Electron Microscopy: Biofilm grown on silicone tubing were fixed in 4% 
paraformaldehyde, 2.5% glutaraldehyde, and 0.1M cacodylate, and prepared for scanning 
electron microscopy (Hitachi Ltd, Tokyo). 
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Cellular autolysis assay  
The autolysis assay was performed as previously described in sodium phosphate buffer 
139. Briefly, overnight cultures were inoculated in fresh TSBG at a final O.D. of 0.002 at 
600nm and grown at 37°C on an orbit shaker at 100RPM to an O.D. of 0.6 at 600nm or 
after 24h. Cultures were then placed on ice for 10 min and 1.5ml were removed and 
centrifuged at 14,000 x g for 5min at 4°C. The supernatants were discarded and the 
pellets were resuspended in 1.5ml of ice cold water and washed thrice at 14,000 x g for 
5min at 4°C. Subsequent to the third wash, the pellets were resuspended in 10mM 
sodium phosphate buffer at pH 6.8 supplemented with 0.5µg/ml of trypsin (Sigma-
Aldrich). 200µl of the suspensions were dispensed in a 96-well flat bottom microtiter 
plates in quintuplet and the remaining wells were filled with ddH2O. Samples were 
incubated at 37°C and O.D. readings were taken every 30 minutes for up to 9 hours at 
600nm in a spectrophotometer. Autolysis was expressed as percent of initial turbidity at 
600nm.  
Murine implantation procedure   
The experimental model for foreign-body associated UTI 29,194 was adapted for the study 
of E. faecalis and E. coli with the following modifications.  Polyethylene tubing (PE10 
outside diameter, 0.6mm, inner diameter, 0.28mm; Becton Dickinson, MD) and 
platinum-cured silicone tubing (SIL025: outside diameter, 0.64mm; inside diameter, 
0.30mm; Braintree Scientific, Inc, MA) were sterilized with 70% ethanol and air-dried.  
A seven-millimeter-long segment of PE10 was fitted onto a 30.5-gauge sterile needle 
(Becton Dickinson). A four to five millimeter-long straight segment of the SIL025 was 
then placed on top of the PE10 segment.  The assembly was then UV-sterilized for 24h.  
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Seven to eight week-old female wild-type C57BL/6Ncr mice were anesthetized with 
inhaled isoflurane and placed on their backs.  The periurethral area was sterilized with 
100% ethanol and 10% povidine-iodine solution.  The needle with both PE10 and SIL025 
was gently inserted in the urethral opening.  The long segment (PE10) was delicately 
advanced with tweezers until the shorter segment (SIL025) was released into the bladder.  
Subsequently, the needle with the PE10 was removed leaving the silicone implant in the 
murine bladder.  The recovery of straight silicone implants was greater than 95% at 24 
hours and approximately 75% seven days following implantation. 
Bacterial infection and colony forming unit (CFU) determination   
Bacterial cells were collected from overnight cultures by centrifugation at 8,000 X g for 5 
min and resuspended in 1x phosphate-buffered saline (PBS) to an approximate optical 
density at 600nm of 1 corresponding to approximately 7x108 CFU/ml. When indicated, 
bacteria were further diluted to OD600 of 0.5. Seven- to eight- week-old female 
C57BL/6Ncr mice with or without silicone implant were anesthetized by inhalation of 
isoflurane and infected by transurethral catheterization as previously described62,325 with 
50µl inocula of PBS or bacterial suspensions (~1-3.5x107 CFU) immediately following 
implantation. For polymicrobial infections, bacterial species were mixed at a 1:1 ratio to 
reach (~1-2x107 CFU/strain). To quantify bacteria present on implants and in mouse 
organs, mice were sacrificed at desired time points by cervical dislocation after 
anesthesia inhalation, and the bladders and kidneys were aseptically harvested. 
Subsequently, the silicone implant was retrieved from the bladder when present, placed in 
PBS, sonicated for 10 min and then vortexed at maximum speed for 3 min.  Bladder and 
pairs of kidneys from each mouse were homogenized in PBS. For bacterial enumeration 
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on implants and tissues, samples were serially diluted and plated on BHI supplemented 
with the appropriate antibiotics or LB plates. Colony forming units (CFU) were 
enumerated after 24h incubation at 37˚C. Experiments were performed at least twice with 
n=5 mice/strain/condition. Biofilms on retrieved implants were visualized by scanning 
electron microscopy at indicated time points.  
Bladder weight determination and plasma protein extravasation 
When indicated, bladders were aseptically removed, bisected, and blotted dry. Bladders 
were placed in pre-weighed eppendorf tubes and weighed. Bladder weight (in grams) was 
determined as the difference between bladder and eppendorf tube weight and that of the 
empty eppendorf tube.  
Plasma protein extravasation (PPE) in the bladder was determined using the Evans blue 
technique326 in non-implanted and implanted animals at 6h post treatments with indicated 
chemicals listed in Table 6. Mice were anesthetized by inhalation of isoflurane and 
30mg/kg Evans Blue (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was administered 
intravenously (i.v.). Animals were sacrificed 15 min later by cervical dislocation. The 
bladder was then excised, bisected, and blotted dry before weighing. Bladders were then 
placed in 1ml of 100% formamide (Sigma-Aldrich) and incubated at 60ºC for 24 h for 
Evans blue extraction. The extracted Evans blue from each bladder was quantified by 
colorimetric measurement at 620 nm with an automated microplate reader. The dye 
content extravasated in each bladder was determined from an Evans blue standard curve 
and expressed as µg/g of tissue. 
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Mass spectrometry analysis 
To assess the presence of substance P following urinary catheterization, non-implanted 
and implanted animals with and without bacterial infections (one/experimental group) 
were sacrificed 3hpi. Bladders were retrieved, homogenized, spun at maximum speed to 
pellet cellular debris, and bladder homogenates were frozen at -80ºC until further use. 
Substance P is an undecapeptide with a molecular weight of 1347.6 and synthetic 
Substance P was purchased from Santa Cruz Biotechnology and used as positive control. 
Under routine electrospray conditions described below the 2+ and 1+ ions at 674m/z and 
1347m/z respectively dominate the spectrum. The peptide does not fragment to yield a 
nice sequence of ions but rather only seems to lose H2O and the C-terminal methionine. 
The ms2 spectrum has two major ions m/z 600, which is the b102+ and m/z 666 the b112+. 
The y9 (m/z 1095) and b2 (m/z 254) are also present to a lesser extent. This is in 
agreement with the literature327.  
C18 SPE columns (Waters, Milford, MA) were used to cleanup bladder homogenates and 
synthesized Substance P control. Substance P elutes in a 50% MeOH fraction. Samples 
were then applied to the SPE columns and the columns were washed (W) and then eluted 
(E). SRM scans were run on all W and E fractions but Substance P was not detected.  
The mass spectrometer used for the study was a Thermo-Finnigan LCQ Deca coupled to 
a Waters capLC. Samples were injected onto a Vydac C18 MS column (150mm 0.3mm 
X 5u) with a flow rate of 6ul/min. At time 0 Solvent A (0.1% formic acid) was held at 
92% and solvent B (80% acetonitrile in 0.1% formic acid) at 8%. Initial conditions were 
held constant for 5 minutes, before beginning a linear gradient which increased to 85%  B 
in the next 45 minutes. The column was allowed to equilibrate for 15 minutes before 
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starting the next run. The spray voltage on the spectrometer was 4.5K and the capillary 
temperature was 200 ºC. For CID experiments helium was used as the collision gas with 
the collision energy set to 30% of the maximum (~5 eV). Spectra were recorded from m/z 
216-2000 in the positive centroid mode. Ions were monitored with a window of +/- 
0.5amu 
Cytokine profiling   
Bladder homogenates from non-implanted and implanted animals with or without 
bacterial infections were microcentrifuged at 14,000 r.p.m. for 5 min and supernatants 
frozen at −80°C until the time of the assay.  Assays were carried out according to 
manufacturers' protocols using the Bio-Plex Pro Mouse Cytokine 23-plex Assay kit from 
Bio-Rad Laboratories (Hercules, CA). 
Histopathology and immunohistochemistry  
For histological analyses, bladders were fixed in methacarn (60% methanol, 30% 
chloroform, and 10% glacial acetic acid) or formalin for 1-2 h at room temperature and 
dehydrated in 70% ethanol overnight at 4ºC.  They were then embedded in paraffin, 
sectioned, and stained with hematoxylin and eosin (H/E) for light microscopy. For 
immunofluorescence examination, unstained bladder sections were deparrafinized with 
xylene (twice for 10 min), rinsed in 100% isopropanol (three times for 5 min), and 
washed with running de-ionized water for 5 min. When indicated, antigen retrieval was 
performed in Citrate Buffer (10mM NaCitrate pH 6.0) as previously described328,329. 
Slides were washed in PBS for 5 min and in blocking buffer (5% Fetal Bovine Serum or 
PBS with 1%BSA and 0.3% TritonX-100) for 1h at room temperature.  This step was 
followed by a PBS wash (three times for 5 min).  The tissue sections were then blocked 
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statically in blocking buffer for 30 min at room temperature. Primary antibodies, raised in 
rabbit against Streptococcus Group D antigen (Lee Laboratories), against human nitric 
oxide synthase 2 (NOS2 or iNOS; Santa Cruz Biotechnology), against rat NK-1 receptor 
(Pierce Biotechnology, Rockford, IL), raised in goat against mouse uroplakin III (Santa 
Cruz Biotechnology, Inc., CA) and against human substance P (Santa Cruz 
Biotechnology), were added in blocking buffer at 1:500 dilution when indicated and 
incubated at room temperature for 1 hour.  After a PBS wash (three times for 5 min), 
tissue sections were incubated with secondary antibody, Alexa Fluor 555-labeled donkey 
anti-rabbit antibody and Alexa Fluor 488-labeled donkey anti-goat antibody, each diluted 
1:1000 in blocking buffer for 30 min at room temperature.  After PBS wash (once for 5 
min), tissues were counterstained with TOPRO-3 (Molecular Probes) or Alexa Fluor 633-
conjugated WGA at 1:1000 dilution in PBS (second wash for 5 min) to reveal nuclear 
morphology, when indicated.  After a third PBS wash for 5 min, immunostained tissues 
were mounted using Prolong Gold Antifade (Molecular Probes) and visualized by CLSM.   
Flow cytometry 
Single cell bladder suspensions were made from minced bladder tissues subjected to 
collagenase/DNAse I digestion. Staining of surface markers was performed using FcR 
block and fluorochrome-conjugated monoclonal antibodies (mAbs).  
To immunophenotype the immune infiltrates, specific combinations of mAbs were 
chosen which distinguish granulocytes (CD11b+Gr1+Ly6G+), monocytes (Ly6G-Ly6C+), 
macrophages (CD11b+F4/80+), dendritic cells (CD11c+F4/80−), basophils (FccR1+), 
eosinophils (SiglecF+), mast cells (cKit+), NK cells (NK1.1+), T cells 
(CD3+CD4+/−CD8+/−), and B cells (CD19+). All antibodies were from BD Pharmagen, 
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Ebioscience or Southern Biotech. Cells were counterstained with propidium iodide. 
Activation status was determined using specific mAbs for MHC-II. Samples were 
acquired on a FACScalibur (BD Biosciences) and data were analyzed using FlowJo 
software (version 7.6.4). The absolute number of cellular infiltrates per bladder was 
calculated by multiplying the percentage of each population from two parameter flow 
cytometry data by the total number of isolated live cells, as determined by 
hemocytometer count following Trypan blue staining. 
Neutrophil depletion  
Mice were rendered neutropenic as previously described 219. Briefly, an anti-Ly6G mAb 
(1A8) from (Bio X Cell, West Lebanon, NH) was administered intraperitoneally on days 
3 and 1 prior to implantation and bacterial challenge. Control mice received IgG isotype 
control 2A3 (Bio X Cell) in the similar manner.   
Gentamicin protection assay 
To quantify intracellular and extracellular bacteria, bladders were aseptically harvested at 
indicated time points.  Bladders were cut in 4 parts and washed three times in 500 µl 
PBS. The wash fractions were pooled, centrifuged at 500 rpm for 5 min to pellet 
exfoliated bladder cells. The supernatants were then serially diluted and plated on LB 
agar supplemented with appropriate antibiotics to obtain the extracellular bacterial 
contents. The dissected bladders were treated with 100µg/ml gentamicin (Sigma-Aldrich) 
for 90 min at 37oC.  Following gentamicin treatment, the bladder tissue was washed twice 
with PBS to eliminate residual antibiotics, homogenized in 1 ml PBS, serially diluted and 
plated on LB agar with appropriate selection antibiotics for quantification of the 
intracellular bacteria.  CFU was enumerated after 24 h of growth at 37oC. 
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UPEC reservoir reactivation  
Non-implanted animals were infected with UTI89HK::GFP as described above. At 
fourteen days post infection, urine was collected, serially diluted and plated for CFU and 
a subset of animals implanted as described above. Animals determined to be bacteriuric 
(bacterial loads greater than or equal to 104 CFU/ml in urine) as counted on titer plates 
the next day were eliminated from further study.  UPEC reservoir reactivation post-
implantation was assessed by CFU enumeration of bacteria on implants and in the organs 
3 or 5 days post-implantation (17 or 19 dpi). UTI89HK::GFP titers greater than 104 
CFU/ml on implants or bladders were considered reactivation events.  Measures of 
reactivation events of animals, which were non-bacteriuric at 14 dpi but non-implanted 
served as controls. 
Mannoside and antibiotic treatment 
For pretreatment experiments, 50µl mannoside (ZH56; 5 mg/kg mouse body weight) or 
PBS was administered intraperitoneally 30min prior to implantation as previously 
described87. As indicated for pre-infection treatment, trimethoprim/sulfamethoxazole 
(TMP-SMZ) was added at 54 and 270 µg/ml, respectively, to the drinking water for three 
days prior to bacterial inoculation. The drinking water was changed every 24h.  
To assess the effects of mannoside and/or TMP-SMZ on established infections, animals 
were implanted and infected for 24h. At 24hpi, TMP-SMZ was added to the drinking at 
the concentrations indicated above and ZH56 or PBS was administered i.p. 6h prior to 
sacrifice. Animals were sacrificed 48hpi.  
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IBC enumeration and visualization  
Implanted and non-implanted animals were infected with UTI89 for 6h. When indicated, 
ZH56 (5mg/kg) or PBS was administered i.p. at 30 min prior to implantation. At 6hpi, 
bladders were harvested, bisected, splayed on silicone plates and fixed in 2% 
paraformaldehyde. LacZ staining of whole bladders was performed as previously 
described330. Punctate violet spots characteristic of IBCs were enumerated by light 
microscopy.    
For IBC visualization, animals were infected with UTI89 constitutively expressing GFP 
(UTI89pCom-GFP). At the indicated time point, bladders were removed, bisected, 
splayed, and fixed as described above. The splayed bladders were then incubated for 20 
min at room temperature with Alexa Fluor 633-conjugated wheat germ agglutinin (WGA; 
1:1000 in PBS; Molecular Probes) for staining of the bladder surface and, when 
indicated, SYTO83 (1:1000 in PBS; Molecular Probes) to stain bacteria. Bladders were 
rinsed with PBS, mounted using Prolong Gold antifade reagent (Invitrogen) and 
examined with a Zeiss LSM510 confocal laser-scanning microscope under a 63X 
objective.  SYTO83 and WGA were excited at 543 and 633 nm, respectively. 
Statistical methods 
Comparisons between groups were conducted by nonparametric two tailed, Mann-
Whitney U test using GraphPad Prism (GraphPad software). A p-value less than 0.05 was 
considered significant. For in vivo experiments, values below the limit of detection 
(LOD) were assigned the appropriate LOD value for statistical analyses.  Colonization 
and infection was defined as organs/implants with bacterial titers above the limit of 
detection at 24 hpi.  
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Table 3: List of strains used in this study 
 
Species and Strains 
Relevant 
Antibiotic 
resistance 
Characteristics References 
E. faecalis 
OG1RF WT Rif
R, FusR 
Parental enterococcal strain, 
derived from the oral isolate from 
OG1 
209 
OG1RFΔatn 
 Rif
R, FusR OG1RF with an in-frame deletion of atn, autolysin deficient This study 
210 
OG1RFΔsrtA RifR, FusR OG1RF with an in-frame deletion of srtA, SrtA deficient This study 
210 
OG1RFΔsrtA/srtA RifR, FusR,  KanR 
OG1RFΔsrtA ectopically 
expressing a wild type copy of 
srtA, SrtA positive 
This study 210 
OG1RF ΔgelE RifR, FusR OG1RF with an in-frame deletion of gelE, gelatinase deficient 
103 
OG1RF Δeep RifR, FusR OG1RF with an in-frame deletion of eep, Eep defective 
This study, 
Frank et al, in 
preparation 
OG1RF Ωef0983 RifR, FusR, CmR 
OG1RF with a transposon 
insertion in ef0983, AhrC 
defective 
This study 114 
E. faecalis 
OG1X Str
R gelE negative from nitrosoguanidine mutagenesis 
209, 331 
UTI89  Parental UPEC UTI89 strain, cystitis isolate 
282 
UTI89ΔfimH 
  
UTI89 with an in-frame deletion 
of fimH, type 1 pili defective 
75 
UTI89ΔsfaA-H 
  
UTI89 with an in-frame deletion 
of sfa operon, S pili defective 
This study, 
Wright et al, 
unpublished 
UTI89ΔsfaA-
H∆fimB-H Kan
R CmR 
UTI89 with in-frame deletion of 
the sfa operon and the fim operon 
from fimB to fimH, S and type1 
pili defective 
This study 
Wright et al, 
unpublished 
UTI89ΔcsgA  UTI89 with an in-frame deletion of csgA, curli deficient 
80 
UTI89ΔcsgB∆csgG  UTI89 with in-frame deletions of csgB and csgG, curli deficient 
80 
UTI89HK::GFP KanR 
UTI89 with an insertion of 
kanamycin cassette and green 
fluorescent protein (GFP) at the 
HK site 
292 
UTI89pCOMGFP KanR UTI89 ectopically expressing GFP 292 
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Table 4: List of plasmids used in this study 
 
 
Table 5: List of primers used in this study 
Primer Sequence (5′-3′) Use Reference 
EF0799f1 GCTCTAGAAAGTTGCAGCTCCGGCAATGCCA
CAACCGACG 
Amplification 
of upstream 
region of atn 
This study 
210 
EF0799sewr GTTACCAAAGATAGCTATTTTTTTCAATCTTA
AATTAACCAACTTTCGTCCCCAACTTTCCTTT
TTTAACTTATATGT 
Amplification 
of upstream 
region of atn 
This study 
210 
EF0799sewf GTTACCAAAGATAGCTATTTTTTTCAATCTTA
AATTAACCAACTTTCGTCCCCAACTTTCCTTT
TTTAACTTATATGT 
Amplification 
of downstream 
region of atn 
This study 
210 
EF0799r1 GCTCTAGAACCCAGTTAACCGCAACTTCTGCT
TCATAAGC 
Amplification 
of downstream 
region of atn 
This study 
210 
EF0799f2 ATTTGCCACCTGCAGCCATT Screening 
of atn deletion 
This study 
210 
EF0799r2 CCGCTCCCTCTTTCTACACG Screening 
of atn deletion 
This study 
210 
EF3056e-f1 GGAATTCCCCCTCTACTAGCCTCCTTACCATT
TTAC 
Screening 
of srtA deletion 
314 
EF3056e-r1 GGAATTCCGTTGATAATGAGTCTGCCGCTAG
TGTATG 
Screening 
of srtA deletion 
314 
 
 
 
Name Relevant Antibiotic resistance Characteristics References 
pABG5 KanR, CmR (E. coli) 
Kan500, Cm20 (E. faecalis) 
Shuttle vector, containing 
rofA promoter for 
expression in Gram 
Positive bacteria 
 
 
332 
pJRS233 Erm750 (E. coli) 
Erm25 (E. faecalis) 
Temperature sensitive 
plasmid for generation of 
in-frame deletions 
311, 312 
pAL1 Kan50 (E. coli) 
Kan500 (E. faecalis) 
Derivative of pABG5, 
Cmr cassette, contains 
rofA promoter 
This study 210 
pAL1::SrtA Kan50 (E. coli) 
Kan500 (E. faecalis) 
For complementation of 
srtA deletion 
This study 210 
pCOM-GFP Kan50 (E. coli) 
 
For expression of GFP 292 
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Table 6: Primers for confirmation of SNPs between OG1RF and OG1X 
Primer Sequence (5′-3′) 
EF0243F1 GGT TGC TCT CTG TTT CTT CTT CTG 
EF0243R1 CGA CAC TAG AAA AGA TGC GCT TCC 
EF1218F1 GTG TTG AAA TAT ACG TTT TCC TTG CG 
EF1218R1 AAG TCA CCA CAA TCA AAC ATA ATG G 
EF1349F1 CG ACA GAT GTC ACT GCT TTA GC 
EF1349R1 GTC TCT CGG TTG TTG AAG TTC C 
EF1778F1 CAG AGA AAA TTC ATG CTC TTG AGC 
EF1778R1 TCG CTG TAA TTT TTT GGC GAT TGC 
EF2575F1 CAT GTG CGT TGA CTT CAT GCA ACG 
EF2575R1 GTG AAT AAG GTC CTA CAG CAG C 
EF2587F1 CTC AAT ACT AAC TCA AGT CAT AGC 
EF2587R1 GGT ACT GCC AAG GTA ATT TAA AGC 
EF2983F1 CAG GAT GAC CTC TAA AAA CCA TGC 
EF2983R1 CAC TAC GTA CAG CAT TTT TCC ACC 
EF3157F1 GCA AGC GGT GAT TCA AGC ATT CG 
EF3157F2 CTG ACA CAG CGA AAC AAT TGT TGC 
EF3157R1 CCA AGC TTG ATA ATG AAA TTT GGC 
EF3285F1 GTC GTA TTT ACA TCA GAA AGC G 
EF3285R1 ACC AAC TCG GGC ACC ATC G 
EF3290F1 AGA TAA GAT TGA AGA AGC AAC TGG 
EF3290R1 CAA ACT CTC TGG AAT TCA GTG C 
 
Table 7: List of inhibitors and antibiotics used in this study 
Name Dosage/route Mode of action Company/References 
Dexamethasone 
Sodium Phosphate 
10mg/kg, i.p.30min 
prior to implantation 
Glucocorticoid, anti-
inflammatory and 
immunosuppressant 
American Regent, 
Inc., Shirley, NY 
245 
CP-99,994 
dihydrochloride 
 
5-10mg/kg, i.p., i.v., 
s.c.30 min and 3h 
post implantation 
(when indicated) 
High affinity 
neurokinin 1 receptor 
(NK1R) antagonist 
Tocris Bioscience, 
Ellisville, MO 
201,202  
CP-96,345 
 
5-10mg/kg, i.p., i.v., 
s.c, 30 min and 3h 
post implantation 
(when indicated) 
High affinity NK1R 
antagonist 
Tocris Bioscience 
199 
Aminoguanidine 
hydrochloride 
200mg/kg 1h and 3h 
post implantation 
(when indicated) 
Irreversible inducible 
nitric oxide synthase 
(iNOS) inhibitor 
Tocris Bioscience 
205 
Cyclophosphamide 150mg/kg at time of infection 
Chemotherapeutic 
agent/prodrug 
Tocris Bioscience 
333,216 
Alfuzosin 
hydrochloride 
60µg/kg, 15min prior 
to implantation 
α1 adrenoreceptor 
antagonist 
Tocris Bioscience 
206,334 
141 
 
REFERENCES 
1 Griebling, T. L. Urologic diseases in America project: trends in resource use for 
urinary tract infections in women. The Journal of urology 173, 1281-1287, 
doi:10.1097/01.ju.0000155596.98780.82 (2005). 
2 Foxman, B. Epidemiology of urinary tract infections: incidence, morbidity, and 
economic costs. Disease-a-month : DM 49, 53-70, doi:10.1067/mda.2003.7 
(2003). 
3 DeFrances, C. J., Lucas, C. A., Buie, V. C. & Golosinskiy, A. 2006 National 
Hospital Discharge Survey. National health statistics reports, 1-20 (2008). 
4 Griebling, T. L. Urologic diseases in america project: trends in resource use for 
urinary tract infections in men. The Journal of urology 173, 1288-1294, 
doi:10.1097/01.ju.0000155595.98120.8e (2005). 
5 Foxman, B. The epidemiology of urinary tract infection. Nature reviews. Urology 
7, 653-660, doi:10.1038/nrurol.2010.190 (2010). 
6 Foxman, B., Barlow, R., D'Arcy, H., Gillespie, B. & Sobel, J. D. Urinary tract 
infection: self-reported incidence and associated costs. Annals of epidemiology 
10, 509-515 (2000). 
7 Foxman, B. et al. Risk factors for second urinary tract infection among college 
women. American journal of epidemiology 151, 1194-1205 (2000). 
8 Hooton, T. M. et al. A prospective study of risk factors for symptomatic urinary 
tract infection in young women. The New England journal of medicine 335, 468-
474, doi:10.1056/NEJM199608153350703 (1996). 
142 
 
9 Ikaheimo, R. et al. Recurrence of urinary tract infection in a primary care setting: 
analysis of a 1-year follow-up of 179 women. Clinical infectious diseases : an 
official publication of the Infectious Diseases Society of America 22, 91-99 
(1996). 
10 Scholes, D. et al. Risk factors for recurrent urinary tract infection in young 
women. The Journal of infectious diseases 182, 1177-1182, doi:10.1086/315827 
(2000). 
11 Huang, H. P., Lai, Y. C., Tsai, I. J., Chen, S. Y. & Tsau, Y. K. Renal 
ultrasonography should be done routinely in children with first urinary tract 
infections. Urology 71, 439-443, doi:10.1016/j.urology.2007.10.049 (2008). 
12 Tambyah, P. A. & Maki, D. G. Catheter-associated urinary tract infection is rarely 
symptomatic: a prospective study of 1,497 catheterized patients. Archives of 
internal medicine 160, 678-682 (2000). 
13 Jain, P., Parada, J. P., David, A. & Smith, L. G. Overuse of the indwelling urinary 
tract catheter in hospitalized medical patients. Archives of internal medicine 155, 
1425-1429 (1995). 
14 Parker, D. et al. Catheter-associated urinary tract infections: fact sheet. Journal of 
wound, ostomy, and continence nursing : official publication of The Wound, 
Ostomy and Continence Nurses Society / WOCN 36, 156-159, 
doi:10.1097/01.WON.0000347656.94969.99 (2009). 
15 Jarvis, W. R. Selected aspects of the socioeconomic impact of nosocomial 
infections: morbidity, mortality, cost, and prevention. Infection control and 
143 
 
hospital epidemiology : the official journal of the Society of Hospital 
Epidemiologists of America 17, 552-557 (1996). 
16 Tambyah, P. A., Knasinski, V. & Maki, D. G. The direct costs of nosocomial 
catheter-associated urinary tract infection in the era of managed care. Infection 
control and hospital epidemiology : the official journal of the Society of Hospital 
Epidemiologists of America 23, 27-31, doi:10.1086/501964 (2002). 
17 Hooton, T. M. et al. Diagnosis, prevention, and treatment of catheter-associated 
urinary tract infection in adults: 2009 International Clinical Practice Guidelines 
from the Infectious Diseases Society of America. Clinical infectious diseases : an 
official publication of the Infectious Diseases Society of America 50, 625-663 
(2010). 
18 Maki, D. G. & Tambyah, P. A. Engineering out the risk for infection with urinary 
catheters. Emerging infectious diseases 7, 342-347 (2001). 
19 Stensballe, J. et al. Infection risk with nitrofurazone-impregnated urinary 
catheters in trauma patients: a randomized trial. Annals of internal medicine 147, 
285-293 (2007). 
20 Lo, E. et al. Strategies to prevent catheter-associated urinary tract infections in 
acute care hospitals. Infection control and hospital epidemiology : the official 
journal of the Society of Hospital Epidemiologists of America 29 Suppl 1, S41-
50, doi:10.1086/591066 (2008). 
21 Trautner, B. W. Management of catheter-associated urinary tract infection. 
Current opinion in infectious diseases 23, 76-82, 
doi:10.1097/QCO.0b013e328334dda8 (2010). 
144 
 
22 Tambyah, P. A. & Maki, D. G. The relationship between pyuria and infection in 
patients with indwelling urinary catheters: a prospective study of 761 patients. 
Archives of internal medicine 160, 673-677 (2000). 
23 Colgan, R. & Williams, M. Diagnosis and treatment of acute uncomplicated 
cystitis. American family physician 84, 771-776 (2011). 
24 Warren, J. W. Catheter-associated urinary tract infections. Infectious disease 
clinics of North America 11, 609-622 (1997). 
25 Goble, N. M., Clarke, T. & Hammonds, J. C. Histological changes in the urinary 
bladder secondary to urethral catheterisation. British journal of urology 63, 354-
357 (1989). 
26 Delnay, K. M., Stonehill, W. H., Goldman, H., Jukkola, A. F. & Dmochowski, R. 
R. Bladder histological changes associated with chronic indwelling urinary 
catheter. The Journal of urology 161, 1106-1108; discussion 1108-1109 (1999). 
27 Vaidyanathan, S. et al. Problems in early diagnosis of bladder cancer in a spinal 
cord injury patient: report of a case of simultaneous production of granulocyte 
colony stimulating factor and parathyroid hormone-related protein by squamous 
cell carcinoma of urinary bladder. BMC urology 2, 8 (2002). 
28 Vaidyanathan, S., Soni, B. M., Bingley, J., Brown, E. & Markey, S. Prevention of 
pressure sore caused by indwelling urinary catheters. Spinal cord 40, 489; author 
reply 490, doi:10.1038/sj.sc.3101356 (2002). 
29 Kurosaka, Y. et al. A non-surgical rat model of foreign body-associated urinary 
tract infection with Pseudomonas aeruginosa. Microbiology and immunology 45, 
9-15 (2001). 
145 
 
30 Peychl, L. & Zalud, R. [Changes in the urinary bladder caused by short-term 
permanent catheter insertion]. Casopis lekaru ceskych 147, 325-329 (2008). 
31 Norden, C. W., Green, G. M. & Kass, E. H. Antibacterial mechanisms of the 
urinary bladder. The Journal of clinical investigation 47, 2689-2700, 
doi:10.1172/JCI105952 (1968). 
32 Parsons, C. L. Pathogenesis of urinary tract infections. Bacterial adherence, 
bladder defense mechanisms. The Urologic clinics of North America 13, 563-568 
(1986). 
33 Saint, S. & Chenoweth, C. E. Biofilms and catheter-associated urinary tract 
infections. Infectious disease clinics of North America 17, 411-432 (2003). 
34 Warren, J. W. Catheter-associated urinary tract infections. International journal 
of antimicrobial agents 17, 299-303 (2001). 
35 Hashmi, S., Kelly, E., Rogers, S. O. & Gates, J. Urinary tract infection in surgical 
patients. American journal of surgery 186, 53-56 (2003). 
36 Garibaldi, R. A., Burke, J. P., Britt, M. R., Miller, M. A. & Smith, C. B. Meatal 
colonization and catheter-associated bacteriuria. The New England journal of 
medicine 303, 316-318, doi:10.1056/NEJM198008073030605 (1980). 
37 Stickler, D. J. Bacterial biofilms in patients with indwelling urinary catheters. 
Nature clinical practice. Urology 5, 598-608, doi:10.1038/ncpuro1231 (2008). 
38 Costerton, J. W. Introduction to biofilm. International journal of antimicrobial 
agents 11, 217-221; discussion 237-219 (1999). 
146 
 
39 Costerton, J. W., Montanaro, L. & Arciola, C. R. Biofilm in implant infections: its 
production and regulation. The International journal of artificial organs 28, 1062-
1068 (2005). 
40 Trautner, B. W. & Darouiche, R. O. Role of biofilm in catheter-associated urinary 
tract infection. American journal of infection control 32, 177-183, 
doi:10.1016/j.ajic.2003.08.005 (2004). 
41 Flemming, H. C., Neu, T. R. & Wozniak, D. J. The EPS matrix: the "house of 
biofilm cells". Journal of bacteriology 189, 7945-7947, doi:10.1128/JB.00858-07 
(2007). 
42 Flemming, H. C. & Wingender, J. The biofilm matrix. Nature reviews. 
Microbiology 8, 623-633, doi:10.1038/nrmicro2415 (2010). 
43 Jacobsen, S. M., Stickler, D. J., Mobley, H. L. & Shirtliff, M. E. Complicated 
catheter-associated urinary tract infections due to Escherichia coli and Proteus 
mirabilis. Clinical microbiology reviews 21, 26-59, doi:10.1128/CMR.00019-07 
(2008). 
44 O'Toole, G., Kaplan, H. B. & Kolter, R. Biofilm formation as microbial 
development. Annual review of microbiology 54, 49-79, 
doi:10.1146/annurev.micro.54.1.49 (2000). 
45 Roberts, A. P., Pratten, J., Wilson, M. & Mullany, P. Transfer of a conjugative 
transposon, Tn5397 in a model oral biofilm. FEMS microbiology letters 177, 63-
66 (1999). 
147 
 
46 Wang, B. Y., Chi, B. & Kuramitsu, H. K. Genetic exchange between Treponema 
denticola and Streptococcus gordonii in biofilms. Oral microbiology and 
immunology 17, 108-112 (2002). 
47 Branda, S. S., Vik, S., Friedman, L. & Kolter, R. Biofilms: the matrix revisited. 
Trends in microbiology 13, 20-26, doi:10.1016/j.tim.2004.11.006 (2005). 
48 Bridier, A., Briandet, R., Thomas, V. & Dubois-Brissonnet, F. Resistance of 
bacterial biofilms to disinfectants: a review. Biofouling 27, 1017-1032, 
doi:10.1080/08927014.2011.626899 (2011). 
49 Donlan, R. M. & Costerton, J. W. Biofilms: survival mechanisms of clinically 
relevant microorganisms. Clinical microbiology reviews 15, 167-193 (2002). 
50 Jensen, E. T., Kharazmi, A., Lam, K., Costerton, J. W. & Hoiby, N. Human 
polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in 
biofilms. Infect Immun 58, 2383-2385 (1990). 
51 Jensen, P. O., Givskov, M., Bjarnsholt, T. & Moser, C. The immune system vs. 
Pseudomonas aeruginosa biofilms. FEMS immunology and medical microbiology 
59, 292-305, doi:10.1111/j.1574-695X.2010.00706.x (2010). 
52 Lewis, K. Multidrug tolerance of biofilms and persister cells. Current topics in 
microbiology and immunology 322, 107-131 (2008). 
53 Yasuda, H., Ajiki, Y., Aoyama, J. & Yokota, T. Interaction between human 
polymorphonuclear leucocytes and bacteria released from in-vitro bacterial 
biofilm models. Journal of medical microbiology 41, 359-367 (1994). 
54 Lewis, K. Riddle of biofilm resistance. Antimicrobial agents and chemotherapy 
45, 999-1007, doi:10.1128/AAC.45.4.999-1007.2001 (2001). 
148 
 
55 Kucheria, R., Dasgupta, P., Sacks, S. H., Khan, M. S. & Sheerin, N. S. Urinary 
tract infections: new insights into a common problem. Postgraduate medical 
journal 81, 83-86, doi:10.1136/pgmj.2004.023036 (2005). 
56 Hidron, A. I. et al. NHSN annual update: antimicrobial-resistant pathogens 
associated with healthcare-associated infections: annual summary of data reported 
to the National Healthcare Safety Network at the Centers for Disease Control and 
Prevention, 2006-2007. Infection control and hospital epidemiology : the official 
journal of the Society of Hospital Epidemiologists of America 29, 996-1011, 
doi:10.1086/591861 (2008). 
57 Frank, D. N., Wilson, S. S., St Amand, A. L. & Pace, N. R. Culture-independent 
microbiological analysis of foley urinary catheter biofilms. PloS one 4, e7811, 
doi:10.1371/journal.pone.0007811 (2009). 
58 Macleod, S. M. & Stickler, D. J. Species interactions in mixed-community 
crystalline biofilms on urinary catheters. Journal of medical microbiology 56, 
1549-1557, doi:10.1099/jmm.0.47395-0 (2007). 
59 Nielubowicz, G. R. & Mobley, H. L. Host-pathogen interactions in urinary tract 
infection. Nature reviews. Urology 7, 430-441, doi:10.1038/nrurol.2010.101 
(2010). 
60 Mulvey, M. A. Adhesion and entry of uropathogenic Escherichia coli. Cellular 
microbiology 4, 257-271 (2002). 
61 Reid, G., van der Mei, H. C., Tieszer, C. & Busscher, H. J. Uropathogenic 
Escherichia coli adhere to urinary catheters without using fimbriae. FEMS 
immunology and medical microbiology 16, 159-162 (1996). 
149 
 
62 Mulvey, M. A. et al. Induction and evasion of host defenses by type 1-piliated 
uropathogenic Escherichia coli. Science 282, 1494-1497 (1998). 
63 Fernandez, L. A. & Berenguer, J. Secretion and assembly of regular surface 
structures in Gram-negative bacteria. FEMS microbiology reviews 24, 21-44 
(2000). 
64 Sauer, F. G., Mulvey, M. A., Schilling, J. D., Martinez, J. J. & Hultgren, S. J. 
Bacterial pili: molecular mechanisms of pathogenesis. Current opinion in 
microbiology 3, 65-72 (2000). 
65 Wu, X. R., Sun, T. T. & Medina, J. J. In vitro binding of type 1-fimbriated 
Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. 
Proceedings of the National Academy of Sciences of the United States of America 
93, 9630-9635 (1996). 
66 Connell, I. et al. Type 1 fimbrial expression enhances Escherichia coli virulence 
for the urinary tract. Proceedings of the National Academy of Sciences of the 
United States of America 93, 9827-9832 (1996). 
67 Hunstad, D. A. & Justice, S. S. Intracellular lifestyles and immune evasion 
strategies of uropathogenic Escherichia coli. Annual review of microbiology 64, 
203-221, doi:10.1146/annurev.micro.112408.134258 (2010). 
68 Dhakal, B. K., Kulesus, R. R. & Mulvey, M. A. Mechanisms and consequences of 
bladder cell invasion by uropathogenic Escherichia coli. European journal of 
clinical investigation 38 Suppl 2, 2-11, doi:10.1111/j.1365-2362.2008.01986.x 
(2008). 
150 
 
69 Bower, J. M., Eto, D. S. & Mulvey, M. A. Covert operations of uropathogenic 
Escherichia coli within the urinary tract. Traffic 6, 18-31, doi:10.1111/j.1600-
0854.2004.00251.x (2005). 
70 Zhou, G. et al. Uroplakin Ia is the urothelial receptor for uropathogenic 
Escherichia coli: evidence from in vitro FimH binding. Journal of cell science 
114, 4095-4103 (2001). 
71 Martinez, J. J., Mulvey, M. A., Schilling, J. D., Pinkner, J. S. & Hultgren, S. J. 
Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. The EMBO 
journal 19, 2803-2812, doi:10.1093/emboj/19.12.2803 (2000). 
72 Martinez, J. J. & Hultgren, S. J. Requirement of Rho-family GTPases in the 
invasion of Type 1-piliated uropathogenic Escherichia coli. Cellular microbiology 
4, 19-28 (2002). 
73 Justice, S. S. et al. Differentiation and developmental pathways of uropathogenic 
Escherichia coli in urinary tract pathogenesis. Proceedings of the National 
Academy of Sciences of the United States of America 101, 1333-1338, 
doi:10.1073/pnas.0308125100 (2004). 
74 Schwartz, D. J., Chen, S. L., Hultgren, S. J. & Seed, P. C. Population dynamics 
and niche distribution of uropathogenic Escherichia coli during acute and chronic 
urinary tract infection. Infect Immun 79, 4250-4259, doi:10.1128/IAI.05339-11 
(2011). 
75 Wright, K. J., Seed, P. C. & Hultgren, S. J. Development of intracellular bacterial 
communities of uropathogenic Escherichia coli depends on type 1 pili. Cellular 
microbiology 9, 2230-2241, doi:10.1111/j.1462-5822.2007.00952.x (2007). 
151 
 
76 Hannan, T. J., Mysorekar, I. U., Hung, C. S., Isaacson-Schmid, M. L. & Hultgren, 
S. J. Early severe inflammatory responses to uropathogenic E. coli predispose to 
chronic and recurrent urinary tract infection. PLoS pathogens 6, e1001042, 
doi:10.1371/journal.ppat.1001042 (2010). 
77 Mysorekar, I. U. & Hultgren, S. J. Mechanisms of uropathogenic Escherichia coli 
persistence and eradication from the urinary tract. Proceedings of the National 
Academy of Sciences of the United States of America 103, 14170-14175, 
doi:10.1073/pnas.0602136103 (2006). 
78 Rosen, D. A., Hooton, T. M., Stamm, W. E., Humphrey, P. A. & Hultgren, S. J. 
Detection of intracellular bacterial communities in human urinary tract infection. 
PLoS medicine 4, e329, doi:10.1371/journal.pmed.0040329 (2007). 
79 Aberg, V. & Almqvist, F. Pilicides-small molecules targeting bacterial virulence. 
Organic & biomolecular chemistry 5, 1827-1834, doi:10.1039/b702397a (2007). 
80 Cegelski, L. et al. Small-molecule inhibitors target Escherichia coli amyloid 
biogenesis and biofilm formation. Nature chemical biology 5, 913-919, 
doi:10.1038/nchembio.242 (2009). 
81 Bouckaert, J. et al. Receptor binding studies disclose a novel class of high-affinity 
inhibitors of the Escherichia coli FimH adhesin. Molecular microbiology 55, 441-
455, doi:10.1111/j.1365-2958.2004.04415.x (2005). 
82 Gouin, S. G., Wellens, A., Bouckaert, J. & Kovensky, J. Synthetic multimeric 
heptyl mannosides as potent antiadhesives of uropathogenic Escherichia coli. 
ChemMedChem 4, 749-755, doi:10.1002/cmdc.200900034 (2009). 
152 
 
83 Pinkner, J. S. et al. Rationally designed small compounds inhibit pilus biogenesis 
in uropathogenic bacteria. Proceedings of the National Academy of Sciences of 
the United States of America 103, 17897-17902, doi:10.1073/pnas.0606795103 
(2006). 
84 Han, Z. et al. Structure-based drug design and optimization of mannoside 
bacterial FimH antagonists. Journal of medicinal chemistry 53, 4779-4792, 
doi:10.1021/jm100438s (2010). 
85 Schierholt, A., Hartmann, M. & Lindhorst, T. K. Bi- and trivalent glycopeptide 
mannopyranosides as inhibitors of type 1 fimbriae-mediated bacterial adhesion: 
variation of valency, aglycon and scaffolding. Carbohydrate research 346, 1519-
1526, doi:10.1016/j.carres.2011.04.023 (2011). 
86 Schwardt, O. et al. Design, synthesis and biological evaluation of mannosyl 
triazoles as FimH antagonists. Bioorganic & medicinal chemistry 19, 6454-6473, 
doi:10.1016/j.bmc.2011.08.057 (2011). 
87 Cusumano, C. K. et al. Treatment and Prevention of Urinary Tract Infection with 
Orally Active FimH Inhibitors. Science translational medicine 3, 109ra115, 
doi:10.1126/scitranslmed.3003021 (2011). 
88 Fisher, K. & Phillips, C. The ecology, epidemiology and virulence of 
Enterococcus. Microbiology 155, 1749-1757, doi:10.1099/mic.0.026385-0 (2009). 
89 Giraffa, G. Enterococci from foods. FEMS microbiology reviews 26, 163-171 
(2002). 
153 
 
90 de Fatima Silva Lopes, M. et al. Antimicrobial resistance profiles of dairy and 
clinical isolates and type strains of enterococci. International journal of food 
microbiology 103, 191-198, doi:10.1016/j.ijfoodmicro.2004.12.025 (2005). 
91 Mohamed, J. A. & Huang, D. B. Biofilm formation by enterococci. Journal of 
medical microbiology 56, 1581-1588, doi:10.1099/jmm.0.47331-0 (2007). 
92 Mohamed, J. A., Huang, W., Nallapareddy, S. R., Teng, F. & Murray, B. E. 
Influence of origin of isolates, especially endocarditis isolates, and various genes 
on biofilm formation by Enterococcus faecalis. Infect Immun 72, 3658-3663, 
doi:10.1128/IAI.72.6.3658-3663.2004 (2004). 
93 Joyanes, P., Pascual, A., Martinez-Martinez, L., Hevia, A. & Perea, E. J. In vitro 
adherence of Enterococcus faecalis and Enterococcus faecium to plastic 
biomaterials. Clinical microbiology and infection : the official publication of the 
European Society of Clinical Microbiology and Infectious Diseases 5, 382-386 
(1999). 
94 Joyanes, P., Pascual, A., Martinez-Martinez, L., Hevia, A. & Perea, E. J. In vitro 
adherence of Enterococcus faecalis and Enterococcus faecium to urinary 
catheters. European journal of clinical microbiology & infectious diseases : 
official publication of the European Society of Clinical Microbiology 19, 124-127 
(2000). 
95 Sahm, D. F. et al. In vitro susceptibility studies of vancomycin-resistant 
Enterococcus faecalis. Antimicrobial agents and chemotherapy 33, 1588-1591 
(1989). 
154 
 
96 Ruggero, K. A., Schroeder, L. K., Schreckenberger, P. C., Mankin, A. S. & 
Quinn, J. P. Nosocomial superinfections due to linezolid-resistant Enterococcus 
faecalis: evidence for a gene dosage effect on linezolid MICs. Diagnostic 
microbiology and infectious disease 47, 511-513 (2003). 
97 Hidron, A. I., Schuetz, A. N., Nolte, F. S., Gould, C. V. & Osborn, M. K. 
Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis. The 
Journal of antimicrobial chemotherapy 61, 1394-1396, doi:10.1093/jac/dkn105 
(2008). 
98 Wiederhold, N. P., Coyle, E. A., Raad, II, Prince, R. A. & Lewis, R. E. 
Antibacterial activity of linezolid and vancomycin in an in vitro 
pharmacodynamic model of gram-positive catheter-related bacteraemia. The 
Journal of antimicrobial chemotherapy 55, 792-795, doi:10.1093/jac/dki106 
(2005). 
99 Molinari, G., Pugliese, V., Schito, G. C. & Guzman, C. A. Bacteria involved in 
the blockage of biliary stents and their susceptibility to antibacterial agents. 
European journal of clinical microbiology & infectious diseases : official 
publication of the European Society of Clinical Microbiology 15, 88-92 (1996). 
100 Uttley, A. H., Collins, C. H., Naidoo, J. & George, R. C. Vancomycin-resistant 
enterococci. Lancet 1, 57-58 (1988). 
101 Leclercq, R., Derlot, E., Duval, J. & Courvalin, P. Plasmid-mediated resistance to 
vancomycin and teicoplanin in Enterococcus faecium. The New England journal 
of medicine 319, 157-161, doi:10.1056/NEJM198807213190307 (1988). 
155 
 
102 Rossolini, G. M., Mantengoli, E., Montagnani, F. & Pollini, S. Epidemiology and 
clinical relevance of microbial resistance determinants versus anti-Gram-positive 
agents. Current opinion in microbiology 13, 582-588, 
doi:10.1016/j.mib.2010.08.006 (2010). 
103 Thomas, V. C. et al. A fratricidal mechanism is responsible for eDNA release and 
contributes to biofilm development of Enterococcus faecalis. Molecular 
microbiology 72, 1022-1036, doi:10.1111/j.1365-2958.2009.06703.x (2009). 
104 Thomas, V. C., Thurlow, L. R., Boyle, D. & Hancock, L. E. Regulation of 
autolysis-dependent extracellular DNA release by Enterococcus faecalis 
extracellular proteases influences biofilm development. Journal of bacteriology 
190, 5690-5698, doi:10.1128/JB.00314-08 (2008). 
105 Shankar, N. et al. Role of Enterococcus faecalis surface protein Esp in the 
pathogenesis of ascending urinary tract infection. Infect Immun 69, 4366-4372, 
doi:10.1128/IAI.69.7.4366-4372.2001 (2001). 
106 Kemp, K. D., Singh, K. V., Nallapareddy, S. R. & Murray, B. E. Relative 
contributions of Enterococcus faecalis OG1RF sortase-encoding genes, srtA and 
bps (srtC), to biofilm formation and a murine model of urinary tract infection. 
Infect Immun 75, 5399-5404, doi:10.1128/IAI.00663-07 (2007). 
107 Singh, K. V., Nallapareddy, S. R. & Murray, B. E. Importance of the ebp 
(endocarditis- and biofilm-associated pilus) locus in the pathogenesis of 
Enterococcus faecalis ascending urinary tract infection. The Journal of infectious 
diseases 195, 1671-1677, doi:10.1086/517524 (2007). 
156 
 
108 Johnson, J. R., Clabots, C., Hirt, H., Waters, C. & Dunny, G. Enterococcal 
aggregation substance and binding substance are not major contributors to urinary 
tract colonization by Enterococcus faecalis in a mouse model of ascending 
unobstructed urinary tract infection. Infect Immun 72, 2445-2448 (2004). 
109 Kristich, C. J. et al. Development and use of an efficient system for random 
mariner transposon mutagenesis to identify novel genetic determinants of biofilm 
formation in the core Enterococcus faecalis genome. Applied and environmental 
microbiology 74, 3377-3386, doi:10.1128/AEM.02665-07 (2008). 
110 Costerton, J. W. & Stewart, P. S. Battling biofilms. Scientific American 285, 74-
81 (2001). 
111 Stewart, P. S. & Costerton, J. W. Antibiotic resistance of bacteria in biofilms. 
Lancet 358, 135-138 (2001). 
112 Brady, R. A., Leid, J. G., Calhoun, J. H., Costerton, J. W. & Shirtliff, M. E. 
Osteomyelitis and the role of biofilms in chronic infection. FEMS immunology 
and medical microbiology 52, 13-22, doi:10.1111/j.1574-695X.2007.00357.x 
(2008). 
113 Costerton, J. W. Cystic fibrosis pathogenesis and the role of biofilms in persistent 
infection. Trends in microbiology 9, 50-52 (2001). 
114 Ballering, K. S. et al. Functional genomics of Enterococcus faecalis: multiple 
novel genetic determinants for biofilm formation in the core genome. Journal of 
bacteriology 191, 2806-2814, doi:10.1128/JB.01688-08 (2009). 
157 
 
115 Hancock, L. E. & Perego, M. The Enterococcus faecalis fsr two-component 
system controls biofilm development through production of gelatinase. Journal of 
bacteriology 186, 5629-5639, doi:10.1128/JB.186.17.5629-5639.2004 (2004). 
116 Hendrickx, A. P., Willems, R. J., Bonten, M. J. & van Schaik, W. LPxTG surface 
proteins of enterococci. Trends in microbiology 17, 423-430, 
doi:10.1016/j.tim.2009.06.004 (2009). 
117 Mohamed, J. A. & Murray, B. E. Influence of the fsr locus on biofilm formation 
by Enterococcus faecalis lacking gelE. Journal of medical microbiology 55, 1747-
1750, doi:10.1099/jmm.0.46729-0 (2006). 
118 Pillai, S. K. et al. Effects of glucose on fsr-mediated biofilm formation in 
Enterococcus faecalis. The Journal of infectious diseases 190, 967-970, 
doi:10.1086/423139 (2004). 
119 Qin, X., Singh, K. V., Weinstock, G. M. & Murray, B. E. Effects of Enterococcus 
faecalis fsr genes on production of gelatinase and a serine protease and virulence. 
Infect Immun 68, 2579-2586 (2000). 
120 Qin, X., Singh, K. V., Weinstock, G. M. & Murray, B. E. Characterization of fsr, 
a regulator controlling expression of gelatinase and serine protease in 
Enterococcus faecalis OG1RF. Journal of bacteriology 183, 3372-3382, 
doi:10.1128/JB.183.11.3372-3382.2001 (2001). 
121 Thomas, V. C. & Hancock, L. E. Suicide and fratricide in bacterial biofilms. The 
International journal of artificial organs 32, 537-544 (2009). 
122 Barken, K. B. et al. Roles of type IV pili, flagellum-mediated motility and 
extracellular DNA in the formation of mature multicellular structures in 
158 
 
Pseudomonas aeruginosa biofilms. Environmental microbiology 10, 2331-2343, 
doi:10.1111/j.1462-2920.2008.01658.x (2008). 
123 Kaplan, J. B., Jabbouri, S. & Sadovskaya, I. Extracellular DNA-dependent 
biofilm formation by Staphylococcus epidermidis RP62A in response to 
subminimal inhibitory concentrations of antibiotics. Research in microbiology 
162, 535-541, doi:10.1016/j.resmic.2011.03.008 (2011). 
124 Kaplan, J. B. et al. Recombinant human DNase I decreases biofilm and increases 
antimicrobial susceptibility in staphylococci. The Journal of antibiotics, 
doi:10.1038/ja.2011.113 (2011). 
125 Martins, M. et al. Presence of extracellular DNA in the Candida albicans biofilm 
matrix and its contribution to biofilms. Mycopathologia 169, 323-331, 
doi:10.1007/s11046-009-9264-y (2010). 
126 Petersen, F. C., Pecharki, D. & Scheie, A. A. Biofilm mode of growth of 
Streptococcus intermedius favored by a competence-stimulating signaling 
peptide. Journal of bacteriology 186, 6327-6331, doi:10.1128/JB.186.18.6327-
6331.2004 (2004). 
127 Qin, Z. et al. Role of autolysin-mediated DNA release in biofilm formation of 
Staphylococcus epidermidis. Microbiology 153, 2083-2092, 
doi:10.1099/mic.0.2007/006031-0 (2007). 
128 Whitchurch, C. B., Tolker-Nielsen, T., Ragas, P. C. & Mattick, J. S. Extracellular 
DNA required for bacterial biofilm formation. Science 295, 1487, 
doi:10.1126/science.295.5559.1487 (2002). 
159 
 
129 Rice, K. C. et al. The cidA murein hydrolase regulator contributes to DNA release 
and biofilm development in Staphylococcus aureus. Proceedings of the National 
Academy of Sciences of the United States of America 104, 8113-8118, 
doi:10.1073/pnas.0610226104 (2007). 
130 Vollmer, W., Joris, B., Charlier, P. & Foster, S. Bacterial peptidoglycan (murein) 
hydrolases. FEMS microbiology reviews 32, 259-286, doi:10.1111/j.1574-
6976.2007.00099.x (2008). 
131 Vollmer, W. & Bertsche, U. Murein (peptidoglycan) structure, architecture and 
biosynthesis in Escherichia coli. Biochimica et biophysica acta 1778, 1714-1734, 
doi:10.1016/j.bbamem.2007.06.007 (2008). 
132 Heilmann, C., Hussain, M., Peters, G. & Gotz, F. Evidence for autolysin-mediated 
primary attachment of Staphylococcus epidermidis to a polystyrene surface. 
Molecular microbiology 24, 1013-1024 (1997). 
133 Heilmann, C. et al. Identification and characterization of a novel autolysin (Aae) 
with adhesive properties from Staphylococcus epidermidis. Microbiology 149, 
2769-2778 (2003). 
134 Eckert, C., Lecerf, M., Dubost, L., Arthur, M. & Mesnage, S. Functional analysis 
of AtlA, the major N-acetylglucosaminidase of Enterococcus faecalis. Journal of 
bacteriology 188, 8513-8519, doi:10.1128/JB.01145-06 (2006). 
135 Mesnage, S., Chau, F., Dubost, L. & Arthur, M. Role of N-acetylglucosaminidase 
and N-acetylmuramidase activities in Enterococcus faecalis peptidoglycan 
metabolism. J Biol Chem 283, 19845-19853, doi:10.1074/jbc.M802323200 
(2008). 
160 
 
136 Joris, B. et al. Modular design of the Enterococcus hirae muramidase-2 and 
Streptococcus faecalis autolysin. FEMS microbiology letters 70, 257-264 (1992). 
137 Beliveau, C., Potvin, C., Trudel, J., Asselin, A. & Bellemare, G. Cloning, 
sequencing, and expression in Escherichia coli of a Streptococcus faecalis 
autolysin. Journal of bacteriology 173, 5619-5623 (1991). 
138 Xu, Y., Jiang, L., Murray, B. E. & Weinstock, G. M. Enterococcus faecalis 
antigens in human infections. Infect Immun 65, 4207-4215 (1997). 
139 Qin, X., Singh, K. V., Xu, Y., Weinstock, G. M. & Murray, B. E. Effect of 
disruption of a gene encoding an autolysin of Enterococcus faecalis OG1RF. 
Antimicrobial agents and chemotherapy 42, 2883-2888 (1998). 
140 Bravetti, A. L. et al. Contribution of the autolysin AtlA to the bactericidal activity 
of amoxicillin against Enterococcus faecalis JH2-2. Antimicrobial agents and 
chemotherapy 53, 1667-1669, doi:10.1128/AAC.00692-08 (2009). 
141 Singh, K. V., Qin, X., Weinstock, G. M. & Murray, B. E. Generation and testing 
of mutants of Enterococcus faecalis in a mouse peritonitis model. The Journal of 
infectious diseases 178, 1416-1420 (1998). 
142 Spirig, T., Weiner, E. M. & Clubb, R. T. Sortase enzymes in Gram-positive 
bacteria. Molecular microbiology 82, 1044-1059, doi:10.1111/j.1365-
2958.2011.07887.x (2011). 
143 Marraffini, L. A., Dedent, A. C. & Schneewind, O. Sortases and the art of 
anchoring proteins to the envelopes of gram-positive bacteria. Microbiology and 
molecular biology reviews : MMBR 70, 192-221, doi:10.1128/MMBR.70.1.192-
221.2006 (2006). 
161 
 
144 Kristich, C. J., Manias, D. A. & Dunny, G. M. Development of a method for 
markerless genetic exchange in Enterococcus faecalis and its use in construction 
of a srtA mutant. Applied and environmental microbiology 71, 5837-5849, 
doi:10.1128/AEM.71.10.5837-5849.2005 (2005). 
145 Bourgogne, A. et al. EbpR is important for biofilm formation by activating 
expression of the endocarditis and biofilm-associated pilus operon (ebpABC) of 
Enterococcus faecalis OG1RF. Journal of bacteriology 189, 6490-6493, 
doi:10.1128/JB.00594-07 (2007). 
146 Fabretti, F. et al. Alanine esters of enterococcal lipoteichoic acid play a role in 
biofilm formation and resistance to antimicrobial peptides. Infect Immun 74, 
4164-4171, doi:10.1128/IAI.00111-06 (2006). 
147 Theilacker, C. et al. Glycolipids are involved in biofilm accumulation and 
prolonged bacteraemia in Enterococcus faecalis. Molecular microbiology 71, 
1055-1069, doi:10.1111/j.1365-2958.2009.06587.x (2009). 
148 Hufnagel, M., Koch, S., Creti, R., Baldassarri, L. & Huebner, J. A putative sugar-
binding transcriptional regulator in a novel gene locus in Enterococcus faecalis 
contributes to production of biofilm and prolonged bacteremia in mice. The 
Journal of infectious diseases 189, 420-430, doi:10.1086/381150 (2004). 
149 Kristich, C. J., Li, Y. H., Cvitkovitch, D. G. & Dunny, G. M. Esp-independent 
biofilm formation by Enterococcus faecalis. Journal of bacteriology 186, 154-163 
(2004). 
150 Tendolkar, P. M., Baghdayan, A. S. & Shankar, N. Putative surface proteins 
encoded within a novel transferable locus confer a high-biofilm phenotype to 
162 
 
Enterococcus faecalis. Journal of bacteriology 188, 2063-2072, 
doi:10.1128/JB.188.6.2063-2072.2006 (2006). 
151 Spoering, A. L. & Gilmore, M. S. Quorum sensing and DNA release in bacterial 
biofilms. Current opinion in microbiology 9, 133-137, 
doi:10.1016/j.mib.2006.02.004 (2006). 
152 Steinberger, R. E. & Holden, P. A. Extracellular DNA in single- and multiple-
species unsaturated biofilms. Applied and environmental microbiology 71, 5404-
5410, doi:10.1128/AEM.71.9.5404-5410.2005 (2005). 
153 Vlassov, V. V., Laktionov, P. P. & Rykova, E. Y. Extracellular nucleic acids. 
BioEssays : news and reviews in molecular, cellular and developmental biology 
29, 654-667, doi:10.1002/bies.20604 (2007). 
154 Bockelmann, U. et al. Bacterial extracellular DNA forming a defined network-
like structure. FEMS microbiology letters 262, 31-38, doi:10.1111/j.1574-
6968.2006.00361.x (2006). 
155 Bockelmann, U., Lunsdorf, H. & Szewzyk, U. Ultrastructural and electron 
energy-loss spectroscopic analysis of an extracellular filamentous matrix of an 
environmental bacterial isolate. Environmental microbiology 9, 2137-2144, 
doi:10.1111/j.1462-2920.2007.01325.x (2007). 
156 Jurcisek, J. A. et al. The PilA protein of non-typeable Haemophilus influenzae 
plays a role in biofilm formation, adherence to epithelial cells and colonization of 
the mammalian upper respiratory tract. Molecular microbiology 65, 1288-1299, 
doi:10.1111/j.1365-2958.2007.05864.x (2007). 
163 
 
157 Hong, W., Juneau, R. A., Pang, B. & Swords, W. E. Survival of bacterial biofilms 
within neutrophil extracellular traps promotes nontypeable Haemophilus 
influenzae persistence in the chinchilla model for otitis media. Journal of innate 
immunity 1, 215-224, doi:10.1159/000205937 (2009). 
158 Cornett, J. B., Redman, B. E. & Shockman, G. D. Autolytic defective mutant of 
Streptococcus faecalis. Journal of bacteriology 133, 631-640 (1978). 
159 van Merode, A. E., van der Mei, H. C., Busscher, H. J. & Krom, B. P. Influence 
of culture heterogeneity in cell surface charge on adhesion and biofilm formation 
by Enterococcus faecalis. Journal of bacteriology 188, 2421-2426, 
doi:10.1128/JB.188.7.2421-2426.2006 (2006). 
160 van Merode, A. E., van der Mei, H. C., Busscher, H. J., Waar, K. & Krom, B. P. 
Enterococcus faecalis strains show culture heterogeneity in cell surface charge. 
Microbiology 152, 807-814, doi:10.1099/mic.0.28460-0 (2006). 
161 Levesque, C. M. et al. Involvement of sortase anchoring of cell wall proteins in 
biofilm formation by Streptococcus mutans. Infect Immun 73, 3773-3777, 
doi:10.1128/IAI.73.6.3773-3777.2005 (2005). 
162 Yamaguchi, M. et al. Role of Streptococcus sanguinis sortase A in bacterial 
colonization. Microbes and infection / Institut Pasteur 8, 2791-2796, 
doi:10.1016/j.micinf.2006.08.010 (2006). 
163 Suree, N., Jung, M. E. & Clubb, R. T. Recent advances towards new anti-infective 
agents that inhibit cell surface protein anchoring in Staphylococcus aureus and 
other gram-positive pathogens. Mini reviews in medicinal chemistry 7, 991-1000 
(2007). 
164 
 
164 Maresso, A. W. & Schneewind, O. Sortase as a target of anti-infective therapy. 
Pharmacological reviews 60, 128-141, doi:10.1124/pr.107.07110 (2008). 
165 Nallapareddy, S. R., Qin, X., Weinstock, G. M., Hook, M. & Murray, B. E. 
Enterococcus faecalis adhesin, ace, mediates attachment to extracellular matrix 
proteins collagen type IV and laminin as well as collagen type I. Infect Immun 68, 
5218-5224 (2000). 
166 Nallapareddy, S. R. et al. Conservation of Ebp-type pilus genes among 
Enterococci and demonstration of their role in adherence of Enterococcus faecalis 
to human platelets. Infect Immun 79, 2911-2920, doi:10.1128/IAI.00039-11 
(2011). 
167 Nallapareddy, S. R., Singh, K. V., Sillanpaa, J., Zhao, M. & Murray, B. E. 
Relative contributions of Ebp Pili and the collagen adhesin ace to host 
extracellular matrix protein adherence and experimental urinary tract infection by 
Enterococcus faecalis OG1RF. Infect Immun 79, 2901-2910, 
doi:10.1128/IAI.00038-11 (2011). 
168 Bourgogne, A. et al. Large scale variation in Enterococcus faecalis illustrated by 
the genome analysis of strain OG1RF. Genome biology 9, R110, doi:10.1186/gb-
2008-9-7-r110 (2008). 
169 Creti, R. et al. Surface protein EF3314 contributes to virulence properties of 
Enterococcus faecalis. The International journal of artificial organs 32, 611-620 
(2009). 
165 
 
170 O'Gara, J. P. ica and beyond: biofilm mechanisms and regulation in 
Staphylococcus epidermidis and Staphylococcus aureus. FEMS microbiology 
letters 270, 179-188, doi:10.1111/j.1574-6968.2007.00688.x (2007). 
171 Lewis, K. Programmed death in bacteria. Microbiology and molecular biology 
reviews : MMBR 64, 503-514 (2000). 
172 Mohamed, J. A. & Murray, B. E. Lack of correlation of gelatinase production and 
biofilm formation in a large collection of Enterococcus faecalis isolates. Journal 
of clinical microbiology 43, 5405-5407, doi:10.1128/JCM.43.10.5405-5407.2005 
(2005). 
173 Pfeffer, J. M., Strating, H., Weadge, J. T. & Clarke, A. J. Peptidoglycan O 
acetylation and autolysin profile of Enterococcus faecalis in the viable but 
nonculturable state. Journal of bacteriology 188, 902-908, 
doi:10.1128/JB.188.3.902-908.2006 (2006). 
174 Lopez, D., Vlamakis, H. & Kolter, R. Biofilms. Cold Spring Harbor perspectives 
in biology 2, a000398, doi:10.1101/cshperspect.a000398 (2010). 
175 Chuang-Smith, O. N., Wells, C. L., Henry-Stanley, M. J. & Dunny, G. M. 
Acceleration of Enterococcus faecalis biofilm formation by aggregation substance 
expression in an ex vivo model of cardiac valve colonization. PloS one 5, e15798, 
doi:10.1371/journal.pone.0015798 (2010). 
176 Schlievert, P. M., Chuang-Smith, O. N., Peterson, M. L., Cook, L. C. & Dunny, 
G. M. Enterococcus faecalis endocarditis severity in rabbits is reduced by IgG 
Fabs interfering with aggregation substance. PloS one 5, 
doi:10.1371/journal.pone.0013194 (2010). 
166 
 
177 Hartstein, A. I., Garber, S. B., Ward, T. T., Jones, S. R. & Morthland, V. H. 
Nosocomial urinary tract infection: a prospective evaluation of 108 catheterized 
patients. Infection control : IC 2, 380-386 (1981). 
178 Tambyah, P. A., Halvorson, K. T. & Maki, D. G. A prospective study of 
pathogenesis of catheter-associated urinary tract infections. Mayo Clinic 
proceedings. Mayo Clinic 74, 131-136 (1999). 
179 Norden, C. W. Study of urinary infections by catheterization. The New England 
journal of medicine 278, 966-967 (1968). 
180 Kaufman, J. M. et al. Bladder cancer and squamous metaplasia in spinal cord 
injury patients. The Journal of urology 118, 967-971 (1977). 
181 Jacobs, S. C. & Kaufman, J. M. Complications of permanent bladder catheter 
drainage in spinal cord injury patients. The Journal of urology 119, 740-741 
(1978). 
182 Dedeic-Ljubovic, A. & Hukic, M. Catheter-related urinary tract infection in 
patients suffering from spinal cord injuries. Bosnian journal of basic medical 
sciences / Udruzenje basicnih mediciniskih znanosti = Association of Basic 
Medical Sciences 9, 2-9 (2009). 
183 Desai, P. J., Pandit, D., Mathur, M. & Gogate, A. Prevalence, identification and 
distribution of various species of enterococci isolated from clinical specimens 
with special reference to urinary tract infection in catheterized patients. Indian 
journal of medical microbiology 19, 132-137 (2001). 
184 Johnson, J. R., Dykstra, D., Brown, J. J., Kringstad, B. & Pryor, J. L. A surface 
swab method for culturing Foley catheters assays the pericatheter (urethral) but 
167 
 
not the urine (luminal) microbial population. The Journal of laboratory and 
clinical medicine 130, 102-109 (1997). 
185 Seno, Y., Kariyama, R., Mitsuhata, R., Monden, K. & Kumon, H. Clinical 
implications of biofilm formation by Enterococcus faecalis in the urinary tract. 
Acta medica Okayama 59, 79-87 (2005). 
186 Baldassarri, L. et al. Glycosaminoglycans mediate invasion and survival of 
Enterococcus faecalis into macrophages. The Journal of infectious diseases 191, 
1253-1262, doi:10.1086/428778 (2005). 
187 Montgomerie, J. Z., Kalmanson, G. M. & Guze, L. B. Virulence of enterococci in 
experimental pyelonephritis. Urological research 5, 99-102 (1977). 
188 Hirose, T., Kumamoto, Y., Tanaka, N., Yoshioka, M. & Tsukamoto, T. Study on 
pathogenesis of Enterococcus faecalis in urinary tract. Urological research 17, 
125-129 (1989). 
189 Tsuchimori, N., Hayashi, R., Shino, A., Yamazaki, T. & Okonogi, K. 
Enterococcus faecalis aggravates pyelonephritis caused by Pseudomonas 
aeruginosa in experimental ascending mixed urinary tract infection in mice. Infect 
Immun 62, 4534-4541 (1994). 
190 Kau, A. L. et al. Enterococcus faecalis tropism for the kidneys in the urinary tract 
of C57BL/6J mice. Infect Immun 73, 2461-2468, doi:10.1128/IAI.73.4.2461-
2468.2005 (2005). 
191 Rosen, D. A., Hung, C. S., Kline, K. A. & Hultgren, S. J. Streptozocin-induced 
diabetic mouse model of urinary tract infection. Infect Immun 76, 4290-4298, 
doi:10.1128/IAI.00255-08 (2008). 
168 
 
192 Creti, R. et al. Survey for virulence determinants among Enterococcus faecalis 
isolated from different sources. Journal of medical microbiology 53, 13-20 
(2004). 
193 Jankoska, G., Trajkovska-Dokic, E., Panovski, N., Popovska-Jovanovska, K. & 
Petrovska, M. Virulence factors and antibiotic resistance in Enterococcus faecalis 
isolated from urine samples. Prilozi / Makedonska akademija na naukite i 
umetnostite, Oddelenie za bioloski i medicinski nauki = Contributions / 
Macedonian Academy of Sciences and Arts, Section of Biological and Medical 
Sciences 29, 57-66 (2008). 
194 Kadurugamuwa, J. L. et al. Noninvasive biophotonic imaging for monitoring of 
catheter-associated urinary tract infections and therapy in mice. Infect Immun 73, 
3878-3887, doi:10.1128/IAI.73.7.3878-3887.2005 (2005). 
195 Hamill, T. M., Gilmore, B. F., Jones, D. S. & Gorman, S. P. Strategies for the 
development of the urinary catheter. Expert review of medical devices 4, 215-225, 
doi:10.1586/17434440.4.2.215 (2007). 
196 Saint, S., Lipsky, B. A. & Goold, S. D. Indwelling urinary catheters: a one-point 
restraint? Annals of internal medicine 137, 125-127 (2002). 
197 Geppetti, P., Nassini, R., Materazzi, S. & Benemei, S. The concept of neurogenic 
inflammation. BJU international 101 Suppl 3, 2-6, doi:10.1111/j.1464-
410X.2008.07493.x (2008). 
198 Bjorling, D. E., Beckman, M. & Saban, R. Neurogenic inflammation of the 
bladder. Advances in experimental medicine and biology 539, 551-583 (2003). 
169 
 
199 Snider, R. M. et al. A potent nonpeptide antagonist of the substance P (NK1) 
receptor. Science 251, 435-437 (1991). 
200 Snider, R. M., Longo, K. P., Drozda, S. E., Lowe, J. A., 3rd & Leeman, S. E. 
Effect of CP-96,345, a nonpeptide substance P receptor antagonist, on salivation 
in rats. Proceedings of the National Academy of Sciences of the United States of 
America 88, 10042-10044 (1991). 
201 McLean, S. et al. Pharmacology of CP-99,994; a nonpeptide antagonist of the 
tachykinin neurokinin-1 receptor. The Journal of pharmacology and experimental 
therapeutics 267, 472-479 (1993). 
202 McLean, S. et al. CP-99,994, a nonpeptide antagonist of the tachykinin NK1 
receptor. Regulatory peptides 46, 329-331 (1993). 
203 Abraham, P., Rabi, S. & Kulothungan, P. Aminoguanidine, selective nitric oxide 
synthase inhibitor, ameliorates cyclophosphamide-induced hemorrhagic cystitis 
by inhibiting protein nitration and PARS activation. Urology 73, 1402-1406, 
doi:10.1016/j.urology.2008.10.039 (2009). 
204 Abraham, P., Rabi, S. & Selvakumar, D. Protective effect of aminoguanidine 
against oxidative stress and bladder injury in cyclophosphamide-induced 
hemorrhagic cystitis in rat. Cell biochemistry and function 27, 56-62, 
doi:10.1002/cbf.1534 (2009). 
205 Griffiths, M. J., Messent, M., MacAllister, R. J. & Evans, T. W. Aminoguanidine 
selectively inhibits inducible nitric oxide synthase. British journal of 
pharmacology 110, 963-968 (1993). 
170 
 
206 Trevisani, M. et al. The influence of alpha1-adrenoreceptors on neuropeptide 
release from primary sensory neurons of the lower urinary tract. European 
urology 52, 901-908, doi:10.1016/j.eururo.2007.01.016 (2007). 
207 Stroncek, D. F., Skubitz, K. M. & McCullough, J. J. Biochemical characterization 
of the neutrophil-specific antigen NB1. Blood 75, 744-755 (1990). 
208 Santin, M., Motta, A., Denyer, S. P. & Cannas, M. Effect of the urine 
conditioning film on ureteral stent encrustation and characterization of its protein 
composition. Biomaterials 20, 1245-1251 (1999). 
209 Ike, Y., Craig, R. A., White, B. A., Yagi, Y. & Clewell, D. B. Modification of 
Streptococcus faecalis sex pheromones after acquisition of plasmid DNA. 
Proceedings of the National Academy of Sciences of the United States of America 
80, 5369-5373 (1983). 
210 Guiton, P. S. et al. Contribution of autolysin and Sortase a during Enterococcus 
faecalis DNA-dependent biofilm development. Infect Immun 77, 3626-3638, 
doi:10.1128/IAI.00219-09 (2009). 
211 An, F. Y., Sulavik, M. C. & Clewell, D. B. Identification and characterization of a 
determinant (eep) on the Enterococcus faecalis chromosome that is involved in 
production of the peptide sex pheromone cAD1. Journal of bacteriology 181, 
5915-5921 (1999). 
212 Chandler, J. R. & Dunny, G. M. Characterization of the sequence specificity 
determinants required for processing and control of sex pheromone by the 
intramembrane protease Eep and the plasmid-encoded protein PrgY. Journal of 
bacteriology 190, 1172-1183, doi:10.1128/JB.01327-07 (2008). 
171 
 
213 Frank, K. L. et al. Use of Recombinase-based in vivo Expression Technology to 
Characterize Enterococcus faecalis Gene Expression During Infection Identifies 
in vivo-Expressed Antisense RNAs and Implicates the Protease Eep in 
Pathogenesis. Infect Immun, doi:10.1128/IAI.05964-11 (2011). 
214 Bjorling, D. E., Wang, Z. Y. & Bushman, W. Models of inflammation of the 
lower urinary tract. Neurourology and urodynamics 30, 673-682, 
doi:10.1002/nau.21078 (2011). 
215 Nishii, H., Nomura, M., Fujimoto, N. & Matsumoto, T. Up-regulation of 
interleukin-6 gene expression in cyclophosphamide-induced cystitis in mice: An 
in situ hybridization histochemical study. International journal of urology : 
official journal of the Japanese Urological Association 13, 1339-1343, 
doi:10.1111/j.1442-2042.2006.01536.x (2006). 
216 Olivar, T. & Laird, J. M. Cyclophosphamide cystitis in mice: behavioural 
characterisation and correlation with bladder inflammation. Eur J Pain 3, 141-
149, doi:10.1053/eujp.1998.0105 (1999). 
217 O'Mahony, D. S., Pham, U., Iyer, R., Hawn, T. R. & Liles, W. C. Differential 
constitutive and cytokine-modulated expression of human Toll-like receptors in 
primary neutrophils, monocytes, and macrophages. International journal of 
medical sciences 5, 1-8 (2008). 
218 Schroder, N. W. et al. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and 
Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, 
lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 
172 
 
are not involved. J Biol Chem 278, 15587-15594, doi:10.1074/jbc.M212829200 
(2003). 
219 Daley, J. M., Thomay, A. A., Connolly, M. D., Reichner, J. S. & Albina, J. E. Use 
of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. Journal of 
leukocyte biology 83, 64-70, doi:10.1189/jlb.0407247 (2008). 
220 Ronald, A. The etiology of urinary tract infection: traditional and emerging 
pathogens. The American journal of medicine 113 Suppl 1A, 14S-19S (2002). 
221 Thurlow, L. R., Thomas, V. C., Fleming, S. D. & Hancock, L. E. Enterococcus 
faecalis capsular polysaccharide serotypes C and D and their contributions to host 
innate immune evasion. Infect Immun 77, 5551-5557, doi:10.1128/IAI.00576-09 
(2009). 
222 Arciola, C. R. et al. Strong biofilm production, antibiotic multi-resistance and 
high gelE expression in epidemic clones of Enterococcus faecalis from 
orthopaedic implant infections. Biomaterials 29, 580-586, 
doi:10.1016/j.biomaterials.2007.10.008 (2008). 
223 Sillanpaa, J. et al. Characterization of the ebp(fm) pilus-encoding operon of 
Enterococcus faecium and its role in biofilm formation and virulence in a murine 
model of urinary tract infection. Virulence 1, 236-246 (2010). 
224 Hendrickx, A. P. et al. SgrA, a nidogen-binding LPXTG surface adhesin 
implicated in biofilm formation, and EcbA, a collagen binding MSCRAMM, are 
two novel adhesins of hospital-acquired Enterococcus faecium. Infect Immun 77, 
5097-5106, doi:10.1128/IAI.00275-09 (2009). 
173 
 
225 Patti, J. M., Allen, B. L., McGavin, M. J. & Hook, M. MSCRAMM-mediated 
adherence of microorganisms to host tissues. Annual review of microbiology 48, 
585-617, doi:10.1146/annurev.mi.48.100194.003101 (1994). 
226 Sillanpaa, J. et al. A family of fibrinogen-binding MSCRAMMs from 
Enterococcus faecalis. Microbiology 155, 2390-2400, doi:10.1099/mic.0.027821-
0 (2009). 
227 Sillanpaa, J., Prakash, V. P., Nallapareddy, S. R. & Murray, B. E. Distribution of 
genes encoding MSCRAMMs and Pili in clinical and natural populations of 
Enterococcus faecium. Journal of clinical microbiology 47, 896-901, 
doi:10.1128/JCM.02283-08 (2009). 
228 Rich, R. L. et al. Ace is a collagen-binding MSCRAMM from Enterococcus 
faecalis. J Biol Chem 274, 26939-26945 (1999). 
229 Mohamed, J. A., Teng, F., Nallapareddy, S. R. & Murray, B. E. Pleiotrophic 
effects of 2 Enterococcus faecalis sagA-like genes, salA and salB, which encode 
proteins that are antigenic during human infection, on biofilm formation and 
binding to collagen type i and fibronectin. The Journal of infectious diseases 193, 
231-240, doi:10.1086/498871 (2006). 
230 Singh, K. V., Nallapareddy, S. R., Sillanpaa, J. & Murray, B. E. Importance of the 
collagen adhesin ace in pathogenesis and protection against Enterococcus faecalis 
experimental endocarditis. PLoS pathogens 6, e1000716, 
doi:10.1371/journal.ppat.1000716 (2010). 
174 
 
231 Breton, Y. L. et al. Isolation and characterization of bile salts-sensitive mutants of 
Enterococcus faecalis. Current microbiology 45, 434-439, doi:10.1007/s00284-
002-3714-3 (2002). 
232 Barford, J. M., Hu, Y., Anson, K. & Coates, A. R. A biphasic response from 
bladder epithelial cells induced by catheter material and bacteria: an in vitro study 
of the pathophysiology of catheter related urinary tract infection. The Journal of 
urology 180, 1522-1526, doi:10.1016/j.juro.2008.06.012 (2008). 
233 Cassatella, M. A. Neutrophil-derived proteins: selling cytokines by the pound. 
Advances in immunology 73, 369-509 (1999). 
234 Denkers, E. Y., Del Rio, L. & Bennouna, S. Neutrophil production of IL-12 and 
other cytokines during microbial infection. Chemical immunology and allergy 83, 
95-114 (2003). 
235 Barreda, D. R., Hanington, P. C. & Belosevic, M. Regulation of myeloid 
development and function by colony stimulating factors. Developmental and 
comparative immunology 28, 509-554, doi:10.1016/j.dci.2003.09.010 (2004). 
236 Kobayashi, Y. Neutrophil infiltration and chemokines. Critical reviews in 
immunology 26, 307-316 (2006). 
237 Romano, M. et al. Role of IL-6 and its soluble receptor in induction of 
chemokines and leukocyte recruitment. Immunity 6, 315-325 (1997). 
238 Kopf, M. et al. Pleiotropic defects of IL-6-deficient mice including early 
hematopoiesis, T and B cell function, and acute phase responses. Annals of the 
New York Academy of Sciences 762, 308-318 (1995). 
175 
 
239 Ingersoll, M. A., Kline, K. A., Nielsen, H. V. & Hultgren, S. J. G-CSF induction 
early in uropathogenic Escherichia coli infection of the urinary tract modulates 
host immunity. Cellular microbiology 10, 2568-2578, doi:10.1111/j.1462-
5822.2008.01230.x (2008). 
240 Eglezos, A., Giuliani, S., Viti, G. & Maggi, C. A. Direct evidence that capsaicin-
induced plasma protein extravasation is mediated through tachykinin NK1 
receptors. European journal of pharmacology 209, 277-279 (1991). 
241 Saban, R. et al. Mast cells mediate substance P-induced bladder inflammation 
through an NK(1) receptor-independent mechanism. American journal of 
physiology. Renal physiology 283, F616-629, doi:10.1152/ajprenal.00096.2002 
(2002). 
242 Saban, R., Saban, M. R., Nguyen, N. B., Hammond, T. G. & Wershil, B. K. Mast 
cell regulation of inflammation and gene expression during antigen-induced 
bladder inflammation in mice. Physiological genomics 7, 35-43 (2001). 
243 Chavez, A., Smith, M. & Mehta, D. New insights into the regulation of vascular 
permeability. International review of cell and molecular biology 290, 205-248, 
doi:10.1016/B978-0-12-386037-8.00001-6 (2011). 
244 Newton, R. Molecular mechanisms of glucocorticoid action: what is important? 
Thorax 55, 603-613 (2000). 
245 Lan, N. C. et al. Mechanisms of glucocorticoid hormone action. Journal of 
steroid biochemistry 20, 77-88 (1984). 
246 Norman, M. & Hearing, S. D. Glucocorticoid resistance - what is known? Current 
opinion in pharmacology 2, 723-729 (2002). 
176 
 
247 Chung, K. F. et al. Difficult/therapy-resistant asthma: the need for an integrated 
approach to define clinical phenotypes, evaluate risk factors, understand 
pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-
Resistant Asthma. European Respiratory Society. The European respiratory 
journal : official journal of the European Society for Clinical Respiratory 
Physiology 13, 1198-1208 (1999). 
248 Dalakas, M. C. Inflammatory myopathies: management of steroid resistance. 
Current opinion in neurology 24, 457-462, doi:10.1097/WCO.0b013e32834a9589 
(2011). 
249 Park, S. J. & Shin, J. I. Complications of nephrotic syndrome. Korean journal of 
pediatrics 54, 322-328, doi:10.3345/kjp.2011.54.8.322 (2011). 
250 Ito, K., Chung, K. F. & Adcock, I. M. Update on glucocorticoid action and 
resistance. The Journal of allergy and clinical immunology 117, 522-543, 
doi:10.1016/j.jaci.2006.01.032 (2006). 
251 Lu, Y. S. et al. Effects of glucocorticoids on the growth and chemosensitivity of 
carcinoma cells are heterogeneous and require high concentration of functional 
glucocorticoid receptors. World journal of gastroenterology : WJG 11, 6373-6380 
(2005). 
252 Strickland, I. et al. High constitutive glucocorticoid receptor beta in human 
neutrophils enables them to reduce their spontaneous rate of cell death in response 
to corticosteroids. The Journal of experimental medicine 193, 585-593 (2001). 
177 
 
253 Goleva, E. et al. Increased glucocorticoid receptor beta alters steroid response in 
glucocorticoid-insensitive asthma. American journal of respiratory and critical 
care medicine 173, 607-616, doi:10.1164/rccm.200507-1046OC (2006). 
254 Leendertse, M. et al. The acute-phase response impairs host defence against 
Enterococcus faecium peritonitis. Immunology 128, e335-342, 
doi:10.1111/j.1365-2567.2008.02967.x (2009). 
255 Leendertse, M. et al. Neutrophils are essential for rapid clearance of Enterococcus 
faecium in mice. Infect Immun 77, 485-491, doi:10.1128/IAI.00863-08 (2009). 
256 Fazal, N. et al. Differential effector responses by circulating/blood and 
tissue/peritoneal neutrophils following burn combined with Enterococcus faecalis 
infection. FEMS immunology and medical microbiology, doi:10.1111/j.1574-
695X.2011.00881.x (2011). 
257 Tsuda, Y., Shigematsu, K., Kobayashi, M., Herndon, D. N. & Suzuki, F. Role of 
polymorphonuclear neutrophils on infectious complications stemming from 
Enterococcus faecalis oral infection in thermally injured mice. J Immunol 180, 
4133-4138 (2008). 
258 Ma, Z. et al. Role of polymorphonuclear neutrophils in the clearance of 
Enterococcus faecalis derived from saliva and infected root canals. Journal of 
endodontics 37, 346-352, doi:10.1016/j.joen.2010.11.033 (2011). 
259 Leendertse, M. et al. TLR2-dependent MyD88 signaling contributes to early host 
defense in murine Enterococcus faecium peritonitis. J Immunol 180, 4865-4874 
(2008). 
178 
 
260 Rakita, R. M. et al. Enterococcus faecalis bearing aggregation substance is 
resistant to killing by human neutrophils despite phagocytosis and neutrophil 
activation. Infect Immun 67, 6067-6075 (1999). 
261 Vanek, N. N. et al. Enterococcus faecalis aggregation substance promotes 
opsonin-independent binding to human neutrophils via a complement receptor 
type 3-mediated mechanism. FEMS immunology and medical microbiology 26, 
49-60 (1999). 
262 Teng, F., Jacques-Palaz, K. D., Weinstock, G. M. & Murray, B. E. Evidence that 
the enterococcal polysaccharide antigen gene (epa) cluster is widespread in 
Enterococcus faecalis and influences resistance to phagocytic killing of E. 
faecalis. Infect Immun 70, 2010-2015 (2002). 
263 Shon, W., Lim, S., Bae, K. S., Baek, S. & Lee, W. The expression of alpha4 
integrins by human polymorphonuclear neutrophils in response to sonicated 
extracts of Enterococcus faecalis. Journal of endodontics 31, 369-372 (2005). 
264 Shigematsu, K., Asai, A., Kobayashi, M., Herndon, D. N. & Suzuki, F. 
Enterococcus faecalis translocation in mice with severe burn injury: a pathogenic 
role of CCL2 and alternatively activated macrophages (M2aMphi and M2cMphi). 
Journal of leukocyte biology 86, 999-1005, doi:10.1189/jlb.0409235 (2009). 
265 La Carbona, S. et al. Comparative study of the physiological roles of three 
peroxidases (NADH peroxidase, Alkyl hydroperoxide reductase and Thiol 
peroxidase) in oxidative stress response, survival inside macrophages and 
virulence of Enterococcus faecalis. Molecular microbiology 66, 1148-1163, 
doi:10.1111/j.1365-2958.2007.05987.x (2007). 
179 
 
266 Verneuil, N. et al. Implication of (Mn)superoxide dismutase of Enterococcus 
faecalis in oxidative stress responses and survival inside macrophages. 
Microbiology 152, 2579-2589, doi:10.1099/mic.0.28922-0 (2006). 
267 Verneuil, N. et al. Effects of the Enterococcus faecalis hypR gene encoding a new 
transcriptional regulator on oxidative stress response and intracellular survival 
within macrophages. Infect Immun 72, 4424-4431, doi:10.1128/IAI.72.8.4424-
4431.2004 (2004). 
268 Baldassarri, L. et al. Receptor-mediated endocytosis of biofilm-forming 
Enterococcus faecalis by rat peritoneal macrophages. The Indian journal of 
medical research 119 Suppl, 131-135 (2004). 
269 Baldassarri, L. et al. Enterococcus spp. produces slime and survives in rat 
peritoneal macrophages. Med Microbiol Immunol 190, 113-120 (2001). 
270 Sussmuth, S. D. et al. Aggregation substance promotes adherence, phagocytosis, 
and intracellular survival of Enterococcus faecalis within human macrophages 
and suppresses respiratory burst. Infect Immun 68, 4900-4906 (2000). 
271 Gentry-Weeks, C. R., Karkhoff-Schweizer, R., Pikis, A., Estay, M. & Keith, J. M. 
Survival of Enterococcus faecalis in mouse peritoneal macrophages. Infect Immun 
67, 2160-2165 (1999). 
272 Kosmidis, C. I. & Chandrasekar, P. H. Management of gram-positive bacterial 
infections in patients with cancer. Leuk Lymphoma, 
doi:10.3109/10428194.2011.602770. 
273 Wisplinghoff, H. et al. Nosocomial bloodstream infections in US hospitals: 
analysis of 24,179 cases from a prospective nationwide surveillance study. 
180 
 
Clinical infectious diseases : an official publication of the Infectious Diseases 
Society of America 39, 309-317, doi:10.1086/421946 
CID32752 [pii] (2004). 
274 Sastry, V. et al. Vancomycin-resistant enterococci: an emerging pathogen in 
immunosuppressed transplant recipients. Transplant Proc 27, 954-955 (1995). 
275 Bonten, M. J., Willems, R. & Weinstein, R. A. Vancomycin-resistant enterococci: 
why are they here, and where do they come from? Lancet Infect Dis 1, 314-325, 
doi:S1473-3099(01)00145-1 [pii] 
10.1016/S1473-3099(01)00145-1 (2001). 
276 Warren, J. W., Muncie, H. L., Jr. & Hall-Craggs, M. Acute pyelonephritis 
associated with bacteriuria during long-term catheterization: a prospective 
clinicopathological study. The Journal of infectious diseases 158, 1341-1346 
(1988). 
277 Donelli, G. & Guaglianone, E. Emerging role of Enterococcus spp in catheter-
related infections: biofilm formation and novel mechanisms of antibiotic 
resistance. J Vasc Access 5, 3-9 (2004). 
278 Donlan, R. M. Biofilms and device-associated infections. Emerging infectious 
diseases 7, 277-281 (2001). 
279 Dickinson, G. M. & Bisno, A. L. Infections associated with indwelling devices: 
infections related to extravascular devices. Antimicrobial agents and 
chemotherapy 33, 602-607 (1989). 
181 
 
280 Dickinson, G. M. & Bisno, A. L. Infections associated with indwelling devices: 
concepts of pathogenesis; infections associated with intravascular devices. 
Antimicrobial agents and chemotherapy 33, 597-601 (1989). 
281 Guiton, P. S., Hung, C. S., Hancock, L. E., Caparon, M. G. & Hultgren, S. J. 
Enterococcal biofilm formation and virulence in an optimized murine model of 
foreign body-associated urinary tract infections. Infect Immun 78, 4166-4175, 
doi:10.1128/IAI.00711-10 (2010). 
282 Mulvey, M. A., Schilling, J. D. & Hultgren, S. J. Establishment of a persistent 
Escherichia coli reservoir during the acute phase of a bladder infection. Infect 
Immun 69, 4572-4579, doi:10.1128/IAI.69.7.4572-4579.2001 (2001). 
283 McTaggart, L. A., Rigby, R. C. & Elliott, T. S. The pathogenesis of urinary tract 
infections associated with Escherichia coli, Staphylococcus saprophyticus and S. 
epidermidis. Journal of medical microbiology 32, 135-141 (1990). 
284 Schilling, J. D., Lorenz, R. G. & Hultgren, S. J. Effect of trimethoprim-
sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice 
infected with uropathogenic Escherichia coli. Infect Immun 70, 7042-7049 (2002). 
285 Barnhart, M. M. & Chapman, M. R. Curli biogenesis and function. Annual review 
of microbiology 60, 131-147, doi:10.1146/annurev.micro.60.080805.142106 
(2006). 
286 Ejernaes, K. Bacterial characteristics of importance for recurrent urinary tract 
infections caused by Escherichia coli. Danish medical bulletin 58, B4187 (2011). 
182 
 
287 Martinez-Medina, M. et al. Biofilm formation as a novel phenotypic feature of 
adherent-invasive Escherichia coli (AIEC). BMC microbiology 9, 202, 
doi:10.1186/1471-2180-9-202 (2009). 
288 Naves, P. et al. Correlation between virulence factors and in vitro biofilm 
formation by Escherichia coli strains. Microbial pathogenesis 45, 86-91, 
doi:10.1016/j.micpath.2008.03.003 (2008). 
289 Rosen, D. A. et al. Molecular variations in Klebsiella pneumoniae and 
Escherichia coli FimH affect function and pathogenesis in the urinary tract. Infect 
Immun 76, 3346-3356, doi:10.1128/IAI.00340-08 (2008). 
290 Mobley, H. L., Chippendale, G. R., Tenney, J. H., Hull, R. A. & Warren, J. W. 
Expression of type 1 fimbriae may be required for persistence of Escherichia coli 
in the catheterized urinary tract. Journal of clinical microbiology 25, 2253-2257 
(1987). 
291 Elliott, T. S., Reid, L., Rao, G. G., Rigby, R. C. & Woodhouse, K. Bladder 
irrigation or irritation? British journal of urology 64, 391-394 (1989). 
292 Wright, K. J., Seed, P. C. & Hultgren, S. J. Uropathogenic Escherichia coli 
flagella aid in efficient urinary tract colonization. Infect Immun 73, 7657-7668, 
doi:10.1128/IAI.73.11.7657-7668.2005 (2005). 
293 Prasad, A., Cevallos, M. E., Riosa, S., Darouiche, R. O. & Trautner, B. W. A 
bacterial interference strategy for prevention of UTI in persons practicing 
intermittent catheterization. Spinal cord 47, 565-569, doi:10.1038/sc.2008.166 
(2009). 
183 
 
294 Macovei, L. et al. Enterococcus faecalis with the gelatinase phenotype regulated 
by the fsr operon and with biofilm-forming capacity are common in the 
agricultural environment. Environmental microbiology 11, 1540-1547, 
doi:10.1111/j.1462-2920.2009.01881.x (2009). 
295 Prabhakara, R. et al. Suppression of the inflammatory immune response prevents 
the development of chronic biofilm infection due to methicillin-resistant 
Staphylococcus aureus. Infect Immun 79, 5010-5018, doi:10.1128/IAI.05571-11 
(2011). 
296 Horvath, D. J., Jr. et al. Morphological plasticity promotes resistance to 
phagocyte killing of uropathogenic Escherichia coli. Microbes and infection / 
Institut Pasteur 13, 426-437, doi:10.1016/j.micinf.2010.12.004 (2011). 
297 Hunstad, D. A., Justice, S. S., Hung, C. S., Lauer, S. R. & Hultgren, S. J. 
Suppression of bladder epithelial cytokine responses by uropathogenic 
Escherichia coli. Infect Immun 73, 3999-4006, doi:10.1128/IAI.73.7.3999-
4006.2005 (2005). 
298 Miyazaki, S. et al. Cytotoxic effect of hemolytic culture supernatant from 
Enterococcus faecalis on mouse polymorphonuclear neutrophils and 
macrophages. Microbiology and immunology 37, 265-270 (1993). 
299 Juneau, R. A., Pang, B., Weimer, K. E., Armbruster, C. E. & Swords, W. E. 
Nontypeable Haemophilus influenzae initiates formation of neutrophil 
extracellular traps. Infect Immun 79, 431-438, doi:10.1128/IAI.00660-10 (2011). 
184 
 
300 Auer, J. & Seager, L. D. Experimental Local Bladder Edema Causing Urine 
Reflux into Ureter and Kidney. The Journal of experimental medicine 66, 741-
754 (1937). 
301 Valle, J. et al. Broad-spectrum biofilm inhibition by a secreted bacterial 
polysaccharide. Proceedings of the National Academy of Sciences of the United 
States of America 103, 12558-12563, doi:10.1073/pnas.0605399103 (2006). 
302 Blattner, F. R. et al. The complete genome sequence of Escherichia coli K-12. 
Science 277, 1453-1462 (1997). 
303 Chen, S. L. et al. Identification of genes subject to positive selection in 
uropathogenic strains of Escherichia coli: a comparative genomics approach. 
Proceedings of the National Academy of Sciences of the United States of America 
103, 5977-5982, doi:10.1073/pnas.0600938103 (2006). 
304 Harding, M. A. & Theodorescu, D. RhoGDI2: a new metastasis suppressor gene: 
discovery and clinical translation. Urologic oncology 25, 401-406, 
doi:10.1016/j.urolonc.2007.05.006 (2007). 
305 Chang, C. C. et al. Oct-3/4 expression reflects tumor progression and regulates 
motility of bladder cancer cells. Cancer research 68, 6281-6291, 
doi:10.1158/0008-5472.CAN-08-0094 (2008). 
306 Reis, L. O. et al. Evolution on experimental animal model for upper urothelium 
carcinogenesis. World journal of urology 28, 499-505, doi:10.1007/s00345-010-
0545-3 (2010). 
185 
 
307 Cohen, S. M., Ohnishi, T., Arnold, L. L. & Le, X. C. Arsenic-induced bladder 
cancer in an animal model. Toxicology and applied pharmacology 222, 258-263, 
doi:10.1016/j.taap.2006.10.010 (2007). 
308 Cohen, S. M., Ohnishi, T., Clark, N. M., He, J. & Arnold, L. L. Investigations of 
rodent urinary bladder carcinogens: collection, processing, and evaluation of urine 
and bladders. Toxicologic pathology 35, 337-347, 
doi:10.1080/01926230701197115 (2007). 
309 St John, A., Boyd, J. C., Lowes, A. J. & Price, C. P. The use of urinary dipstick 
tests to exclude urinary tract infection: a systematic review of the literature. 
American journal of clinical pathology 126, 428-436, 
doi:10.1309/C69RW1BT7E4QAFPV (2006). 
310 Trautner, B. W. et al. Increased expression of type-1 fimbriae by nonpathogenic 
Escherichia coli 83972 results in an increased capacity for catheter adherence and 
bacterial interference. The Journal of infectious diseases 198, 899-906, 
doi:10.1086/591093 (2008). 
311 Perez-Casal, J., Okada, N., Caparon, M. G. & Scott, J. R. Role of the conserved 
C-repeat region of the M protein of Streptococcus pyogenes. Molecular 
microbiology 15, 907-916 (1995). 
312 Perez-Casal, J. F., Dillon, H. F., Husmann, L. K., Graham, B. & Scott, J. R. 
Virulence of two Streptococcus pyogenes strains (types M1 and M3) associated 
with toxic-shock-like syndrome depends on an intact mry-like gene. Infect Immun 
61, 5426-5430 (1993). 
186 
 
313 Paulsen, I. T. et al. Role of mobile DNA in the evolution of vancomycin-resistant 
Enterococcus faecalis. Science 299, 2071-2074, doi:10.1126/science.1080613 
(2003). 
314 Kline, K. A. et al. Mechanism for sortase localization and the role of sortase 
localization in efficient pilus assembly in Enterococcus faecalis. Journal of 
bacteriology 191, 3237-3247, doi:10.1128/JB.01837-08 (2009). 
315 Granok, A. B., Parsonage, D., Ross, R. P. & Caparon, M. G. The RofA binding 
site in Streptococcus pyogenes is utilized in multiple transcriptional pathways. 
Journal of bacteriology 182, 1529-1540 (2000). 
316 Datsenko, K. A. & Wanner, B. L. One-step inactivation of chromosomal genes in 
Escherichia coli K-12 using PCR products. Proceedings of the National Academy 
of Sciences of the United States of America 97, 6640-6645, 
doi:10.1073/pnas.120163297 (2000). 
317 Murphy, K. C. & Campellone, K. G. Lambda Red-mediated recombinogenic 
engineering of enterohemorrhagic and enteropathogenic E. coli. BMC molecular 
biology 4, 11, doi:10.1186/1471-2199-4-11 (2003). 
318 Chen, S. L. et al. Positive selection identifies an in vivo role for FimH during 
urinary tract infection in addition to mannose binding. Proceedings of the 
National Academy of Sciences of the United States of America 106, 22439-22444, 
doi:10.1073/pnas.0902179106 (2009). 
319 Ewing, B. & Green, P. Base-calling of automated sequencer traces using phred. II. 
Error probabilities. Genome research 8, 186-194 (1998). 
187 
 
320 Ewing, B., Hillier, L., Wendl, M. C. & Green, P. Base-calling of automated 
sequencer traces using phred. I. Accuracy assessment. Genome research 8, 175-
185 (1998). 
321 Thompson, J. D., Higgins, D. G. & Gibson, T. J. CLUSTAL W: improving the 
sensitivity of progressive multiple sequence alignment through sequence 
weighting, position-specific gap penalties and weight matrix choice. Nucleic acids 
research 22, 4673-4680 (1994). 
322 Gilmore, K. S., Srinivas, P., Akins, D. R., Hatter, K. L. & Gilmore, M. S. Growth, 
development, and gene expression in a persistent Streptococcus gordonii biofilm. 
Infect Immun 71, 4759-4766 (2003). 
323 Ferrieres, L., Hancock, V. & Klemm, P. Specific selection for virulent urinary 
tract infectious Escherichia coli strains during catheter-associated biofilm 
formation. FEMS immunology and medical microbiology 51, 212-219, 
doi:10.1111/j.1574-695X.2007.00296.x (2007). 
324 Sizemore, R. K., Caldwell, J. J. & Kendrick, A. S. Alternate gram staining 
technique using a fluorescent lectin. Applied and environmental microbiology 56, 
2245-2247 (1990). 
325 Schilling, J. D., Mulvey, M. A. & Hultgren, S. J. Dynamic interactions between 
host and pathogen during acute urinary tract infections. Urology 57, 56-61 (2001). 
326 Saria, A. & Lundberg, J. M. Evans blue fluorescence: quantitative and 
morphological evaluation of vascular permeability in animal tissues. Journal of 
neuroscience methods 8, 41-49 (1983). 
188 
 
327 Beaudry, F. & Vachon, P. Determination of substance P in rat spinal cord by 
high-performance liquid chromatography electrospray quadrupole ion trap mass 
spectrometry. Biomedical chromatography : BMC 20, 1344-1350, 
doi:10.1002/bmc.703 (2006). 
328 Brown, R. W. & Chirala, R. Utility of microwave-citrate antigen retrieval in 
diagnostic immunohistochemistry. Modern pathology : an official journal of the 
United States and Canadian Academy of Pathology, Inc 8, 515-520 (1995). 
329 Shi, S. R., Chaiwun, B., Young, L., Cote, R. J. & Taylor, C. R. Antigen retrieval 
technique utilizing citrate buffer or urea solution for immunohistochemical 
demonstration of androgen receptor in formalin-fixed paraffin sections. The 
journal of histochemistry and cytochemistry : official journal of the 
Histochemistry Society 41, 1599-1604 (1993). 
330 Justice, S. S., Lauer, S. R., Hultgren, S. J. & Hunstad, D. A. Maturation of 
intracellular Escherichia coli communities requires SurA. Infect Immun 74, 4793-
4800, doi:10.1128/IAI.00355-06 (2006). 
331 Ike, Y., Clewell, D. B., Segarra, R. A. & Gilmore, M. S. Genetic analysis of the 
pAD1 hemolysin/bacteriocin determinant in Enterococcus faecalis: Tn917 
insertional mutagenesis and cloning. Journal of bacteriology 172, 155-163 
(1990). 
332 Wertman, K. F., Wyman, A. R. & Botstein, D. Host/vector interactions which 
affect the viability of recombinant phage lambda clones. Gene 49, 253-262 
(1986). 
189 
 
333 Hengstler, J. G., Fuchs, J. & Oesch, F. DNA strand breaks and DNA cross-links 
in peripheral mononuclear blood cells of ovarian cancer patients during 
chemotherapy with cyclophosphamide/carboplatin. Cancer research 52, 5622-
5626 (1992). 
334 Reid, J. L. & Vincent, J. Clinical pharmacology and therapeutic role of prazosin 
and related alpha-adrenoceptor antagonists. Cardiology 73, 164-174 (1986). 
 
 
